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Role of ABC transporters in pharmacokinetics
Absorption, distribution, metabolism, and excretion (ADME) are key determinants of drug 
efficacy and safety because these processes determine the availability of a drug at its target 
site. Before a drug reaches its site of action, it needs to cross several cellular barriers. 
Passage of a compound over these barriers is partly determined by its physicochemical 
characteristics, such as molecular size, lipophilicity, hydrogen bond donating or accepting 
capacity, or charge distribution.1 However, predictions of cell permeability based on these 
characteristics did not always correlate to the actual permeability of compounds, and 
further studies revealed that transport via membrane transporters also plays a vital role in 
this process. The human genome encodes for more than 400 transporters, including uptake 
transporters of the solute-carrier (SLC) transporter family and efflux transporters of the 
ATP binding cassette (ABC) transporter family, many of which are known to influence the 
absorption, distribution, and excretion of drugs.2-4
In total, the ABC transporter family consists of 49 members.5 P-glycoprotein (P-gp/
ABCB1), multidrug resistance-associated proteins (MRP/ABCC), and breast cancer resistance 
protein (BCRP/ABCG2) are efflux transporters of the ABC family that have been shown to 
transport clinically relevant drugs.2, 6 In general, transporters of the ABC family comprise two 
nucleotide binding domains (NBD) and two transmembrane domains (TMD). However, some 
transporters have an extra transmembrane domain (MRP1, MRP2, MRP3), while BCRP is a 
half-transporter, consisting of only one NBD and one TMD, that needs to dimerize to form a 
fully functional ABC transporter (Fig. 1).6, 7 The mechanism of substrate translocation across 
the membrane by these transporters has been investigated for more than 30 years. Functional 
and mutational analyses have mainly studied how ATP-hydrolytic activity is important for 
the activity of the transporter, and how these proteins can transport such a wide variety of 
substrates.8 These studies, first focusing on P-glycoprotein but later also on MRP1, 2, and 3, 
revealed that ATP binding and hydrolysis at the NBDs is necessary for transport function and 
that the TMDs form the main site for drug binding.7, 9, 10 Crystal structures of ABC transporters 
aid in visualizing the conformation of the transporter in different states of the transport 
cycle. Several bacterial ABC transporters have been successfully crystallized because of their 
relatively good water solubility, but to date this has only been achieved for one mammalian 
transporter, mouse P-glycoprotein.11 This paper described two crystal structures with cyclic 
peptide inhibitors bound, providing a molecular basis for polyspecific drug binding sites in 
P-glycoprotein. Homology models for other mammalian ABC transporters based on this 
structure combined with mutational analysis studies are a good starting point for a better 
understanding of the binding pockets of these transporters.
MRP1-5, BCRP, and P-gp are expressed in many epithelia in the body, either at the apical 
or basolateral cell membrane depending on the cell type.6, 12-16 Because efflux transporters 
are widely distributed in the body and they transport many different compounds, these 
proteins form a protective network against toxic compounds and drugs.5, 6 This thesis 
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Figure 1 Molecular topology of the drug efflux transporters P-gp, MRP1-5, and BCRP
NBD, nucleotide binding domain; NH
2
, aminoterminus; COOH, carboxyterminus.
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describes the role of intestinal and blood-brain barrier transporters in the disposition of a 
class of central nervous system (CNS) drugs, the cannabinoid type 1 receptor antagonists.
Expression and function of efflux transporters in the intestine
Oral administration is the most common route of administration for CNS drugs because 
it is non-invasive, convenient, and relatively cost-effective. However, with this type of 
administration, the systemic availability of a drug strongly depends on the passage through 
the intestinal wall and liver. If systemic availability is limited, the availability of a drug to the 
brain obviously will also be reduced. 
There are two main routes through which compounds can enter the portal circulation: 
the paracellular and the transcellular route.17-19 Small hydrophilic, ionized drugs can 
be absorbed via the paracellular route, but their passage is limited by the presence of 
tight junctions between the epithelial cells. Therefore, the contribution of this route to 
absorption is considered to be small.18 This implies that most drugs enter the circulation 
via the transcellular route, where influx or efflux transporters at the apical and basolateral 
membranes of the cell, and metabolizing enzymes in the cytosol, could affect their 
bioavailability.20, 21 The lower intestinal tract consists of duodenum, jejunum, ileum, and 
colon, each of which segment expresses a range of influx and efflux transporters. 
The main ABC transporters that are expressed in the intestine are MRP1-5, BCRP, and 
P-gp (Fig. 2). MRP1 is mainly expressed on the basolateral membranes of intestinal crypt 
cells.22 MRP3 is also localized to the basolateral membrane of intestinal cells, whereas 
P-glycoprotein, BCRP, and MRP2 are expressed apically.13, 16, 23-27 The cellular localization 
of MRP4 is still unclear, with either apical or basolateral localization in intestinal cell lines, 
and, to date, no immunohistochemical confirmation of the localization of MRP4 in human 
intestine.28-30 MRP5 has been detected at the mRNA level in the intestinal CaCo-2 cell line, 
but protein expression was not found, so its importance for intestinal drug transport remains 
to be investigated.31 
Transporter expression in the epithelial cells lining the lower intestine is variable over the 
length of the tract (Table 1).17, 32-34 MRP2 is highly abundant in small intestine, whereas it is 
virtually absent towards the end of the intestinal tract.33-36 BCRP expression appears to be 
highest in the middle or lower part of the intestine and seems to decline along the length of 
the intestinal tract, whereas MRP3, MRP4, and P-gp expression seems to increase towards 
the distal part of the intestine.33, 34, 36-38 The varying expression of efflux transporters in the 
intestine is expected to influence the site of intestinal absorption of a drug that is substrate 
for one or more of these transporters.39
Multiple studies have been performed to determine the involvement of efflux transporters 
in the oral availability of drugs, using in vitro models, such as CaCo-2 cells, or in vivo 
models, e.g. knockout animals, or inhibitors of efflux transporters in animals or humans. 
12
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Figure 2 Localization of ATP-dependent drug efflux transporters in the intestinal wall 
Transparency of MRP5 means that the relevance of this transporter for intestinal transport is 
unknown. Question mark behind MRP4 means that the exact location of this transporter has not 
been identified in intestinal tissue. 
Figure 3 Localization of ATP-dependent drug efflux transporters in the human blood-
brain barrier
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These studies have especially revealed a role for P-gp, BCRP, and MRP2 in decreasing the 
oral availability of drugs, whereas MRP3 could increase bioavailability.39-41 For example, 
the oral availability of the anti-cancer drug paclitaxel is increased from 9% in wild type 
to 36% in P-gp knockout mice, and inhibition of P-gp in wild type mice with the mixed 
P-gp/BCRP inhibitor elacridar (GF120918) increased the oral availability to 40%.42 Also in 
humans, elacridar increased the oral availability of paclitaxel from 4 to 30%, indicating the 
importance of P-gp in limiting its oral availability.43, 44 Inhibition of both BCRP and P-gp with 
elacridar increased the oral availability of the anti-cancer drug topotecan 9-fold in mice, 
and from 40% to 97% in humans.45-47 Although the role of MRP2 in decreasing the oral 
availability of drugs at the intestinal level appears to be less important than that of P-gp 
or BCRP, it appears to reduce the systemic exposure of the toxic food derived carcinogen 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice.48 In contrast, using 
Mrp3 knockout mice, Kitamura and colleagues revealed a role for MRP3 in increasing the 
oral availability of methotrexate, because the systemic methotrexate exposure appeared 
to be lower in these animals.41 Studies regarding the role of efflux transporters on oral 
bioavailability of CNS drugs have mainly focused on P-gp. In humans, P-gp inhibition with 
itraconazole, verapamil, or quinidine increased the exposure of the orally administered 
anti-depressant paroxetine, anti-psychotic agent risperidone, and analgesic drug morphine 
Table 1 Rank order of mRNA expression of efflux transporters in different intestinal 
segments
Segment Rank order
Duodenum MRP3 >> P-gp > MRP2 > MRP5 > MRP4 > MRP133
BCRP >> P-gp ≈ MRP2 > MRP334
Jejunum BCRP ≈ MRP2 > P-gp ≈ MRP3 >  MRP5 ≈ MRP6 ≈ MRP1 ≈ MRP4 > MDR332
MRP2 ≈ P-gp > BCRP > MRP336
BCRP >> MRP2 ≈ P-gp > MRP3 >> MRP6 ≈ MRP4 ≈ MRP1 ≈ MRP549
BCRP > P-gp >> MRP2 > MRP334
Ileum P-gp > MRP3 >> MRP1 ≈ MRP4 ≈ MRP5 > MRP233
BCRP ≈ P-gp >> MRP2 > MRP334
Colon MRP3 >> P-gp > MRP4 ≈ MRP5 > MRP1 >> MRP233
MRP3 > P-gp >> BCRP > MRP236
BCRP > P-gp > MRP3 >> MRP234
32, 33 mRNA expression levels determined by TaqMan quantitative real time PCR (Q-PCR) and 
normalized to enterocyte-specific villin expression.
34 mRNA expression levels determined by TaqMan Q-PCR and normalized to 18S expression.
36 mRNA expression levels determined by TaqMan Q-PCR and normalized to expression level of 
cytoplasmic protein cyclophilin A.
49 mRNA expression levels determined by TaqMan Q-PCR and normalized to geometric mean of 
cyclophilin A and major vault protein LRP.
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by 56%, 82%, and 60%, respectively.50-52 These examples emphasize the role of intestinal 
efflux transporters in determining the oral availability of (CNS) drugs.
Interplay of metabolizing enzymes and transporters in the intestine
Another factor that can influence the oral availability of a drug is biotransformation via 
metabolizing enzymes, in both the intestine and the liver. Metabolism of drugs is important 
for their detoxication and elimination from the body. Although the liver has always been 
pointed out as the key player in first-pass metabolism, more recent studies have shown 
that metabolism in the intestine can also play a substantial role in this process.53, 54 The 
intestine expresses multiple metabolizing enzymes, including cytochrome P450 (CYP) 
metabolizing enzymes, uridine 5’-diphospho glucuronosyltransferases (UGT), glutathione 
S-transferases (GST), and sulfotransferases (SULT), which produce oxidized (Phase I), and 
glucuronide-, glutathione-, and sulfate-conjugated (Phase II) metabolites, respectively.55 
CYP3A4 is the most abundant CYP in the intestine, and it has overlapping substrate 
specificity with the efflux transporter P-gp. Multiple studies have shown that CYP3A4 
and P-gp cooperate in limiting the absorption of shared substrates.56 Many of the Phase 
II glucuronide-, sulfate-, and glutathione-conjugated products are substrates of MRPs and 
BCRP.5 One can imagine that these efflux transporters and Phase II metabolizing enzymes 
work in concert to rapidly eliminate harmful compounds from the body. Indeed, interplay 
between multiple enzyme-transporter combinations has been shown for metabolism and 
transport of different compounds, e.g. GST-MRP1 for 1-chloro-2,3-dinitrobenzene, SULT-
BCRP for 4-methylumbelliferone, UGT-BCRP for apigenin and 4-methylumbelliferone, and 
UGT-MRP2/3 for raloxifene and morphine.57-62 Some studies even suggest a synergistic 
interplay between these proteins, in which transport of metabolites increases the total 
metabolite formation.57, 63 The theory behind this synergism is based on the possibility that 
transport of metabolites from cells increases the metabolic rate through a reduction of 
product inhibition of the enzyme by intracellular metabolites. However, this hypothesis of 
synergistic interplay needs further experimental support by using in vitro model systems, 
in which an enzyme and a transporter can be introduced or knocked out individually or 
together, to study the effect of transport on total UGT-mediated metabolism.
Expression and function of efflux transporters at the blood-brain barrier
After passage of the intestine, the liver, and, subsequently, entering the general circulation, 
the final step for a CNS drug to reach the brain is passage through the blood-brain barrier 
(BBB). The BBB consists of endothelial cells that are tightly coupled to each other by tight 
junctions and which reside on a basal membrane that is surrounded by astrocytes. Together 
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with efflux transporters that are expressed at the luminal surface of the endothelial cells, 
a barrier arises that protects the brain from potentially harmful compounds, including 
drugs.64-67 The efflux transporters expressed at the luminal membrane of the human 
BBB are P-gp, BCRP, MRP1, MRP4, and MRP5, of which BCRP and P-gp have the highest 
abundance (Fig. 3).68-74
The importance of efflux transporters at the BBB in determining the brain concentration 
of drugs was discovered by a true case of serendipity. Schinkel et al. had developed 
Mdr1a-/- knockout mice to evaluate the physiological role of Mdr1a, one of the orthologues 
of P-gp in mice.75 In order to treat a mite infestation they sprayed the whole population of 
bred mice with ivermectin, which is normally a safe procedure. However, at this occasion 
it caused several deaths among the animals, which appeared to be due to neurotoxicity. 
Genotyping revealed that all deceased animals were Mdr1a-/- knockout mice, indicating 
that Mdr1a plays an important role in protecting the CNS against this drug. Further analysis 
showed that this was due to efflux of ivermectin via Mdr1a at the BBB, thereby reducing 
the brain concentration of this compound. Additional studies using knockout animals for 
different efflux transporters showed the importance of P-gp, BCRP, and MRP4 in reducing 
the brain concentrations of various types of drug, of which P-gp is considered to be the 
most important gatekeeper of the brain.76-83 In humans, efflux transporters at the BBB are 
thought to limit the brain penetration of drugs that should enter the brain, such as anti-HIV 
medication, anti-epileptic and anti-cancer drugs, anti-depressants, and anti-psychotics.84-86 
Therefore, transport of lead compounds via efflux transporters at the BBB is taken into 
consideration in the early development of CNS drugs, to prevent failure in later stages of 
drug development because of poor brain penetration.4
Difficulties in the development of CNS drugs
Although the demand for new CNS drugs is growing, the success rate of the clinical 
development of these drugs is lower than for drugs with other indications.87 As explained 
above, the development of new CNS drugs is complicated because they need to be able 
to pass two barriers, the intestine and the BBB. A higher lipophilicity of compounds would 
favour the passage over membranes and diffusion into the brain tissue.88 On the other 
hand, higher lipophilicity limits the solubility of compounds, thereby decreasing oral 
bioavailability.88 Therefore, research has focused on other ways to get these compounds 
into the brain, for example through transport by uptake transporters in combination 
with limited transport by efflux transporters at the intestinal wall or BBB.88, 89 However, 
optimization of these compound characteristics to improve its membrane penetration 
might also adversely affect the target efficacy of the compound. Therefore, prodrugs 
are being developed that have improved oral availability or BBB penetration, e.g. due to 
increased water solubility, lipophilicity, or transport via uptake transporters, and that are 
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Figure 4 Chemical structure of rimonabant (Accomplia®)
Rimonabant was the first and only CB1 receptor antagonist that was released on the market to 
date. 
converted to the parent compound by local conditions or enzymes at their site of action.88, 
89 In addition, there have also been efforts to develop nanotechnologies that can aid in 
the delivery of drugs at the intestine or the BBB.90 The project described in this thesis is 
part of the Top Institute Pharma project T5-105, which used nanotechnologies to improve 
oral availability and brain penetration of CNS drugs, focusing on cannabinoid type 1 (CB1) 
receptor antagonists.91-94
Development of CB1 receptor antagonists as an anti-obesity drug
Obesity is an illness defined by abnormal or excessive body fat accumulation that presents 
a risk to health. It is becoming an increasing burden to society and at least 2.8 million adults 
die each year as a result of overweight or obesity.95 This is mainly due to co-morbidities 
that occur with increased intra-abdominal visceral body fat due to abnormal metabolic 
factors, leading to insulin resistance and type 2 diabetes, atherosclerosis, and cardiovascular 
disease.96 During the past three decades, increasing  evidence has pointed towards an 
important role for the endocannabinoid system, of which the CB1 receptor is one of the key 
players, in the development of obesity.
The CB1 receptor is expressed in central and peripheral tissues, such as brain, spinal cord, 
adipose tissue, skeletal muscle, liver, gut, and pancreas.99 It belongs to the class A of G-protein 
coupled receptors and it has several natural agonists, of which the endocannabinoids 
anandamide and 2-arachidonoylglycerol and the cannabinoid derived from cannabis, 
∆9-tetrahydrocannabinol, have been used frequently to study the physiological function 
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of the receptor. Activation of the CB1 receptor reduces pain, anxiety, body temperature, 
blood pressure, gastrointestinal motility, hormone production, and smooth muscle tone, 
and induces neuroprotective effects.98 Complementary to the known CB1 receptor agonists, 
Sanofi-Aventis developed a CB1 receptor antagonist, N-(piperidin-1-yl)-5-(4-chlorophenyl)-
1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride (Fig. 4), that had 
a 1000-folder higher inhibitory affinity for the CB1 receptor than for the CB2 receptor.100 This 
antagonist, which actually turned out to be an inverse agonist, was named SR141716A or 
rimonabant, and because of its high selectivity for the CB1 receptor it could be used as an 
additional tool to understand the physiological functions of the CB1 receptor.100 
One of these studies, by Arnone et al. (1997), showed that rimonabant reduces food and 
ethanol intake in mice.101 Further studies confirmed the involvement of the CB1 receptor 
in regulation of feeding behaviour, metabolism, and energy balance through central and 
peripheral mechanisms in several tissues (summarized in Table 2).97, 98 In obesity, the 
endocannabinoid system appears to be hyperactivated, contributing to dyslipidemia, insulin 
resistance, and overweight. For this reason, it was hypothesized that antagonism of the CB1 
receptor would reduce food intake and improve cardiometabolic risk factors, and therefore 
could serve as an anti-obesity therapy.97, 99 Indeed, in rodents, antagonism of the receptor 
with rimonabant led to reduced food intake and weight reduction.102 Subsequently, one CB1 
receptor antagonist was available for therapy and several CB1 receptor antagonists were 
Table 2 Responses to modulation of the endocannabinoid system via the CB1 receptor 
(adapted from Andre et al)96-98
Site of action Stimulation Overactivation Inhibition
Brain ↑ food intake ↑ body weight / waist 
circumference
↓ food intake / waist 
circumference
Gastrointestinal 
tract
↓ satiety
↑food assimilation
↑ body weight /waist 
circumference
Liver ↑lipogenesis ↑ dyslipidemia
↑ steatosis
↓ lipogenesis
Pancreasa ↑insulin ↑ insulin resistance ↓ insulin 
hypersecretion
Muscle ↓ glucose uptake
↓ fatty acid 
oxidation
↑ insulin resistance
↓ energy expenditure
↓ insulin resistance 
↑ glucose uptake
↑ energy expenditure
Adipose tissue ↓ adiponectin
↓ leptin
↑ lipogenesis
↑ visceral fat
↑ dyslipidemia
↑ insulin resistance
↑ adiponectin
↑ lipolysis
↓ fat energy storage
↑ thermogenesis
a CB2 receptor is also expressed in pancreas and there is still controversy about the respective 
role of CB1 or CB2 activation in insulin secretion.
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under development for the treatment of obesity at the start of this PhD project in January 
2008.102, 103 
Rimonabant (Acomplia) was the first and only selective CB1 receptor antagonist 
for therapeutic use in humans and was released on the European market in June 2006. 
Clinical studies in humans showed that rimonabant reduces body weight and waist 
circumference, and improves cardiometabolic risk factors, including triglycerides, low and 
high density lipoprotein-cholesterol, fasting glucose, and glycosylated hemoglobin A1c 
levels.104, 105 However, meta-analysis of the clinical studies performed with rimonabant, by 
Christensen and colleagues (2007) and the Food and Drug Administration (FDA), revealed 
that rimonabant treatment was also associated with more psychiatric adverse events, such 
as depressive mood disorders, anxiety, suicidal ideation, and sleeping disorders.106, 107 These 
findings prevented approval of rimonabant for the US market by the FDA in July 2007. In 
the same period, the European Medicines Agency (EMA) decided to add restrictions for 
prescription of the drug, and after additional clinical studies, it decided to suspend the drug 
from the European market in October 2008 due to the neuropsychiatric side effects.  
Using efflux transporters in the development of peripheral CB1 receptor 
antagonists
Some of the metabolic effects of rimonabant were not entirely explained by weight loss, 
but appear to be due to an effect of rimonabant on CB1 receptors in peripheral tissues 
(Table 2).96 On the other hand, the psychiatric side effects of rimonabant are caused by 
inhibition of the CB1 receptor in the brain. Therefore, it was hypothesized that peripheral 
CB1 receptor antagonists that do not enter the brain could still have beneficial effects on 
cardiometabolic risk factors without the psychiatric side effects.99, 103, 108
This provided an interesting challenge: to develop CB1 receptor antagonists with limited 
brain penetrance. As emphasized in the introduction, efflux transporters can be involved in 
limiting the access of drugs to the brain. Therefore, it would be interesting to use this brain-
limiting mechanism in the development of peripheral CB1 receptor antagonists to reduce 
their brain penetration, and, consequently, their psychiatric side effects. Transport via efflux 
transporters at the BBB has already been proven to be a useful trait for some drugs, such as 
domperidone and loperamide, that exert beneficial effects in the periphery, but would have 
had unwanted side effects if distributed to the brain.64, 109, 110 If efflux transport proves to be 
useful to restrict CB1 receptor antagonists to the periphery, it might be used as a selection 
criterion in early drug development of these compounds. 
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Aim of this thesis
The research that resulted in this thesis was focused on the identification and characterization 
of efflux transporters that might play a role in the disposition of CB1 receptor antagonists 
at two important barriers in the body: the intestinal wall and the blood-brain barrier (BBB). 
To identify potential peripheral CB1 receptor antagonists, we investigated a series of 
3,4-diarylpyrazoline CB1 receptor antagonists for their interaction with the efflux transporters 
MRP1-4, and P-gp. The results of these studies are described in Chapters 2 and 3.
To further investigate the interplay between drug metabolizing enzymes and transporters 
in the intestine, we used a model compound, 7-hydroxycoumarin (7-HC), and investigated 
which transporters are involved in the transport of the glucuronide metabolite of 7-HC. In 
collaboration with one of the TI Pharma project partners, the Department of Pharmacy of 
the University of Groningen (Prof. dr. Groothuis), we investigated the effect of metabolite 
transport via efflux transporters on the function of UGTs in vitro using HEK293 cells, and ex 
vivo using human intestinal tissue. The results of these studies are described in Chapters 4 
and 5.
Finally, in Chapter 6 of this thesis we describe the molecular mechanisms of substrate 
transport by one of the major intestinal and BBB transporters, MRP4, in more detail. We 
aimed to elucidate the importance of the amino acids Phe368 in TM6, and Trp995 and Arg998 in 
TM12 of MRP4 for the transport of different substrates via this transporter.
The implications of the work presented in this thesis for the development of CB1 receptor 
antagonists as anti-obesity drugs and, in greater perspective, for CNS drug development are 
discussed in Chapter 7.
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Abstract
Cannabinoid type 1 (CB1) receptor antagonists have been developed for the treatment of 
obesity, but a major disadvantage is that they cause unwanted psychiatric effects. Selective 
targeting of peripheral CB1 receptors might be an option to circumvent these side effects. 
Multidrug resistance-associated proteins (MRPs) can influence the pharmacokinetics 
of drugs and thereby affect their disposition in the body. In this study, we investigated 
the interaction of the prototypic CB1 receptor antagonist rimonabant and a series of 
3,4-diarylpyrazoline CB1 receptor antagonists with MRP1, MRP2, MRP3, and MRP4 in vitro. 
Their effect on ATP-dependent transport of estradiol 17-β-D-glucuronide was measured 
in inside-out membrane vesicles isolated from transporter-overexpressing HEK293 cells. 
Rimonabant inhibited MRP1 transport activity more potently than MRP4 (Ki of 1.4 µM and 4 
µM, respectively), whereas the 3,4-diarylpyrazolines were stronger inhibitors of MRP4 than 
MRP1-mediated transport. A number of CB1 receptor antagonists, including rimonabant, 
stimulated MRP2 and MRP3 transport activity at low, but inhibited E
2
17βG transport at 
high substrate concentrations. The interaction of 3,4-diarylpyrazolines and rimonabant 
with MRP1-4 indicate their potential for drug-drug interactions. Preliminary in vivo data 
suggested that for some 3,4-diarylpyrazolines the relatively lower brain efficacy may be 
related to their inhibitory potency against MRP4 activity. Furthermore, this study shows 
that the modulatory effects of the 3,4-diarylpyrazolines were influenced by their chemical 
properties, and that small variations in structure can determine the affinity of these 
compounds for efflux transporters and thereby affect their pharmacokinetic behavior.
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Introduction
The cannabinoid type 1 (CB1) receptor is involved in regulation of feeding behavior, 
metabolism, and energy balance.1 Studies in rodents have shown that antagonism of 
this receptor leads to reduced food intake and weight reduction.2 Several CB1 receptor 
antagonists were developed for the treatment of obesity, and clinical studies showed a 
reduction in appetite, weight loss, and improved metabolic risk factors.2, 3 Rimonabant was 
the first and only selective CB1 receptor antagonist approved for therapeutic use. However, 
the drug was withdrawn from the market within two years of its introduction, because 
psychiatric adverse effects, in particular depression, were revealed in additional clinical 
studies.4, 5 
The CB1 receptor is expressed in brain and peripheral tissues such as adipose, skeletal 
muscle, liver, gut, and pancreas.1 In the brain, activation of the endocannabinoid system 
appears to be involved in coping with stress and anxiety. Therefore, the psychiatric side 
effects seen for CB1 receptor antagonists could be due to inhibition of the endocannabinoid 
system.3 It is believed that the positive effect of antagonists on metabolic factors could 
also be mediated via peripheral CB1 receptors.1 Indeed, a recent study with a peripheral 
CB1 receptor antagonist in obese mice showed that this antagonist could improve the 
cardiometabolic risk in these mice without inhibition of the central CB1 receptor.6 Therefore, 
peripheral CB1 receptor antagonists might have therapeutic potential for improving 
metabolic risk in obese patients, without causing psychiatric side effects.
Multidrug resistance-associated proteins (MRPs) are efflux transporters that can influence 
drug disposition by transporting a wide variety of substrates out of the cell, preventing drugs 
from entering specific tissues or organs (e.g. intestine and brain), or increasing elimination 
of compounds, e.g. via liver and kidney.7, 8 MRP1, MRP2, MRP3, and MRP4 belong to the ATP-
binding cassette (ABC) transporter subfamily C, and have overlapping substrate specificities.9 
MRP1 is present in many tissues, with highest protein expression in lung, adrenal gland, 
heart, and skeletal muscle, and lower amounts in brain, choroid plexus, spleen, kidney, 
intestine, testes, placenta, and liver.10-13 It is expressed basolaterally in most tissues, but it 
has an apical localization in brain capillary endothelial cells.12, 13 MRP2 is highly expressed 
in liver, and lower expression levels can be found in the apical membranes of kidney 
tubules, gastrointestinal tract, gall bladder, placenta, and bronchi.14, 15 MRP3 is expressed in 
kidney, colon, small intestine, liver, and gall bladder, where it is found mostly in basolateral 
membranes.16 MRP4 is widely distributed in tissues and blood cells and has a dual membrane 
localization, which is basolateral in prostate tubuloacinar cells, hepatocytes, and choroid 
plexus, and apical in kidney proximal tubule cells, and brain capillary endothelium.13, 17 The 
expression of MRP1-4 at locations which are involved in drug disposition and penetration 
suggests that they influence drug concentrations in plasma and different organs, and, 
because of their presence in the blood-brain barrier (BBB) and choroid plexus, MRP4 and 
MRP1 might play a role in restricting CB1 receptor antagonists from the brain.
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Interaction of a drug with efflux transporters could not only influence its own 
pharmacokinetics, but it can also change the disposition of other compounds that are 
substrates for the same transporter. Studies describing the interaction of CB1 receptor 
antagonists with MRP1-4 may not only give information on the pharmacokinetics of these 
antagonists, but also on possible drug-drug interactions. Here, we investigated the in 
vitro effect of a series of 3,4-diarylpyrazoline CB1 receptor antagonists (Fig. 1)18 and the 
prototypic CB1 receptor antagonist rimonabant on MRP1-4 transport activity. In addition, 
for some 3,4-diarylpyrazolines, we related their transporter interaction to preliminary in 
vivo pharmacodynamic effects measured in rats.
Figure 1 Chemical structure of CB1 receptor antagonists
Core structure of 3,4-diarylpyrazoline derivatives 4, 11-17, and 23 (A) with the chemical structures 
of R for the N-substituent of these compounds (B).18 Structure of rimonabant (C). 
A B
C
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Materials and methods
Materials
[6,7-3H(N)]-estradiol 17-β-D-glucuronide (41.8 Ci/mmol) was purchased from Perkin Elmer 
(Groningen, the Netherlands). Bac-to-Bac and Gateway system, DMEM + Glutamax-I culture 
medium, and fetal calf serum were purchased from Invitrogen (Breda, the Netherlands). 
Triple flasks (500 cm2) were purchased from Sanbio BV Biological Products (Uden, 
the Netherlands). Estradiol 17-β-D-glucuronide (E
2
17βG), adenosine 5’-triphosphate 
magnesium salt (from bacterial source) and adenosine 5’-monophosphate monohydrate 
(from yeast) were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Protein 
concentrations were determined with a Bio-Rad protein assay kit from Bio-Rad Laboratories 
(Veenendaal, the Netherlands). Monoclonal mouse-anti-human MRP3 antibody M3II-21 
was purchased from Abcam (Cambridge, UK). Monoclonal mouse-anti-human MRP1 (QCRL-
1) was kindly provided by dr. S.P.C. Cole (Queen’s University Cancer Research Institute, 
Kingston, Canada). 3,4-Diarylpyrazoline CB1 receptor antagonists18 and rimonabant were 
kindly provided by Solvay Pharmaceuticals (Hannover, Germany - Solvay Pharmaceuticals 
is now Abbott). 
Generation of baculovirus
Full-length human MRP1, MRP2, and MRP3 were cloned separately into the Gateway 
pDONR221vector. The sequence of MRP1 was equal to GenBank accession number 
NM_004996 except for three silent mutations at bp 1684, 1704, and 4002, which are 
known polymorphisms.19 The sequence of MRP2 was equal to NM_000392 except for three 
silent mutations at bp 264, 1167, and 3972, of which C3972T is a known polymorphism, 
and the sequence of MRP3 was equal to NM_003786.20 Consequently, constructs were also 
cloned into a VSV-G improved pFastBacDual vector for mammalian cell transduction using 
the Gateway system.21 Full-length human MRP4 and enhanced yellow fluorescent protein 
(eYFP), which was used as a negative control, were already cloned before.21 Baculoviruses 
were produced as described in the Bac-to-Bac manual (Invitrogen).
Cell culture and transduction of HEK293 cells
HEK293 cells were grown in DMEM-Glutamax-I supplemented with 10% fetal calf serum 
at 37°C under 5% CO
2
-humidified air. HEK293 cells were cultured in 500 cm2 triple flasks 
until 40% confluent, after which culture medium was removed and 25 ml medium and 10 
ml eYFP, MRP1, MRP2, MRP3, or MRP4 baculovirus was added. Cells were incubated for 15 
min at 37°C, after which a further 40 ml medium was added. 5 mM sodium butyrate was 
added 24 hours after transduction. Three days after transduction, cells were harvested by 
centrifugation at 5000g for 5 minutes.
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Isolation of membrane vesicles and protein analysis
Membranes were isolated according to a previously described method with slight 
modifications.22 In brief, harvested cell pellets were resuspended in ice-cold homogenization 
buffer (0.5 mM sodium phosphate and 0.1 mM EDTA) supplemented with protease inhibitors 
(100 µM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml 
pepstatin, and 1 µM E-64) and shaken at 4°C for 30 minutes. Lysed cells were centrifuged at 
100,000g for 30 min at 4°C, and the pellets were homogenized in ice-cold TS buffer (10 mM 
Tris-HEPES, and 250 mM sucrose, pH 7.4) supplemented with protease inhibitors described 
above, using a tight-fitting Dounce homogenizer for 25 strokes. After centrifugation at 
1000g for 20 minutes at 4°C, the supernatant was centrifuged at 100,000g for 60 min at 
4°C. The resulting pellet was resuspended in TS buffer without protease inhibitors and 
passed through a 27-gauge needle 25 times. Protein concentration was determined by Bio-
Rad protein assay kit. Crude membrane vesicles were dispensed in aliquots, frozen in liquid 
nitrogen, and stored at -80°C until further use.
Western blotting
Membrane vesicle preparations were solubilized in SDS-polyacrylamide gel electrophoresis 
sample buffer and separated on SDS gel, containing 7.5% acrylamide, according to Laemmli. 
Subsequently, they were blotted on nitrocellulose membrane using the iBlot dry blotting 
system (Invitrogen). Monoclonal mouse-anti-human MRP1 (QCRL-1, 1:700) and MRP3 
(M3II-21, 1:200) antibodies and affinity-purified, polyclonal rabbit-anti-human MRP2 (pAb 
hM2-p2, 1:500) and MRP4 (pAb hM4-p4, 1:1000) were used to detect transporters.23, 24 The 
secondary antibodies used in 1:10000 dilution were fluorescent goat-anti-mouse IRdye800 
(Rockland Immunochemicals, Gilbertsville, USA) and goat-anti-rabbit Alexa Fluor 680 
(Invitrogen). Signals were visualized using the Odyssey imaging system (Li-Cor Biosciences, 
Lincoln, NE).
Vesicular transport assays
Uptake of [3H]E
2
17βG into membrane vesicles was performed using a rapid filtration 
technique.25 30 µl reaction mix consisted of TS buffer, 4 mM ATP, 10 mM MgCl
2
, E
2
17βG 
and 7.5 µg of membrane vesicles. 0.1 (MRP1), 0.15 (MRP2, MRP4), and 0.2 µCi (MRP3) 
[3H]E
2
17βG was used, supplemented with unlabeled E
2
17βG to concentrations indicated 
in legends. The reaction was started when the mixture was incubated at 37°C and then 
stopped by placing samples on ice and adding 150 µl of ice-cold TS buffer. A Multiscreen
HTS
 
HV, 0.45 µM, PVDF 96-well filter plate was pre-washed with TS buffer and diluted samples 
were filtered through this filter plate using a Multiscreen
HTS
-Vacuum Manifold filtration 
device (Millipore, Etten-Leur, the Netherlands). The filters were washed twice with TS-buffer 
and were then separated from the plate. After addition of 2 ml of scintillation fluid to each 
filter and subsequent liquid scintillation counting, uptake of [3H]E
2
17βG into membrane 
vesicles was determined by measuring radioactivity associated with the filters. In control 
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experiments, ATP was substituted with AMP. Net ATP-dependent transport was calculated 
by subtracting values measured in the presence of AMP from those measured in the 
presence of ATP. Time-dependent transport was found to be linear up to 5 minutes for 
MRP1, MRP2, and MRP4, and up to 3 minutes for MRP3 (results not shown).
Vesicular interaction assays
To evaluate the inhibitory effects of 3,4-diarylpyrazolines and rimonabant on [3H]E
2
17βG 
uptake in MRP1, 2, 3, and 4 inside-out membrane vesicles, the abovementioned transport 
assay was performed in the absence or presence of 10 and 100 µM of CB1 receptor 
antagonists. The concentration-dependent effect of 1-100 µM of compounds 13, 15, and 
rimonabant was measured at three different E
2
17βG concentrations: 0.16, 1, and 5 µM for 
MRP1; 2, 20, and 200 µM for MRP2; 0.08, 1, and 5 µM for MRP3; and 0.1, 0.3, and 1 µM for 
MRP4. ATP-dependent transport was calculated. 
Determination of actual concentrations of 3,4-diarylpyrazolines and rimonabant with LC-
MS/MS
The actual amount of CB1 receptor antagonists dissolved under vesicular transport assay 
conditions was measured. eYFP vesicles (7.5 µg) were added in each well to mimic the 
vesicle environment. The reaction mixture without [3H]E
2
17βG was added on ice and only 
the AMP-condition was measured. The 96-wells plate was mixed and the total reaction 
mixture from one well was transferred to an eppendorf tube at room temperature. 
Sample was spinned down at maximum speed (16,000-20,000g) for 5 minutes at room 
temperature and 10 µl of supernatant was reconstituted in 50% acetonitrile/water and 
0.1% trifluoroacetic acid (TFA) prior to LC-MS/MS analysis. Determination of actual 
concentration was carried out using an Accela U-HPLC (Thermo Fisher Scientific) coupled 
to a TSQ Vantage (Thermo Fisher Scientific) triple quadropole mass spectrometer.  The CB1 
receptor antagonists were separated on a Zorbax Eclipse Plus column (50 x 2.1 mm, 1.8 µm 
particle size; Agilent). The elution gradient was: 0 min 50% B, 5 min 90% B, 6 min 50% B. 
Solvent A consisted of 0.1% TFA in ultrapure water and solvent B consisted of 0.1% TFA in 
acetonitrile. The column temperature was set at 40°C and the flow rate was 200 µl/min. 
The effluent from the HPLC was passed directly into the electrospray ion source. Positive 
electrospray ionization was achieved using a nitrogen sheath gas with ionization voltage at 
4 kV. The capillary temperature was set at 350°C. Detection of each analyte was based on 
isolation of the protonated molecular ion, [M+H]+, and subsequent MS/MS fragmentations 
and a selected reaction monitoring (SRM) were carried out. The conditions per compound 
are summarized in Table 1. CB1 receptor antagonist 4 or 16 was used as internal standard 
and the response ratio of test compound to internal standard was used to determine the 
concentration. Actual assay concentration of compound was measured in duplicate in at 
least three independent experiments.
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In vivo pharmacodynamic effect of 3,4-diarylpyrazolines on CP55,940 induced hypotension 
in rat
The ED
50
 of 3,4-diarylpyrazolines for attenuation of 5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]phenol (CP55,940)-induced hypotension in male, normotensive, 
anaesthetized Wistar rats was determined according to a previously described method using 
different intravenous doses (n = 2 per dose) of CB1 receptor antagonists 10 minutes before 
CP55,940 (0.1 mg/kg i.v.) administration.26 Hypotension was achieved within 1 minute after 
administration of the CB1 receptor agonist CP55,940, and the lowest blood pressure was the 
measure of the hypotensive effect. ED
50
 was calculated on the linear part of the percentage 
dose response curve and is the dose of antagonist that inhibited the hypotensive effect of 
CP55,940 by 50%. Experiments were approved by the local ethics committee on animal 
experimentation at Solvay Pharmaceuticals in Weesp.
Kinetic Analysis
All data were expressed as means ± S.E.M.. Curve fitting of the resulting concentration-
dependent transport curves and determination of IC
50
 values for the CB1 receptor antagonists 
was performed by non-linear regression analysis using GraphPad Prism software, version 
5.02 (GraphPad Software Inc., San Diego, CA). The following equation was fitted to the data: 
y = bottom + (top-bottom)/(1 + 10(logIC50 - x)*hill slope), in which x is log inhibitor concentration and 
y is expressed as uptake versus control (%). Michaelis-Menten fit was used for MRP1, MRP3, 
and MRP4 E
2
17βG curves, allosteric sigmoidal fit for MRP2. Log (inhibitor or stimulator) vs 
response with variable slope was used to plot the inhibition and stimulation curves with 
Table 1 LC-MS/MS conditions for detection of CB1 receptor antagonists
Compound Retention time
(min)
Parent
(m/z)
Product 1 (CE)
(m/z) (eV)
Product 2 (CE)
(m/z) (eV)
S-lens
(V)
4 3.2 420.182 255.060 (27) 375.140 (13) 115
11 4.2 448.222 255.100 (26) 375.080 (16) 108
12 4.2 448.221 255.060 (30) 375.050 (14) 111
13 3.8 434.204 255.060 (26) 375.090 (14) 109
14 3.5 446.205 255.090 (28) 375.100 (16) 118
15 4.8 474.245 255.070 (29) 375.100 (28) 127
16 5.4 488.261 255.060 (31) 375.090 (19) 130
17 4.0 478.184 255.050 (28) 375.000 (15) 113
23 2.6 510.169 255.080 (29) 375.100 (15) 127
rimonabant 3.2 463.163 299.000 (46) 363.020 (29) 125
CE: collision energy
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13, 15, or rimonabant. Results of the inhibition assay for interaction of MRP1/4 with 13 and 
rimonabant were analyzed using Dixon’s method combined with linear regression analysis 
to estimate the inhibitory constant (Ki). Statistical differences were determined using a 
one-way analysis of variance with Dunnett’s multiple comparison test in GraphPad Prism. 
Differences were considered to be significant at p < 0.05. 
Results
Expression of MRP1, MRP2, MRP3, and MRP4 in isolated membrane vesicles
Immunoblot analysis performed on membrane vesicles from HEK293 cells overexpressing 
MRP1, MRP2, MRP3, and MRP4 demonstrated that all four transporters were successfully 
expressed (data not shown). MRP1 seemed to be less glycosylated as indicated by a band 
at approximately 160 kD, but this had no influence on its transport activity (Fig. 2A). The 
negative control, consisting of membrane vesicles from eYFP-overexpressing HEK293 cells, 
showed no expression of MRP1-4.
 
Concentration-dependent transport of E
2
17βG into MRP1, MRP2, MRP3, and MRP4 
overexpressing membrane vesicles
Concentration-dependent uptake of E
2
17βG into membrane vesicles was measured after 
5 minutes for all transporters and typical curves are shown in Figure 2A-D. ATP-dependent 
E
2
17βG transport reached maximum activities (V
max
) of 31 ± 1, 2220 ± 100, and 94 ± 5 pmol 
mg-1 min-1 for MRP1, MRP3, and MRP4, respectively. The affinity of E
2
17βG (K
m
) for MRP1, 
MRP3, and MRP4 was 7.5 ± 0.1 µM, 56 ± 6 µM, and 15 ± 3 µM, respectively. Repetition of 
the experiment for each transporter gave comparable kinetic parameters, only the V
max
 of 
MRP3 varied between different batches of membrane vesicles, due to different expression 
levels of the transporter. Transport activity of MRP2 followed a sigmoidal relationship with 
increased E
2
17βG concentration (Fig. 2B). A Hill slope of 1.6 ± 0.03 was calculated for MRP2 
activity, which is indicative of positive cooperativity.
Effects of 3,4-diarylpyrazolines and rimonabant on MRP1-, MRP2-, MRP3-, and MRP4-
mediated E
2
17βG transport
Based on the kinetics of E
2
17βG uptake by MRP1-4, the following E
2
17βG concentrations, 
well below the K
m
, were chosen for interaction studies with 3,4-diarylpyrazolines and 
rimonabant (Fig. 1): 0.16 µM for MRP1, 20 µM for MRP2, 0.08 µM for MRP3, and 0.12 µM 
for MRP4. In the case of MRP2, 20 µM substrate was used to measure both stimulation and 
inhibition.
Figure 3 shows the effect of 10 and 100 µM of the CB1 receptor antagonists on 
E
2
17βG transport by MRP1-4. Due to poor solubility, the actual concentrations of the 
3,4-diarylpyrazolines and rimonabant were 3- to 100-fold lower than the predicted 
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Figure 2 Kinetics of ATP-dependent E
2
17βG transport into membrane vesicles of 
HEK293 cells overexpressing MRP1-4
Concentration-dependent E
2
17βG transport was determined after 5 minutes for MRP1 (A), MRP2 
(B), MRP3 (C), and MRP4 (D). ATP-dependent eYFP values were subtracted from corresponding ATP-
dependent MRP values and K
m
 and V
max
 were determined by non-linear regression analysis. Data 
points represent the mean ± S.E.M. of triplicate measurements in a representative experiment.
Figure 3 Effect of CB1 receptor antagonists on ATP-dependent transport of E
2
17βG into 
MRP1-, MRP2-, MRP3-, or MRP4-overexpressing membrane vesicles
Transport was measured during five minutes at concentrations of 0.16, 20, 0.08, and 0.12 µM 
E
2
17βG, for MRP1 (A), MRP2 (B), MRP3 (C), and MRP4 (D), respectively, in the absence (white 
bars) or presence of CB1 receptor antagonists. Due to their poor solubility, concentrations in the 
low range varied between 0.4 and 2.2 µM (grey bars) and between 4 and 33 µM (black bars) 
for the 10-fold higher range. Actual concentrations of CB1 receptor antagonists corresponding 
to the grey bars were 2.2 µM for compound 4, 0.7-1.3 µM for 11-23, and 0.4 µM for rimonabant. 
Actual concentrations corresponding to the black bars were 33 µM for CB1 receptor antagonist 
4, 7 µM for 11-12, 12 µM for 13-14, 1-3 µM for 15-23, and 4 µM for rimonabant. ATP-dependent 
uptake in absence of CB1 receptor antagonists was set at 100% (white bar) and was also measured 
in presence of 100 µM E
2
17βG (black bar). Mean ± S.E.M. of three independent experiments is 
shown. Statistically significant differences from vehicle control: * p < 0.05, ** p < 0.01, and *** p 
< 0.001. 
Figure 3 on next page
A B
C D
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Figure 3 continued
A
B
C
D
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concentrations (see legend of Fig. 3). The highest concentration of the series of 
3,4-diarylpyrazolines inhibited MRP4 transport activity (Fig. 3D) more potently than MRP1 
(Fig. 3A). Of the 3,4-diarylpyrazolines, compounds 4, and 12-14 significantly inhibited 
MRP1- and MRP4-mediated E
2
17βG transport. Compound 13 had the highest inhibitory 
effect on both transporters, with -34 ± 13% and -72 ± 8% for MRP1 and MRP4, respectively. 
Transport of E
2
17βG by MRP1 and MRP4 was not inhibited by compounds 15-17, and 23, 
whereas compound 11 did inhibit MRP4, but not MRP1. Rimonabant inhibited MRP1 more 
potently than MRP4, viz. -84 ± 4% versus -58 ± 3% (Fig. 3A and 4D). In contrast to MRP1 and 
MRP4, MRP2 transport activity was stimulated by most compounds, at both concentrations 
tested (Fig. 3B). At the lower concentration, compounds 15-17 significantly increased 
uptake of E
2
17βG into MRP2 vesicles (256-305%). Stimulation of MRP2 was strongest at 
the high concentration of compounds 4-14 (543-734%) and less by 15-17 (349-412%) and 
rimonabant (513%). Compound 23 did not significantly increase transport. Figure 3C shows 
that, although E
2
17βG itself inhibited transport, MRP3-mediated E
2
17βG transport was 
significantly stimulated by rimonabant and most 3,4-diarylpyrazolines, of which 11 and 13 
had the highest stimulatory effect (approx. 155%).
Mechanism of modulation of MRP1-4 transport by compounds 13, 15, and rimonabant
To get a better understanding of the mechanism of interaction, we measured concentration-
dependent effects of certain CB1 receptor antagonists on MRP1-4 transport at three different 
E
2
17βG concentrations for each transporter (Fig. 4). 3,4-Diarylpyrazoline derivatives 13 and 
15, and rimonabant were selected for further investigation because the magnitude of their 
effects on the transport activity were different. 
Increasing E
2
17βG concentrations did not decrease the potency of 3,4-diarylpyrazolines 13 
and 15, and rimonabant for inhibiting MRP1 and MRP4 (Fig. 4A-C and 4J-L); the percentage 
of inhibition and the IC
50
 values of 13 and rimonabant for MRP4 and MRP1 were similar at 
different E
2
17βG concentrations. Dixon plots for 13- and rimonabant-mediated inhibition of 
MRP4 and MRP1 show that the lines intersected virtually at the x-axis for both compounds, 
which is indicative of non-competitive inhibition (Fig. 5A-C). The intersections corresponded 
to a Ki of approximately 1.4 µM of rimonabant for MRP1, 4 µM of rimonabant for MRP4, and 
7 µM of 13 for MRP4. 3,4-Diarylpyrazoline 15 did not inhibit MRP1 transport activity at any of 
the concentrations tested and only moderately inhibited MRP4 (Fig. 4A-C and 4J-L). 
MRP2-mediated transport was stimulated by compounds 13, 15, and rimonabant at the 
lowest E
2
17βG concentration of 2 µM (Fig. 4D). Stimulation was decreased at 20 µM E
2
17βG, 
and transport was inhibited at 200 µM of E
2
17βG (Fig. 4D-F). Rimonabant and 15 appeared to 
have the same stimulatory and inhibitory potency on MRP2-mediated transport.
MRP3-mediated  E
2
17βG transport was stimulated at low substrate concentration, which 
gradually disappeared at higher substrate concentrations (Fig. 4G-I). At a concentration of 
15 µM E
2
17βG, high concentrations of compounds 13, 15, and rimonabant inhibited E
2
17βG 
transport via MRP3 (data not shown). 
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Figure 4 Effect of CB1 receptor antagonists 13 (), 15 (, dotted line), and rimonabant 
() on MRP-mediated E
2
17βG transport at different substrate concentrations
E
2
17βG concentrations were 0.16 (A), 1 (B), and 5 µM (C) for MRP1. For MRP2, these were 2 (D), 
20 (E), and 200 µM (F), for MRP3 0.08 (G), 1 (H), and 5 µM (I), and for MRP4 0.1 (J), 0.3 (K), and 1 
µM (L). ATP-dependent transport was determined after five minutes for MRP1, MRP2, and MRP4, 
and after 2 minutes for MRP3. Transport rates were expressed as a percentage of uptake measured 
in the absence of the CB1 receptor antagonist tested against the log drug concentration. Two to 
three independent experiments were performed in duplicate. Mean ± S.E.M. of n = 3-6 is shown. 
A B C
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Figure 5 Dixon plots of inhibition of MRP1- 
and MRP4-mediated ATP-dependent 
E
2
17βG transport by rimonabant and 
3,4-diarylpyrazoline 13
The reciprocal of transport velocity (1/V) of 
different substrate concentrations is plotted 
against the inhibitor concentration. Dixon 
plots of inhibition of MRP1 (A) and MRP4 (B) 
by rimonabant, and of MRP4 by 13 (C) at three 
different E
2
17βG concentrations are shown ( 
0.16 µM,  1 µM, and  5 µM for E
2
17βG 
MRP1, and for MRP4,  0.1 µM,  0.3 µM, 
and  1 µM E
2
17βG). Linear regression analysis 
was used for plotting lines and determination 
of Ki. Data represent the mean 1/V of duplicate 
measurements in a representative experiment. 
In vivo pharmacodynamic effect of 3,4-diarylpyrazolines on CP55,940 induced hypotension 
in rat
To get an impression of the relative brain penetration of the 3,4-diarylpyrazolines, the CB1 
receptor-mediated blood pressure effect of compounds 4, 11, 14, and 15 was compared 
with their in vitro CB1 receptor binding affinity. For this purpose, in rats, the initial rapid 
effect was measured of CB1 receptor antagonists on CP55,940-induced hypotension, which 
is considered to originate primarily from a central sympathetic response.27 Table 2 describes 
the effective intravenous dose (ED
50
) that was needed for 50% inhibition of the hypotensive 
effect of CP55,940, and the binding affinity (expressed as Ki) of these compounds for the CB1 
receptor, as determined previously.18 The in vivo data show that CB1 receptor antagonist 15 
A
B
C
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had the lowest ED
50
 value. If the ED
50
 of 15 relative to its binding affinity is extrapolated to 
compounds 4, 11, and 14 on basis of their Ki values for the CB1 receptor, ED50 values of 0.14, 
0.02 , and 0.15 mg/kg, respectively, would have been expected. However,  the actual ED
50
 
values of compounds 4, 11, and 14 (Table 2) were  >2, about 10, and 4.7 times higher than 
expected, indicating a lower brain permeability compared to 15.
Discussion 
This study shows that CB1 receptor antagonists interacted with the efflux transporters MRP1, 
MRP2, MRP3, and MRP4. E
2
17βG was used as a model substrate to investigate the effect of 
CB1 receptor antagonists on transport activity of these transporters. The kinetic parameters 
for E
2
17βG found in this study were comparable with literature.28-30 Unlike MRP1, MRP3, and 
MRP4, MRP2 transported E
2
17βG in a positive cooperative manner, which was previously 
demonstrated by others.31, 32
Actual tested concentrations of the very lipophilic CB1 receptor antagonists in the 
experimental assays were determined by LC-MS/MS and were 3- to 100-fold lower than 
expected. This may be due to incomplete dissolution or non-specific binding. In our study, 
compounds 15-17 stimulated MRP2 better than compounds 4-14 at low concentrations. In 
contrast, the opposite was found at higher concentrations, where the actual concentrations 
of compounds 15-17 were lower (1-3 µM) than those of 4-14 (7-33 µM) (Fig. 3). This indicates 
that compounds 15-17, which contain N-substituents that make them more lipophilic, have 
a higher potency in affecting MRP2 but have a limited effect due to their low solubility. The 
same was found for MRP3, and the lack of effect of compounds 15-23 on MRP1 and MRP4 
might also be explained by their low actual concentrations.
Although we used E
2
17βG as a substrate for all transporters, the effect of the CB1 
Table 2 Pharmacodynamic characteristics of the CB1 receptor antagonists
Compound CB1 rb 
a 
Ki (nM)
ED
50
 (mg/kg, i.v.) b
4 223 ± 103 > 0.3
11 30 ± 14 0.2
14 231 ± 66 0.7
15 155 ± 69 0.1
a CB1 rb, displacement of specific CP55,940 binding in CHO cells stably 
transfected with human CB1 receptor, expressed as Ki ± S.E.M. (nM), adapted 
from Lange and colleagues.18
b Dose of CB1 receptor antagonist that attenuates CP55,940 induced 
hypotension in rats (n = 2 per dose) with 50%.
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receptor antagonists on transport of this substrate via MRP1-4 was different. MRP1- and 
MRP4-mediated transport was inhibited by several CB1 receptor antagonists. The inhibitory 
affinity of rimonabant was somewhat higher for MRP1-mediated E
2
17βG transport than for 
MRP4-mediated transport, with a Ki of approximately 1.4 µM versus 4 µM. The maximum 
plasma concentration found in male human subjects treated with a therapeutic dose of 
rimonabant is 0.4 µM.33 Rimonabant and 3,4-diarylpyrazoline 13 appeared to inhibit MRP1 
and MRP4 in a non-competitive manner (Fig. 5A-C). In addition, MRP1 and MRP4 were 
stimulated at low substrate and rimonabant concentrations, indicating that rimonabant 
probably does not compete for the E
2
17βG binding site of both transporters (Fig. 4A and 4J). 
Whether rimonabant and the 3,4-diarylpyrazolines are only inhibitors or also substrates of 
MRP1 or MRP4 cannot be concluded from this study.
In contrast to MRP1 and MRP4, MRP2-mediated transport was stimulated by all CB1 
receptor antagonists, except for compound 23. The results presented in this study suggest 
that 3,4-diarylpyrazolines and rimonabant stimulate MRP2 allosterically at low E
2
17βG 
concentrations and compete for the E
2
17βG binding site at high concentrations. This type of 
interaction is supported by other studies.31, 34, 35 The study of Zelcer et al. (2003) showed that 
several aromatic compounds, most of them containing sulfoxide or tosyl groups, stimulate 
MRP2-mediated transport of E
2
17βG into membrane vesicles. Compounds that normalized 
the stimulated transport rates at increasing concentrations, such as sulfinpyrazone 
and indomethacin, also appeared to be substrates for MRP2.31, 35 3,4-Diarylpyrazolines 
chemically resemble sulfinpyrazone, which, together with the fact that compounds 13, 
15, and rimonabant might compete with E
2
17βG at higher substrate concentrations, could 
indicate that they are substrates for MRP2.
The CB1 receptor antagonists had comparable effects on MRP3 transport activity, but 
their effects were less pronounced than for MRP2 (Fig. 4G-I). Other studies reported that 
MRP3-mediated E
2
17βG transport activity can be inhibited as well as stimulated by different 
compounds, e.g. E3040-sulfate, indomethacin, benzbromarone.32, 36, 37 This indicates that the 
3,4-diarylpyrazolines and rimonabant would interact with a modulating site and the substrate 
site of MRP3, causing stimulation of E
2
17βG transport at low substrate concentrations and 
inhibition at higher substrate concentrations due to competition for the substrate site.
Our results show that rimonabant and 3,4-diarylpyrazolines can modulate MRP1-4 
transport activity, which implicates the possibility of drug-drug interactions. Because of the 
brief clinical use of rimonabant, few data are available on its in vivo interaction potential 
with drug transporters.  Rimonabant was found to moderately affect the pharmacokinetics 
of the P-glycoprotein (P-gp/ABCB1) substrate cyclosporine A, but not of tacrolimus and 
digoxin.38, 39 
The pharmacokinetic data available for rimonabant do not suggest an important role for 
the MRPs in determining its disposition. Rimonabant is shown to accumulate in fat tissue, 
spleen, thyroid, thymus, liver, plasma, and brain and is reported to cross the placental 
barrier.40, 41 Although rimonabant showed a strong interaction with MRP1, its accumulation 
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in the brain and passage across the placental barrier indicates that it is either a poor 
substrate of this transporter, or MRP1 is not efficacious enough as a barrier for rimonabant.
MRP1 and MRP4 are expressed at the blood-brain barrier and the choroid plexus, 
where these transporters could be involved in limiting the brain penetration of the 
3,4-diarylpyrazoline CB1 receptor antagonists. Because there are only minor differences in 
the structures of the 3,4-diarylpyrazolines, the rate and extent of passive diffusion of these 
compounds into the brain and other tissues is expected to be similar, which should reflect 
in a similar relationship between ED
50
 and CB1 receptor binding affinity (Ki). However, there 
was a difference in ED
50
 values for compounds 4, 11, 14, and 15, which could not solely be 
attributed to differences in CB1 receptor binding affinities. The ED
50
 of compounds 4, 11, 
and 14 relative to their Ki values were higher as compared to the ED50/Ki ratio of compound 
15 (Table 2). This suggests that an active mechanism is lowering the concentration of 
compounds 4, 11 and 14 at the site of action, resulting in increased ED
50
 values. The rapid 
hypotensive action of CB1 receptor agonists was shown to be primarily dependent on 
centrally-mediated sympathetic tone, which could implicate that compounds 4, 11 and 14, 
but not 15, have a higher ED
50
 because they are less brain permeable.27 Our in vitro data 
suggest that MRP4 might be involved. To draw definite conclusions about the involvement 
of MRP1-4 in influencing tissue concentrations of 3,4-diarylpyrazolines, in vivo studies 
should be performed using specific transport inhibitors and/or Mrp knockout mice.
In addition, it will be important to measure direct transport of CB1 receptor antagonists 
by MRP1-4 in vitro. Isolated membrane vesicles are likely not useful for this purpose due to 
high nonspecific binding to lipid membranes and high passive diffusion of the lipophilic CB1 
receptor antagonists (unpublished results). Cell-based accumulation or vectorial transport 
studies may be more suitable. Furthermore, the role of the blood-brain barrier and intestinal 
ABC transporters P-gp and breast cancer resistance protein (BCRP/ABCG2) as possible CB1 
receptor antagonist efflux pumps should be investigated. The role of influx transporters 
should also be considered in the tissue distribution of the CB1 receptor antagonists, but 
it is to be expected that uptake of these lipophilic compounds will be governed largely by 
passive diffusion.
In conclusion, we have shown that 3,4-diarylpyrazolines and rimonabant inhibited 
MRP1- and MRP4-mediated E
2
17βG transport and stimulated MRP2- and MRP3-mediated 
transport at low E
2
17βG concentrations. Stimulation of MRP2 and MRP3 shifted to inhibition 
at increasing substrate concentrations. The effect of these compounds on the transport 
activity of MRP1-4 shows the potential for possible drug-drug interactions. Preliminary in vivo 
data suggested that MRP4 could be involved in the lower brain permeability of some of the 
3,4-diarylpyrazolines. The actual role of MRPs in tissue distribution of 3,4-diarylpyrazolines 
and rimonabant remains to be investigated. In addition, this study shows that the modulatory 
effects of the 3,4-diarylpyrazolines were influenced by the properties of their N-substituent, 
which indicates that small variations in their chemical structure can determine the affinity 
for the efflux transporters and thereby possibly affect their pharmacokinetic behavior.
42
Chapter 2
2
Acknowledgements
We thank Abbott Healthcare Products B.V. (formerly Solvay Pharmaceuticals) for providing 
the in vivo pharmacology data (Tiny J. P. Adolfs). We thank dr. Kevin Weigl (Abbott Products 
GmbH) for his critical reading of the manuscript. This work was funded by the Dutch Top 
Institute Pharma and was performed within the framework of project T5-105.
References
 
1. Di Marzo, V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov. Today 2008, 13, 
1026-1041.
2. Boyd, S. T.; Fremming, B. A. Rimonabant-a selective CB1 antagonist. Ann. Pharmacother. 2005, 39, 684-690.
3. Bifulco, M.; Santoro, A.; Laezza, C.; Malfitano, A. M. Cannabinoid receptor CB1 antagonists: state of the art 
and challenges. Vitam. Horm. 2009, 81, 159-189.
4. Jones, D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat. Rev. Drug Discov. 2008, 7, 
961-962.
5. Nissen, S. E.; Nicholls, S. J.; Wolski, K.; Rodés-Cabau, J.; Cannon, C. P.; Deanfield, J. E. et al. Effect of rimonabant 
on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the 
STRADIVARIUS randomized controlled trial. JAMA 2008, 299, 1547-1560.
6. Tam, J.; Vemuri, V. K.; Liu, J.; Bátkai, S.; Mukhopadhyay, B.; Godlewski, G. et al. Peripheral CB1 cannabinoid 
receptor blockade improves cardiometabolic risk in mouse models of obesity. J. Clin. Invest 2010, 120, 2953-
2966.
7. Zhou, S. F.; Wang, L. L.; Di, Y. M.; Xue, C. C.; Duan, W.; Li, C. G. et al. Substrates and inhibitors of human 
multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 2008, 
15, 1981-2039.
8. Yu, X. Q.; Xue, C. C.; Wang, G.; Zhou, S. F. Multidrug resistance associated proteins as determining factors of 
pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab 2007, 8, 787-802.
9. Kruh, G. D.; Belinsky, M. G. The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537-7552.
10. Flens, M. J.; Zaman, G. J.; van der Valk, P.; Izquierdo, M. A.; Schroeijers, A. B.; Scheffer, G. L. et al. Tissue 
distribution of the multidrug resistance protein. Am. J. Pathol. 1996, 148, 1237-1247.
11. Rao, V. V.; Dahlheimer, J. L.; Bardgett, M. E.; Snyder, A. Z.; Finch, R. A.; Sartorelli, A. C. et al. Choroid plexus 
epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the 
blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U. S. A 1999, 96, 3900-3905.
12. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and 
BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237.
13. Nies, A. T.; Jedlitschky, G.; König, J.; Herold-Mende, C.; Steiner, H. H.; Schmitt, H. P. et al. Expression and 
immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. 
Neuroscience 2004, 129, 349-360.
14. Nies, A. T.; Keppler, D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007, 453, 643-659.
15. van Aubel, R. A.; Hartog, A.; Bindels, R. J.; Van Os, C. H.; Russel, F. G. Expression and immunolocalization of 
multidrug resistance protein 2 in rabbit small intestine. Eur. J. Pharmacol. 2000, 400, 195-198.
16. Scheffer, G. L.; Kool, M.; de Haas, M.; de Vree, J. M.; Pijnenborg, A. C.; Bosman, D. K. et al. Tissue distribution 
and induction of human multidrug resistant protein 3. Lab Invest 2002, 82, 193-201.
17. Russel, F. G.; Koenderink, J. B.; Masereeuw, R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux 
transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 2008, 29, 200-207.
18. Lange, J. H.; van Stuivenberg, H. H.; Veerman, W.; Wals, H. C.; Stork, B.; Coolen, H. K. et al. Novel 
3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg. Med. 
Chem. Lett. 2005, 15, 4794-4798.
19. Conrad, S.; Kauffmann, H. M.; Ito, K.; Deeley, R. G.; Cole, S. P.; Schrenk, D. Identification of human multidrug 
resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 2001, 46, 
656-663.
20. Ito, S.; Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S.; Otsubo, K. Polymorphism of the ABC transporter genes, 
MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11, 175-184.
21. El-Sheikh, A. A.; van den Heuvel, J. J.; Koenderink, J. B.; Russel, F. G. Interaction of nonsteroidal anti-
43
CB1 receptor antagonists interact with MRP1-4
2
inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated 
methotrexate transport. J. Pharmacol. Exp. Ther. 2007, 320, 229-235.
22. El-Sheikh, A. A.; van den Heuvel, J. J.; Krieger, E.; Russel, F. G.; Koenderink, J. B. Functional role of arginine 375 
in transmembrane helix 6 of multidrug resistance protein 4 (MRP4/ABCC4). Mol. Pharmacol. 2008, 74, 964-
971.
23. Smeets, P. H.; van Aubel, R. A.; Wouterse, A. C.; van den Heuvel, J. J.; Russel, F. G. Contribution of multidrug 
resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of 
MRP4 (ABCC4) as a novel PAH transporter. J. Am. Soc. Nephrol. 2004, 15, 2828-2835.
24. van Aubel, R. A.; Smeets, P. H.; Peters, J. G.; Bindels, R. J.; Russel, F. G. The MRP4/ABCC4 gene encodes a novel 
apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP 
and cGMP. J. Am. Soc. Nephrol. 2002, 13, 595-603.
25. van Aubel, R. A.; Koenderink, J. B.; Peters, J. G.; Van Os, C. H.; Russel, F. G. Mechanisms and interaction 
of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance 
protein Mrp2 expressed in insect cells. Mol. Pharmacol. 1999, 56, 714-719.
26. Lange, J. H.; Coolen, H. K.; van Stuivenberg, H. H.; Dijksman, J. A.; Herremans, A. H.; Ronken, E. et al. Synthesis, 
biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and 
selective CB(1) cannabinoid receptor antagonists. J. Med. Chem. 2004, 47, 627-643.
27. Vollmer, R. R.; Cavero, I.; Ertel, R. J.; Solomon, T. A.; Buckley, J. P. Role of the central autonomic nervous system 
in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J. Pharm. Pharmacol. 
1974, 26, 186-192.
28. Loe, D. W.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. ATP-dependent 17ß-estradiol 17-(ß-D-glucuronide) 
transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem. 1996, 271, 
9683-9689.
29. Zeng, H.; Liu, G.; Rea, P. A.; Kruh, G. D. Transport of amphipathic anions by human multidrug resistance 
protein 3. Cancer Res. 2000, 60, 4779-4784.
30. Chen, Z. S.; Lee, K.; Kruh, G. D. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by 
multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 2001, 276, 
33747-33754.
31. Zelcer, N.; Huisman, M. T.; Reid, G.; Wielinga, P.; Breedveld, P.; Kuil, A. et al. Evidence for two interacting ligand 
binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 2003, 278, 
23538-23544.
32. Bodó, A.; Bakos, E.; Szeri, F.; Váradi, A.; Sarkadi, B. Differential modulation of the human liver conjugate 
transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 2003, 278, 23529-23537.
33. Turpault, S.; Kanamaluru, V.; Lockwood, G. F.; Bonnet, D.; Newton, J. Rimonabant pharmacokinetics in healthy 
and obese subjects. Clinical Pharmacology & Therapeutics 2006, 79, 50.
34. Bakos, E.; Evers, R.; Sinko, E.; Varadi, A.; Borst, P.; Sarkadi, B. Interactions of the human multidrug resistance 
proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 2000, 57, 760-768.
35. Evers, R.; de, H. M.; Sparidans, R.; Beijnen, J.; Wielinga, P. R.; Lankelma, J. et al. Vinblastine and sulfinpyrazone 
export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 2000, 83, 
375-383.
36. Akita, H.; Suzuki, H.; Hirohashi, T.; Takikawa, H.; Sugiyama, Y. Transport activity of human MRP3 expressed in 
Sf9 cells: comparative studies with rat MRP3. Pharm. Res. 2002, 19, 34-41.
37. Bodó, A.; Bakos, E.; Szeri, F.; Váradi, A.; Sarkadi, B. The role of multidrug transporters in drug availability, 
metabolism and toxicity. Toxicol. Lett. 2003, 140-141, 133-143.
38. Amundsen, R.; Asberg, A.; Robertsen, I.; Vethe, N. T.; Bergan, S.; Hartmann, A. et al. Rimonabant affects 
cyclosporine A, but not tacrolimus pharmacokinetics in renal transplant recipients. Transplantation 2009, 87, 
1221-1224.
39. Kanamaluru, V.; Lockwood, G.; Bonnet, D.; Newton, J. Lack of effect of rimonabant on the pharmacokinetics 
of digoxin. Journal of Clinical Pharmacology 2005, 45, 1081.
40. Barna, I.; Till, I.; Haller, J. Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and 
SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution 
within the brain. Eur. Neuropsychopharmacol. 2009, 19, 533-541.
41. EMEA. Scientific discussion about Accomplia (rimonabant), 2006. 
 Ref Type: Internet Communication

 Chapter 3
 
Exploiting transport activity of P-glycoprotein at the 
blood-brain-barrier for the development of peripheral 
cannabinoid type 1 receptor antagonists
Hanneke G.M. Wittgen1, Rick Greupink1, Jeroen J.M.W. van den Heuvel1, Petra H.H. van den 
Broek1, Heike Dinter-Heidorn2, Jan B. Koenderink1, Frans G.M. Russel1
1 Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical 
Centre, Nijmegen Centre for Molecular Life Sciences, the Netherlands
2 Abbott Products GmbH, Hannover, Germany
Published in Molecular Pharmaceutics, May 2012 (9), p. 1351-1360
Reproduced with permission from Molecular Pharmaceutics, March 2012, doi 10.1012/mp200617z.
Copyright © 2012 American Chemical Society.
46
Chapter 3
3
Abstract
Although the CB1 receptor antagonist/inverse agonist rimonabant has positive effects 
on weight loss and cardiometabolic risk factors, neuropsychiatric side effects have 
prompted researchers to develop peripherally acting derivatives. Here, we investigated 
for a series of 3,4-diarylpyrazoline CB1 receptor antagonists if transport by the brain efflux 
transporter P-gp could be used as a selection criterion in the development of such drugs. 
All 3,4-diarylpyrazolines and rimonabant inhibited P-gp transport activity in membrane 
vesicles isolated from HEK293 cells overexpressing the transporter, but only the 1,1-dioxo-
thiomorpholino analogue 23 exhibited a reduced accumulation (-38 ± 2%) in these cells, 
which could be completely reversed by the P-gp/BCRP inhibitor elacridar. In addition, 23 
appeared to be a BCRP substrate, whereas rimonabant was not. In rats, the in vivo brain/
plasma concentration ratio of 23 was significantly lower than for rimonabant (0.4 ± 0.1 vs. 
6.2 ± 1.6, p < 0.001). Co-administration of elacridar resulted in an 11-fold increase of the 
brain/plasma ratio for 23 (p < 0.01) and only 1.4-fold for rimonabant (p<0.05), confirming 
the involvement of P-gp and possibly BCRP in limiting the brain entrance of 23 in vivo. In 
conclusion, these data support the conception that efflux via transporters such as P-gp and 
BCRP can limit the brain penetration of CB1 receptor antagonists, and that this property 
could be used in the development of peripheral antagonists.
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Introduction
The cannabinoid type 1 (CB1) receptor is part of the endocannabinoid system, which is 
involved in regulation of feeding behavior, metabolism and energy balance.1 Stimulation 
of the CB1 receptor in animals increases food intake and promotes weight gain, whereas 
inhibition of the receptor has opposite effects.2 Therefore, several antagonists or inverse 
agonists of the CB1 receptor were developed for the treatment of obesity.2 Rimonabant 
[N-piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide] was the first and only selective CB1 receptor antagonist/inverse agonist 
approved for therapeutic use, after clinical studies had proved its positive effects on 
reduction of appetite, weight loss, and metabolic risk factors.2, 3 However, additional clinical 
studies revealed neuropsychiatric adverse effects, in particular depression, which led to 
withdrawal of the drug from the market within two years after its introduction.4, 5
In the brain, activation of the endocannabinoid system appears to be involved in coping 
with stress and anxiety. Therefore, the psychiatric side effects of rimonabant are generally 
thought to be due to central CB1 receptor antagonism.3 Although it is well established that 
CB1 receptor inhibition in the brain reduces food intake, the presence of CB1 receptors 
in peripheral tissues, such as adipose tissue, skeletal muscle, liver, gut, and pancreas, has 
also been postulated to play a role in metabolism and energy expenditure.1, 6 This implies 
that the positive effect on metabolic risk factors could also be mediated via peripheral 
CB1 receptors, which prompted the development of peripherally acting CB1 receptor 
antagonists.6, 7 Recently, it was shown in obese mice that selective inhibition of peripheral 
CB1 receptors indeed enabled the reduction of cardiometabolic risk factors, without the 
disturbing central nervous system side effects.8, 9
P-glycoprotein (P-gp, also known as MDR1/ABCB1) is one of the most important drug 
efflux transporters expressed at the luminal side of brain capillary endothelial cells that 
form the blood-brain barrier.10 P-gp is a member of the ATP-binding cassette (ABC) family 
and it transports a wide variety of substrates in an ATP-dependent manner.11 Studies with 
P-gp knockout mice showed that P-gp has an important role as gatekeeper of the brain.12 
This brain-penetration-limiting property of P-gp has been shown to be advantageous in the 
development of drugs such as domperidone and loperamide, that exert beneficial effects 
in the periphery, but would have unwanted side effects if also distributed to the brain.13-15 
Consequently, transport of CB1 receptor antagonists via P-gp might also be used as an 
instrument to limit their brain penetration.
In this study, we investigated whether in vitro transport affinity for P-gp can be used to 
select CB1 receptor antagonists with limited in vivo brain penetration. For this purpose, 
we studied the interaction of a series of 3,4-diarylpyrazoline CB1 receptor antagonists (Fig. 
1)16 and the prototypic CB1 receptor antagonist rimonabant with P-gp transport activity 
in membrane vesicles overexpressing the transporter. We then determined whether the 
compounds were substrates of P-gp, using a cellular accumulation assay, and for one 
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selected 3,4-diarylpyrazoline CB1 receptor antagonist we compared its brain penetration to 
rimonabant in rats, with and without coadministration of a potent P-gp inhibitor.
Materials and methods
Materials
[3H]N-methyl quinidinium chloride ([3H]NMQ) (85 Ci/mmol) and N-methyl quinidine (NMQ) 
were purchased from Solvo Biotechnology (Szeged, Hungary). Bac-to-Bac and Gateway 
system, and Dulbecco Eagle’s modified medium (DMEM) + Glutamax-I culture medium 
were from Invitrogen (Breda, the Netherlands). Fetal calf serum was purchased from 
Greiner (Alphen a/d Rijn, the Netherlands), triple flasks (500 cm2) from Sanbio BV Biological 
Products (Uden, the Netherlands), and rat tail collagen (type I) from First Link Limited (United 
Figure 1 Chemical structure of 3,4-diarylpyrazoline CB1 receptor antagonists 4, 11-17, 
23, and rimonabant 
CB1 receptor affinity (Ki) values of the compounds have been described previously.
16 
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Kingdom). Hank’s Balanced Salt Solution (HBSS), optiMEM and 100x penicillin/streptomycin 
solution were purchased from Invitrogen (Breda, the Netherlands). Quinidine, adenosine 
5’-triphosphate magnesium salt (from bacterial source), adenosine 5’-monophosphate 
monohydrate (from yeast), and sodium butyrate were purchased from Sigma-Aldrich 
(Zwijndrecht, the Netherlands), and elacridar (GF120918) from Sequoia Research Products 
Limited (Pangbourne, United Kingdom). Protein concentrations were determined with a Bio-
Rad protein assay kit from Bio-Rad Laboratories (Veenendaal, the Netherlands). Monoclonal 
mouse-anti-human P-gp antibody C219 was purchased from Abcam (Cambridge, UK). 
Racemic mixtures of 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine 
derivatives 4, 11-17, and 23 (purity >95%, except for 15 and 17 it was 90%)16, in this paper 
referred to as 3,4-diarylpyrazoline CB1 receptor antagonists, and rimonabant (purity >95%), 
were kindly provided by Abbott Products GmbH (Hannover, Germany).
Generation of baculovirus
Full-length human P-glycoprotein (MDR1) was cloned from human kidney cDNA into the 
Gateway pDONR221 vector. The sequence of P-gp was equal to GenBank accession number 
NM_000927, except for one silent mutation at bp 1235. Subsequently, the P-gp construct 
was cloned into a VSV-G improved pFastBacDual vector for mammalian cell transduction 
using the Gateway system.17 Full-length human enhanced yellow fluorescent protein (eYFP) 
was cloned as described previously.17 Baculoviruses were produced using the Bac-to-Bac 
system, as described by the manufacturer (Invitrogen).
Cell culture
HEK293 cells were grown in DMEM-Glutamax-I supplemented with 10% fetal calf serum at 
37°C under 5% CO
2
-humidified air. MDCKII and MDCKII-BCRP cells18 were grown in DMEM-
Glutamax-I supplemented with 10% fetal calf serum and 50 U/ml penicillin and 50 µg/ml 
streptomycin at 37°C under 5% CO
2
-humidified air.
Transduction of HEK293 cells with P-gp
For the production of membrane vesicles, HEK293 cells were cultured in 500 cm2 triple 
flasks until 40% confluent, after which culture medium was removed and 25 ml medium and 
10 ml eYFP or P-gp baculovirus was added. Cells were incubated for 15 min at 37°C, after 
which a further 40 ml medium was added. 5 mM sodium butyrate was added 4-8 hours after 
transduction. Three days after transduction, cells were harvested by centrifugation at 3500g 
for 10 minutes. For the accumulation assay, 24-wells plates were coated with a 100 µg/ml 
rat tail collagen (type I) solution for at least two hours at 37°C. Coating was washed with 
phosphate-buffered saline once, and HEK293 cells were seeded 150,000 cells/well. Next 
day, cells were transduced with eYFP or P-gp virus, using 100 µl virus:medium mixture (2:3). 
After 15 minutes of incubation at room temperature, 400 µl medium and sodium butyrate 
was added up to 5 mM. Three days after transduction, the experiment was performed.
50
Chapter 3
3
Isolation of membrane vesicles and protein analysis
Membranes were isolated according to a previously described method.19 In brief, harvested 
cell pellets were lysed in ice-cold homogenization buffer supplemented with protease 
inhibitors at 4°C for 30 minutes. Lysed cells were centrifuged at 100,000g for 30 min at 
4°C, and the pellets were homogenized in ice-cold TS buffer (10 mM Tris-HEPES, and 
250 mM sucrose, pH 7.4) supplemented with protease inhibitors, using a tight-fitting 
Dounce homogenizer for 25 strokes. After centrifugation at 1000g for 20 minutes at 4°C, 
the supernatant was centrifuged at 100,000g for 60 min at 4°C. The resulting pellet was 
resuspended in TS buffer without protease inhibitors and passed through a 27-gauge needle 
25 times. Protein concentration was determined using the Bio-Rad protein assay kit. Crude 
membrane vesicles were dispensed in aliquots, frozen in liquid nitrogen, and stored at -80°C 
until further use.
Western blotting
HEK293-ctrl and -P-gp cell pellets were lysed in ultrapure water containing DNAse I (20 
U/µl) (Invitrogen) and Complete mini protease inhibitor cocktail (Roche Diagnostics, 
the Netherlands). A 40 µg protein sample of cell lysate and 15 µg of membrane vesicles 
were solubilized in SDS-polyacrylamide gel electrophoresis buffer and separated on SDS 
gel, containing 7.5% acrylamide, according to Laemmli. Subsequently, they were blotted 
on nitrocellulose membrane using the iBlot dry blotting system (Invitrogen). Monoclonal 
mouse-anti-human P-gp (C219, 1:250), followed by incubation with the secondary antibody 
fluorescent goat-anti-mouse IRdye800 (1:10000) (Rockland Immunochemicals, Gilbertsville, 
USA) was used for detection of P-gp. Signal was visualized using the Odyssey imaging system 
(Li-Cor Biosciences, Lincoln, NE).
Vesicular transport interaction assay
The effect of 3,4-diarylpyrazolines and rimonabant on P-gp-mediated [3H]NMQ uptake 
was measured in P-gp-overexpressing membrane vesicles. Uptake of [3H]NMQ into 
membrane vesicles was performed using a rapid filtration technique.20 The 30 µl reaction 
mix consisted of TS buffer, 4 mM ATP, 10 mM MgCl
2
, 7.5 µg of membrane vesicles, 0.015 
µCi [3H]NMQ supplemented with unlabeled NMQ to 100 nM, and 0, 10, or 100 µM of CB1 
receptor antagonist. The reaction was started when the mixture was incubated at 37°C, 
and stopped after two minutes by placing samples on ice and adding 150 µl of ice-cold TS 
buffer. A Multiscreen
HTS
 HV, 0.45 µM, glass fiber 96-well filter plate was prewashed with 
TS buffer and diluted samples were filtered through this filter plate using a Multiscreen
HTS
-
Vacuum Manifold filtration device (Millipore, Etten-Leur, the Netherlands). The filters were 
washed twice with TS-buffer and were then separated from the plate. After addition of 2 
ml of scintillation fluid to each filter and subsequent liquid scintillation counting, uptake of 
[3H]NMQ into membrane vesicles was determined by measuring radioactivity associated 
with the filters, and uptake of total NMQ was calculated. In control experiments, ATP was 
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substituted with AMP. Net ATP-dependent transport was calculated by subtracting values 
measured in the presence of AMP from those measured in the presence of ATP. 
Accumulation assay in HEK293-P-gp cells
To determine whether the 3,4-diarylpyrazolines or rimonabant were substrates of P-gp, we 
investigated the accumulation of these compounds in HEK293 cells overexpressing P-gp or, 
as negative control, eYFP, in a 24-wells plate. Cells were washed once with Tris-HEPES buffer 
(10 mM HEPES, 132 mM NaCl, 4.2 mM KCl, 1 mM CaCl
2
, 1 mM MgCl
2
, 5.5 mM D(+)-glucose, 
calibrated to pH 7.4 using 1M Tris solution), before incubation with Tris-HEPES buffer 
containing 1 µM CB1 receptor antagonists or quinidine, a well-known P-gp substrate, in 
absence or presence of 2 µM elacridar. After one hour at 37°C, cells were washed once with 
Tris-HEPES buffer containing 0.5% BSA, and washed twice with Tris-HEPES buffer. Cells were 
lysed using 1 ml 50% acetonitrile + internal standard (one of the CB1 receptor antagonists 
or NMQ) + 0.1% trifluoroacetic acid. Protein was precipitated for 30 minutes at -20°C, and 
samples were centrifuged for 5 minutes at 16,000g. Supernatant was analyzed using LC-MS/
MS analysis.
Accumulation assay in MDCKII-BCRP cells
To determine whether 23 and rimonabant were substrates of BCRP, we investigated 
accumulation of these compounds into MDCKII (control) and MDCKII-BCRP cells. Cells 
were grown until 100% confluency in 24-wells plates and washed once with HBSS before 
30 minute preincubation with optiMEM. After preincubation, cells were incubated with 
optiMEM containing 1 µM of 23 or rimonabant in absence or presence of 2 µM elacridar. 
After one hour at 37°C, cells were washed twice with HBSS + 0.5% BSA, and twice with HBSS. 
Cells were lysed using 1 ml 50% acetonitril + internal standard (17 or rimonabant) + 0.1% 
trifluoroacetic acid. Protein was precipitated for 30 minutes at -20°C, and samples were 
centrifuged for 5 minutes at 16,000g. Supernatant was analyzed using LC-MS/MS analysis.
Experimental animals
Male Wistar rats (Charles River, Kisslegg, Germany) of 250–450 g were housed under a 12 h 
dark/light cycle at constant humidity and temperature. Animals were permitted free access 
to tap water and standard lab chow. All experiments were approved by the committee for 
care and use of laboratory animals of Abbott Products GmbH in Ludwigshafen and were 
performed according to strict governmental and international guidelines.
Effect of P-gp on disposition of 23, rimonabant, and quinidine in rat brain
Elacridar and 23 were dissolved in ethanol/PEG400/5% glucose solution  (20:60:20), 
rimonabant was dissolved in ethanol/PEG-25 hydrogenated castor oil/water (10:10:80), and 
quinidine was dissolved in 5% dextrose solution. Male Wistar rats (n = 24) were anaesthetized 
using isoflurane, and divided in two groups (n = 12), of which one group was injected 
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intravenously with the P-gp inhibitor elacridar (6 mg/kg). 30 minutes after treatment with 
elacridar or vehicle, each group was divided in three groups, and was injected intravenously 
with rimonabant (1 mg/kg), 23 (1 mg/kg), or quinidine (10 mg/kg) (n = 4 for each group). One 
hour after injection of the test compounds, animals were sacrificed and plasma and brain 
were collected. PBS was added to the brain (8v:w) and tissue was homogenized using the 
Geno/Grinder (Spex Sample Prep, USA). Proteins in samples were precipitated by addition 
of 400 µl acetonitrile (with internal standard) to 100 µl brain homogenate or 50 µl plasma, 
and samples were centrifuged at 2000g for 10 minutes. Supernatant was 1:1 diluted with 
10 mM ammonium acetate (pH 3) and the concentration of 23, rimonabant, quinidine, and 
elacridar in brain and plasma was determined using LC-MS/MS. Subsequently, the brain/
plasma concentration ratios were calculated for the different treatment groups. 
LC-MS/MS quantification of CB1 receptor antagonists
Concentrations of the CB1 receptor antagonists and quinidine in the cell accumulation 
assays were measured using an Accela U-HPLC (Thermo Fisher Scientific) coupled to a TSQ 
Vantage (Thermo Fisher Scientific) triple quadropole mass spectrometer.  The compounds 
were separated on a Zorbax Eclipse Plus C18 column (50 x 2.1 mm, 1.8 µm particle size; 
Agilent), preceded by a Zorbax Eclipse Plus C18 Guard column (12.5 x 1.2 mM, 5 µM). The 
elution gradient was as follows: 0 min 50% B, 5 min 90% B, 6 min 50% B for the CB1 receptor 
antagonists, and 0 min 10% B, 3 min 40% B, 4 min 10% B, 9 min 10% B for quinidine and 
NMQ. Solvent A consisted of 0.1% trifluoroacetic acid (TFA) in ultrapure water and solvent B 
consisted of 0.1% TFA in acetonitrile. The column temperature was set at 40°C and the flow 
rate was 200 µl/min. The effluent from the HPLC was passed directly into the electrospray 
ion source. The capillary temperature was set at 350°C. Positive electrospray ionization 
was achieved using a nitrogen sheath gas with ionization voltage at 4 kV. For the in vivo 
experiment, the concentrations of 23, rimonabant, quinidine, and elacridar were measured 
using an Ab Sciex 5500 Qtrap and compounds were separated on a Phenomenex Kinetex 
C18 column (2.1 x 30 mm, 2.6 µm particle size). The elution gradient was: 0 min 1% B, 
0.4 min 99% B, 1.5 min 99% B, 1.51 min 1% B. Solvent A consisted of 10 mM ammonium 
acetate (pH 3) and solvent B of 100% acetonitrile. Flow rate was 900 µl/min, and the 
capillary temperature was set at 950°C. Positive electrospray ionization was achieved 
using a nitrogen sheath gas with ionization voltage at 5.5 kV. Detection of each analyte 
was based on isolation of the protonated molecular ion, [M+H]+, and subsequent MS/MS 
fragmentations and a selected reaction monitoring (SRM) were carried out (Table 1). Brain 
concentration (ng/g) was divided by the plasma concentration (ng/ml) to obtain the brain/
plasma concentration ratio.
Calculation of physicochemical characteristics of test compounds
The physicochemical characteristics in Table 3 were calculated using add-ins in the program 
ChemBio3D Ultra version 12.0 (Cambridge Software). For the octanol:water participation 
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coefficient (cLogP) the add-in CambridgeSoft cLogP: partition coefficient was used. For the 
calculated polar surface area (cPSA) we used the add-in CambridgeSoft Molecular Topology: 
molecular polar surface area. 
Kinetic analysis
All data were expressed as mean ± S.E.M. Statistical difference for all experiments, except 
the vesicular transport assays, were determined using an unpaired Student’s t-test in 
Graphpad Prism software (version 5.02; Graphpad Software Inc., San Diego, CA). For the 
vesicular transport data, a one-way analysis of variance with Dunnett’s multiple comparison 
test was performed using GraphPad Prism. Differences were considered to be significant at 
p < 0.05. 
Results
Expression of P-gp in HEK293 cells
Immunoblot analysis performed on lysate and membrane vesicles from HEK293 cells 
confirmed the successful overexpression of P-gp (Fig. 2). The prototypic P-gp substrate 
N-methyl quinidine (NMQ) was taken up into these vesicles in an ATP-dependent fashion, 
Table 1 LC-MS/MS conditions for detection of the compounds studied
Compound Parent
(m/z)
Product 1
(m/z)
Product 2
(m/z)
Product 3
(m/z)
4 420 255 375
11 448 255 375
12 448 255 375
13 434 255 375
14 446 255 375
15 474 255 375
16 488 255 375
17 478 255 375
23 510 255a 375
rimonabant 463 299 363a
quinidine 325 172 307 160a
NMQ 339 58 160
elacridar 564 167a
a Product ion used for quantification of test compounds for in vivo experiment.
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Cell lysate (A) or membrane vesicles (B) of HEK-ctrl (ctrl) and HEK-P-gp (P-gp) cells were used for 
blotting.
Figure 3 Effect of CB1 receptor antagonists on ATP-dependent transport of NMQ into 
P-gp-overexpressing membrane vesicles
Transport was measured after two minutes at a concentration of 100 nM NMQ in the absence 
(white bar) or presence of CB1 receptor antagonists (black and grey bars). Due to their poor 
solubility, concentrations in the low range varied between 0.4 and 2.2 µM (grey bars) and for the 
10-fold higher range between 4 and 33 µM (black bars). Actual concentrations of CB1 receptor 
antagonists corresponding to the grey bars were 2.2 µM for 4, 0.7-1.3 µM for 11-23, and 0.4 µM 
for rimonabant. Actual concentrations corresponding to the black bars were 33 µM for 4, 7 µM 
for 11-12, 12 µM for 13-14, 1-3 µM for 15-23, and 4 µM for rimonabant. ATP-dependent uptake 
in absence of CB1 receptor antagonists was set at 100% (white bar) and was also measured in 
presence of 100 µM NMQ (black bar). Mean ± S.E.M.of three independent experiments is shown. 
Statistically significant differences from vehicle control were determined with one-way ANOVA, 
and a post-hoc Dunnett’s test: * p < 0.05, ** p < 0.01, and *** p < 0.001.
A
B
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and absolute transport values of NMQ without inhibitor varied between 8 and 28 pmol mg-1 
min-1, dependent on the batch of vesicles used (Fig. 3).
Effects of 3,4-diarylpyrazoline CB1 receptor antagonists and rimonabant on P-gp-mediated 
NMQ transport into membrane vesicles
To investigate whether the CB1 receptor antagonists interact with P-gp, we studied their 
effects on P-gp-mediated transport. In Figure 3, the effect of 10 and 100 µM of the CB1 
receptor antagonists on ATP-dependent NMQ transport by P-gp is shown. Previously, we 
have reported that the actual concentrations of these compounds in the assay are 3- to 
100-fold lower because of their poor water solubility (see legend of Fig. 3).19 Nevertheless, 
even at these low concentrations, significant inhibition could be detected. At the lowest 
concentration tested, 15-17 and rimonabant inhibited P-gp transport by 67 ± 3%, 73 ± 1%, 
53 ± 5%, and 79 ± 1%, respectively, whereas 4, 11-14, and 23 had no or only little inhibitory, 
or even stimulatory effects. At the highest concentration, all compounds inhibited NMQ 
transport almost completely, except for 23, which only inhibited transport by 59 ± 20% (Fig. 
3). 
Identification of CB1 receptor antagonists that are substrates of P-gp in vitro
To identify whether the 3,4-diarylpyrazolines or rimonabant were transported via P-gp, the 
accumulation of 1 µM of these compounds in HEK293 cells overexpressing P-gp (HEK293-
P-gp) or HEK293 control cells (HEK293-ctrl) was measured. Functional transport activity of 
P-gp in this assay was established by means of the control substrate quinidine, of which the 
accumulation was reduced to 34 ± 0.7% in HEK293-P-gp cells compared to HEK293-ctrl cells 
(Fig. 4K and Table 2). Next, we investigated the accumulation of the 3,4-diarylpyrazolines, 
and showed that accumulation of 23 in HEK293-P-gp cells was reduced significantly to 62 
± 2% compared to HEK293-ctrl cells (p<0.001), whereas the cellular accumulation of the 
other CB1 receptor antagonists, including rimonabant, was not significantly reduced (Fig. 
4A-J, and a summary of normalized data in Table 2). The P-gp inhibitor elacridar, which had 
no effect on accumulation of quinidine and 23 in HEK293-ctrl cells, reversed the reduced 
accumulation of both quinidine and 23 in HEK293-P-gp cells to the levels found in HEK293-
ctrl cells (Fig. 5).
Accumulation of 23 and rimonabant in MDCKII-BCRP cells
Since elacridar is an inhibitor of not only P-gp but also of the brain efflux transporter breast 
cancer resistance protein (BCRP)21, we studied whether 23 and rimonabant are BCRP 
substrates. We measured the accumulation of 1 µM of these compounds in MDCKII cells 
overexpressing BCRP (MDCKII-BCRP) or control MDCKII cells (Fig. 6). Overexpression of 
BCRP significantly reduced the accumulation of 23 to 63 ± 10% of control cells, which could 
be reversed by addition of elacridar (Fig. 6A). There was no effect of BCRP overexpression or 
inhibition on rimonabant accumulation (Fig. 6B).
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Figure 4 Accumulation of CB1 receptor antagonists in HEK293 cells overexpressing P-gp 
or a control protein
Accumulation was measured after one hour of exposure to the compounds at 37°C. 1 µM of 4 (A), 
11 (B), 12 (C), 13 (D), 14 (E), 15 (F), 16 (G), 17 (H), 23 (I), rimonabant (J) or quinidine (K), a known 
P-gp substrate, was used. Each experimental condition was performed in triplicate and mean ± 
S.E.M. of a representative experiment from three independent experiments is shown. Statistical 
significance of accumulation in P-gp versus control condition was determined using an unpaired 
Student’s t-test: ** p = 0.0034, and *** p < 0.0001.
A B C D
E F G H
J KI
57
P-gp efflux limits brain penetration of CB1 receptor antagonists
3
Table 2 Accumulation of CB1 receptor antagonists in HEK293 cells overexpressing P-gp 
Figure 5 Effect of elacridar on P-gp-mediated transport of quinidine and 23
Accumulation of quinidine (A) and 23 (B) into HEK293 cells overexpressing P-gp or control protein 
was determined after one hour of exposure to 1 µM of quinidine or 23 in absence (black bar) or 
presence (white bar) of 2 µM elacridar. Mean ± S.E.M. of seven (quinidine) or eight (23) independent 
experiments in triplicate are shown. Statistical significant differences were determined using an 
unpaired Student’s t-test: * p = 0.022, and *** p < 0.0001 compared to control condition, # p < 
0.0001, and ^ p = 0.012 compared to condition without elacridar.
Compound Accumulation in P-gp cells
vs. control (%)a
Ratio control:P-gp
quinidine 34 ± 0.8*** 2.9
4 100 ± 5.5 1.0
11 103 ± 5.5 1.0
12 101 ± 3.5 1.0
13 100 ± 3.4 1.0
14 110 ± 7.3 1.0
15 100 ± 0.7 1.0
16 102 ± 2.4 1.0
17 102 ± 3.9 1.0
23 62 ± 2.2*** 1.6
rimonabant 102 ± 3.6 1.0
a Mean ± S.E.M. of normalized values of three independent experiments.
*** p < 0.001 compared to control (100 ± 0%) using one-way ANOVA test.
A B
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Effect of elacridar on brain penetration of 23 and rimonabant in rats
Blood-brain barrier penetration of 23 and rimonabant was determined by measuring their 
brain and plasma concentrations one hour after i.v. administration to rats in the absence or 
presence of elacridar. Quinidine was included in the experiment to verify the P-gp inhibitory 
action of elacridar. Plasma concentration of elacridar at the end of the experiment was 730 
± 60 nM, which is expected to have almost completely inhibited the in vivo P-gp transport 
during the experiment.22 In absence of elacridar, the concentration of 23 in the brain was 
significantly lower than that of rimonabant, 0.048 ± 0.007 nmol/g versus 0.33 ± 0.09 nmol/g 
(p = 0.016) (Fig. 7A), whereas the plasma concentration of 23 was higher, although not 
significantly, than that of rimonabant, 114 ± 22 nM and 60 ± 50 nM, respectively (p = 0.17) 
(Fig. 7B). Administration of elacridar did not affect the plasma concentrations of 23 and 
rimonabant (Fig. 7B), but it did induce an 11-fold increase in brain/plasma concentration 
ratio of 23, from 0.4 ± 0.1 to 4.7 ± 0.9 (p < 0.001) (Fig. 7D), which was comparable to the 
10-fold increase of quinidine brain/plasma ratio (p = 0.009) (Fig. 7C). The brain/plasma ratio 
of rimonabant was already 16-fold higher than that of 23 in absence of elacridar (p < 0.001), 
and was only 1.4-fold increased from 6.2 ± 1.6 to 8.7 ± 0.6 after administration of elacridar 
(p = 0.026) (Fig. 7D). 
Figure 6 Effect of elacridar on accumulation of 23 and rimonabant in MDCKII and 
MDCKII-BCRP cells
Uptake was measured after one hour of exposure to 1 µM of 23 (A) or rimonabant (B) in absence 
(black bar) or presence (white bar) of 2 µM of the P-gp/BCRP inhibitor elacridar. Mean ± S.E.M. 
of three independent experiments in triplicate are shown. Statistical significant differences were 
determined using an unpaired Student’s t-test: * p = 0.021 compared to control condition, and ^ p 
= 0.0008 compared to condition without elacridar.
A B
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Figure 7 The effect of elacridar on the brain penetration of 23, rimonabant and 
quinidine in rats
Half of the rats was injected intravenously with elacridar (6 mg/kg) 30 minutes prior to intravenous 
injection of quinidine (10 mg/kg), 23 (1 mg/kg) or rimonabant (1 mg/kg). Concentration of 
the compounds in plasma and brain was measured one hour after administration of the test 
compound. (A) Brain concentrations of 23 and rimonabant in absence of elacridar. Mean ± S.E.M. 
of 4 rats is shown. Statistical analysis was performed using an unpaired Student’s t-test: * p = 
0.0163. (B) Plasma concentrations of 23 and rimonabant in absence (black bar) and presence 
(white bar) of elacridar. Mean ± S.E.M. of 4 rats is shown, except for 23 with elacridar (n = 3). 
Statistical analysis using an unpaired Student’s t-test showed no significant differences. (C and D) 
Brain/plasma concentration ratio of quinidine (C) and 23 and rimonabant (D) in absence (black 
bar) or presence (white bar) of elacridar. Mean ± S.E.M. of 4 rats is shown, except for 23 with 
elacridar (n = 3). Statistical analysis was performed using an unpaired Student’s t-test: * p = 0.026, 
** = 0.0087, and  *** p = 0.0002 when compared to condition without elacridar, # p = 0.0004 when 
compared to brain/plasma ratio of 23 without elacridar.
A B
C D
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Discussion
To circumvent the neuropsychiatric side effects of CB1 receptor antagonists, but maintain 
their beneficial cardiometabolic action, peripherally acting derivatives are being developed. 
In this study, we showed that the drug efflux transporter P-gp and, possibly, BCRP is involved 
in limiting the brain penetration of 3,4-diarylpyrazoline CB1 receptor antagonists, and that 
transport of a compound via P-gp can be used as a selection criterion in the development of 
peripheral CB1 receptor antagonists.
The inhibitory effect of the CB1 receptor antagonists on P-gp transport activity was 
measured to get an indication whether these compounds interact with the transporter and 
are possible substrates. We demonstrated that all 3,4-diarylpyrazolines and rimonabant 
inhibited P-gp-mediated transport in membrane vesicles (Fig. 3), indicating interaction of 
the compounds with P-gp. However, the accumulation assays in HEK293-ctrl and -P-gp cells 
revealed that only 23 was a substrate of P-gp, because the accumulation of this compound 
was significantly reduced in P-gp overexpressing cells (Fig. 4I), and could be reversed to 
control levels with the P-gp inhibitor elacridar23 (Fig. 5B). Interestingly, rimonabant, which 
did not appear to be a substrate in the cell assay (Fig. 4J), was the most potent inhibitor 
of P-gp in the vesicular transport assay (Fig. 3), whereas 23 was a less potent inhibitor and 
a good substrate. This shows that inhibition of a compound in the vesicular interaction 
assay does not necessarily implicate its P-gp substrate activity. A better prediction could 
be achieved if the assay is also used to determine the mode of inhibition, differentiating 
between competitive (interaction with substrate binding pocket) and noncompetitive 
inhibitors (allosteric modulators that are less likely to be substrates).
Because the interaction with P-gp per se does not seem to be sufficient for the CB1 
receptor antagonists to be transported, we further examined the structural features 
of the P-gp substrate 23. This suggested that an electronegative group in addition to a 
heterocyclic ring structure, both present in the 1,1-dioxo-thiomorpholine group of this 
compound, are important for transport of these pyrazole CB1 receptor antagonists via 
P-gp. Other studies further support this theory, as the peripheral CB1 receptor antagonist 
AM6545 [5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-
dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide], which contains exactly the same 
substituent as 23, is also a P-gp substrate.8 In addition, another study showed that adding an 
electronegative group, either methylsulfanyl, -sulfinyl, or -sulfonyl,  to the imidazole core of 
similar CB1 receptor antagonists improved their transport via P-gp.24 This knowledge could 
be used to optimize P-gp substrate affinity among this class of CB1 receptor antagonists.
As 23 appeared to be a substrate of P-gp, this compound was selected for a pharmacokinetic 
interaction study with elacridar in rats, to verify whether P-gp is also relevant in limiting its 
brain concentration in vivo. Because 23 also appeared to be a BCRP substrate, the effect of 
the mixed P-gp/BCRP inhibitor elacridar on brain penetration could have also been the result 
of BCRP inhibition (Fig. 6). Rimonabant, which was neither a P-gp nor a BCRP substrate, and 
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which is known to distribute to the brain8, 25, served as a positive control for brain penetration. 
Indeed, the brain/plasma ratio of 23 was lower than that of rimonabant, and was largely 
increased by elacridar, whereas the inhibitor had only minor effects on the brain/plasma 
ratio of rimonabant (Fig. 7). Together with the data from the cellular accumulation assays, 
this suggests that P-gp, and possibly BCRP, are the limiting factors for brain penetration of 23 
and not of rimonabant. Because P-gp is more abundant than BCRP at the blood-brain barrier 
of rats, and the potency of elacridar for BCRP inhibition is about 10- to 70-fold lower than 
for P-gp inhibition, the effect of BCRP on the brain penetration of 23 might have been less 
important, implicating a major role for P-gp in limiting the brain concentration of 23.22, 26-28 
However, because BCRP is more abundantly expressed in human than in rodent blood-brain 
barrier, it would be interesting to investigate the possibility to select for BCRP substrate 
activity in addition to P-gp activity to further reduce brain penetration of peripheral CB1 
receptor antagonists.29
The difference between 23 and the other CB1 receptor antagonists is not only the P-gp 
transport affinity but also the polar surface area of this compound. Compounds with a PSA 
over > 90 are considered to have a low probability to cross the blood-brain barrier.24, 30, 31 
Addition of the electronegative group dramatically increases the polar surface area (PSA) of 
23 (Table 3). Indeed, the brain/plasma ratio of 23 was much lower than that of rimonabant. 
However, the dramatic effect of elacridar on the brain/plasma ratio of 23, increasing the 
ratio to the level of rimonabant, suggests that active transport plays a dominant role over 
PSA in determining the blood-brain barrier passage of 23.
Table 3 Calculated physicochemical properties of the CB1 receptor antagonists
Compound cLogP a cPSAb
(Å2)
4 2.69 77
11 3.74 77
12 3.53 77
13 3.22 77
14 4.02 77
15 5.13 77
16 5.69 77
17 4.70 77
23 3.00 112
rimonabant 6.47 48
a calculated octanol:water partition coefficient 
b calculated polar surface area
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A general problem of using P-gp transport activity as a strategy to develop peripheral 
CB1 receptor antagonists could be a low oral absorption, because of the expression of P-gp 
in the intestine.32 However, the oral availability of the structurally related peripheral CB1 
receptor antagonist and P-gp substrate AM6545 was not restricted by P-gp as its plasma 
concentration was similar after oral and peritoneal dosing.8 Furthermore, in the CaCo-2 cell 
model for oral availability, AM6545 had an efflux ratio of 1.1, which indicates that absorption 
is not limited by active transport.8 After oral administration, local drug concentrations in the 
intestine could reach high levels that saturate P-gp and limit its impact on absorption.33 This 
contrasts to the situation at the blood-brain barrier where a much lower concentration of 
the compound will be presented to P-gp via the plasma.33 Cellular assays to estimate the 
intestinal penetration have also been performed with the CB1 receptor antagonists from 
this study, and the efflux ratio for 23 in CaCo-2 cells was 1.5, and 28% of the dose passed 
a monolayer of LLC-PK1 cells overexpressing P-gp (data not shown). This suggests that 
intestinal P-gp activity is not expected to limit the oral availability of 23.
Although inhibition of the central CB1 receptor plays an important role in the food 
intake lowering and weight reducing effects of rimonabant, studies with recently developed 
peripherally acting CB1 receptor antagonists have shown that these compounds decrease 
cardiometabolic risk factors, and even weight in obese mice.8, 9, 34, 35 To further evaluate the 
beneficial effects of inhibition of the peripheral CB1 receptor in obesity and its comorbidities, 
antagonists that target these receptors are needed that have a good pharmacokinetic and 
pharmacodynamic profile. The present study showed that P-gp and possibly BCRP transport 
could be used as a tool for selection of peripheral CB1 receptor antagonists, which could be 
a novel strategy for the development of this type of compound. The pharmacokinetic profile 
of 23 offers a good starting point, provided its affinity for the CB1 receptor (Ki of 830 ± 170 
nM)16 is increased during lead optimization. It should be noted that our data represent brain 
penetration after single dose administration, whereas in clinical practice patients receive 
chronic treatment with CB1 receptor antagonists. Long-term studies are required to verify 
that, also upon repeated administration, brain concentrations remain below the level that 
could lead to central side effects. 
In summary, by using an in vitro cellular accumulation assay we selected a 
3,4-diarylpyrazoline CB1 receptor antagonist as a substrate of P-gp, and showed that 
P-gp and possibly BCRP limited the in vivo brain concentration of this compound in rats. 
Our results imply that it should be possible to further develop peripheral CB1 receptor 
antagonists based on their properties as substrates for brain efflux transporters. 
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Abstract
Coumarin (1, 2-benzopyrone) is a natural compound that has been used as a fragrance 
in food and perfume industry, and could have therapeutic usefulness in the treatment of 
lymphedema and different types of cancer. Previously, several pharmacokinetic studies of 
coumarin have been performed in humans, which revealed extensive first-pass metabolism 
of the compound. 7-Hydroxycoumarin (7-HC) and its glucuronide (7-HC-G) are the main 
metabolites formed in humans, and via this route, 80-90 percent of the absorbed coumarin 
is excreted into urine, mainly as 7-HC-G. Active transport processes play a role in the urinary 
excretion of 7-HC-G, however, until now, the transporters involved remained to be elucidated. 
In this study, we investigated whether the efflux transporters multidrug resistance-associated 
proteins (MRP) 1-4, breast cancer resistance protein (BCRP), or P-glycoprotein (P-gp), play a 
role in 7-HC and 7-HC-G transport. For this purpose, we measured uptake of the metabolites 
into membrane vesicles overexpressing these transporters. Our results showed that 7-HC is 
not transported by any of the efflux transporters tested, whereas 7-HC-G was a substrate 
of MRP3 and MRP4. These results are in line with the pharmacokinetic profile of coumarin, 
and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the 
coumarin metabolite 7-HC-G from liver and kidney.
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Introduction
Coumarin (1, 2-benzopyrone) is a natural compound that is found in many plants, e.g. the 
tonka bean and cinnamon bark oil (Fig. 1A). It has been used as a fragrance in perfume and 
food, and coumarin and its metabolites have also been shown to be effective as a medicinal 
therapy, reducing lymphedema and having anti-tumor activity.1, 2 However, in rodents, 
coumarin causes hepatotoxicity, which led to restricted usage of this compound in the food 
and fragrance industry and in medicinal therapy.3
Because coumarin is naturally present in food and is suggested to have a potential 
therapeutic value, many studies have been performed to obtain insight into its pharmacokinetic 
characteristics in humans. Sampling human plasma after oral administration of coumarin 
showed that, although almost completely absorbed, only 2-6% reaches the systemic 
circulation.4 This is due to extensive first-pass metabolism of coumarin to 7-hydroxycoumarin 
(7-HC) by cytochrome P450 (CYP) 2A6 , and, subsequently, to its glucuronide (7-HC-G) and 
sulfate (7-HC-S) conjugates by uridine 5’-diphospho glucuronosyltransferases (UGTs) and 
sulfotransferases, respectively.1, 4-6 Because coumarin 7-hydroxylation is mainly mediated via 
CYP2A6, it has been used as a model substrate for CYP2A6 activity in humans.1 In addition, 
7-HC is used as a model substrate for the investigation of glucuronidation activity of liver and 
intestinal models because many UGTs have the capability to glucuronidate this compound 
(Fig. 1).7-9
7-HC-G represents the main metabolite in plasma, indicating that it is formed in intestine 
or liver, and at a low dose of coumarin, approximately 80-90% of the absorbed dose of 
coumarin is excreted in urine, mainly as 7-HC-G, whereas less than one percent is excreted 
via the feces.10-12 At higher doses of coumarin, the metabolism seems to become saturated, 
which is reflected in a lower percentage of 7-HC and 7-HC-G excretion in urine (55-63%).3, 13
The clearance of 7-HC-G exceeds the glomerular filtration rate, therefore, it is considered 
to be actively secreted into the urine by the tubular segments in the kidney.12 Efflux 
transporters belonging to the ATP-binding cassette (ABC) family, such as multidrug-resistance 
associated proteins (MRPs), breast cancer resistance protein (BCRP), and P-glycoprotein (P-
gp) are known to play a role in the active tubular secretion of compounds from the kidney.14, 
15 Until now, the ABC transporters involved in the disposition of the 7-hydroxycoumarin 
metabolites have not been identified. To study the role of the most important drug efflux 
transporters in the handling of 7-HC and 7-HC-G, we determined the ATP-dependent uptake 
of these metabolites in membrane vesicles overexpressing MRP1-4, P-gp, and BCRP.
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Materials and methods
Materials
7-hydroxycoumarin (7-HC), 7-hydroxycoumarin glucuronide (7-HC-G), adenosine 
5’-triphosphate magnesium salt (ATP) (from bacterial source), adenosine 5’-monophosphate 
monohydrate (from yeast), estrone sulfate (E
1
S), estradiol 17-β-D-glucuronide (E
2
17βG), DL-
dithiothreitol (DTT) and reduced glutathione (GSH) were purchased from Sigma-Aldrich 
(Zwijndrecht, the Netherlands). Multiscreen
HTS
 filter plates and Vacuum Manifold filtration 
device were from Millipore (Etten-Leur, the Netherlands). [6,7-3H(N)]-E
2
17βG (41.8 Ci/
mmol) and [6,7-3H(N)]-E
1
S (54,3 Ci/mmol) were purchased from Perkin Elmer (Groningen, 
the Netherlands). ([3H])-N-methyl quinidine (NMQ) was from Solvo Biotechnology (Szeged, 
Hungary).
Production of membrane vesicles overexpressing the efflux transporters
HEK293 cells were transduced with baculovirus encoding MRP1-4, BCRP, P-gp, or enhanced 
yellow fluorescent protein (negative control protein), and three days after transduction, 
cells were harvested and membrane vesicles were made, following a previously described 
protocol, with the exception that during vesicle isolation, the homogenized cells were spun 
down at 4000g instead of 1000g for 20 minutes.16 Protein expression and the functionality 
of each batch of membrane vesicles were confirmed via immunoblot (data not shown) and 
in a radioactive vesicular transport assay using [3H]-E
2
17βG for MRP1-4, and [6,7-3H(N)]-E
1
S 
for BCRP, according to the protocols described previously and using concentrations and time 
points as indicated in the legend of Figure 2.16, 17 Functionality of P-gp vesicles was tested 
following the protocol of the vesicular transport assay described below, with the exception 
that 0.015 µCi [3H]-NMQ in a total concentration of 100 nM NMQ was used instead of 7-HC 
or 7-HC-G. Furthermore, samples were separated using a pre-washed Multiscreen
HTS
 HV, 
0.45 µM, glass fiber 96-well filter plate. NMQ was extracted from the filters using 2 ml of 
scintillation fluid, and by subsequent liquid scintillation counting of [3H]NMQ associated 
with the filters the uptake of total NMQ into the membrane vesicles was calculated.
Figure 1 Chemical structures of coumarin (A), 7-hydroxycoumarin (B), and 
7-hydroxycoumarin glucuronide (C)
A B C
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Vesicular transport assay with 7-HC and 7-HC-G
Uptake of 7-HC and 7-HC-G into membrane vesicles was performed using a rapid filtration 
technique. 30 µl reaction mix consisted of TS buffer (10 mM Tris-HEPES, and 250 mM 
sucrose, pH 7.4), 4 mM ATP, 10 mM MgCl
2
, 7-HC or 7-HC-G, and 7.5 µg of membrane vesicles. 
Concentrations of 7-HC and 7-HC-G and time points taken for measurements are indicated in 
the figure legends. To test the effect of GSH on transport of 7-HC via MRP1-4 and transport 
of 7-HC-G via MRP1 and MRP2, the experiment was also performed in presence of 3 mM 
GSH and 10 mM DTT to prevent oxidation of GSH.18, 19 The reaction was started when the 
mixture was incubated at 37°C, and stopped by placing the samples on ice and adding 150 
µl of ice-cold TS buffer. A Multiscreen
HTS
 HV, 0.45 µM, PVDF 96-well filter plate was pre-
washed with TS buffer and diluted samples were filtered through this filter plate using a 
Multiscreen
HTS
-Vacuum Manifold filtration device. The filters were washed twice with TS-
buffer and were then separated from the plate. Compounds were extracted from filters by 
incubation with 20% acetonitrile for 1 hour at room temperature and vortexing thoroughly, 
and extracted samples were analyzed by HPLC.  In control experiments, ATP was substituted 
with AMP. Net ATP-dependent transport was calculated by subtracting values measured in 
the presence of AMP from those measured in the presence of ATP.
HPLC analysis of 7-HC and 7-HC-G
The concentration of 7-HC and 7-HC-G in the samples was analyzed using reversed-phase 
high performance liquid chromatography (HPLC) and fluorescence detection with excitation 
and emission wavelength set at 316 nm and 382 nm. The HPLC consisted of a P2000 pump, 
an AS3000 autosampler and a FL3000 fluorescence detector (Thermo-Separation Products). 
Compounds were separated on a Grace-Smart RP-18 column (150x4.6 mm, 5 µm, Grace 
Division Discovery Sciences). The temperature of the column was set at 40°C and the 
injection volume was 50 µl. The mobile phase composition was 5% methanol and 0.2% 
acetic acid in water for solvent A, and 50% acetonitrile with 0.1% tetrahydrofuran for solvent 
B. Separation was achieved using a linear gradient from 20% B to 50% B in 8 minutes, with a 
flow rate of 1 ml/min. Standard curve calibrations were performed on a concentration range 
of 7-HC (0.3 – 5 µM) and 7-HC-G (10 – 500 nM). Limit of quantification was 10 nM for 7-HC-G 
and 20 nM for 7-HC.
Data analysis
All data were expressed as mean ± S.E.M.. Curve fitting of the concentration-dependent 
transport data was performed using Michaelis-Menten kinetic analysis in GraphPad Prism 
software, version 5.02 (GraphPad Software Inc., San Diego, CA).  
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Results
Identification of transporters involved in 7-HC and 7-HC-G transport
Transport of 7-HC and 7-HC-G via MRP1-4, BCRP, or P-gp, was investigated using membrane 
vesicles overexpressing these transporters. After incubation with 400 µM 7-HC, all values 
for 7-HC in the membrane vesicles were below the detection limit, and there was no ATP-
dependent increase of 7-HC (data not shown). Addition of 3 mM reduced gluthatione 
(GSH), a well-known co-factor for MRP-mediated transport, did not increase 7-HC uptake 
Figure 2 Transport of control substrates via MRP1-4, BCRP, and P-gp
Transport  of these substrates into membrane vesicles containing these transporters or control 
protein (ctrl) was used as a measure of functionality of the transporters. (A) ATP-dependent 
transport of 100 nM estradiol-17β-D-glucuronide (E
2
17βG) via MRP1, MRP3, and MRP4 during 
5 minutes. (B) Transport of 50 µM of E
2
17βG via MRP2 during 5 minutes. (C) BCRP-mediated 
transport of 300 nM estrone sulfate (E
1
S) during 5 minutes. (D) ATP-dependent transport of 100 
nM N-methyl quinidine (NMQ) via P-gp during 1 minute. Mean ± S.E.M. of triplicate values of an 
experiment with one of the used batches of membrane vesicles is depicted for each transporter.
A B
C D
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into MRP1-4 vesicles (data not shown). Transport of control substrates via MRP1-4, BCRP, 
and P-gp illustrated functionality of all transporters (Fig. 2). Therefore, the lack of ATP-
dependent increase of 7-HC under the given circumstances, suggests that 7-HC is not a 
substrate for these transporters. Values for 7-HC-G in the presence of AMP were also below 
the detection limit for the glucuronide metabolite 7-HC-G after incubation with 400 µM 
7-HC-G. However, there was a clear ATP-dependent increase of 7-HC-G into MRP3- and 
MRP4-overexpressing vesicles, which was highest for MRP4 (Fig. 3). No ATP-dependent 
uptake of 7-HC-G was observed in membrane vesicles overexpressing MRP1, MRP2, BCRP, 
or P-gp under the conditions used, and addition of 3 mM GSH did not increase transport via 
MRP1 and MRP2. This indicates that 7-HC-G is a substrate of MRP3 and MRP4, and not of 
the other transporters.
Kinetic characteristics of  7-HC-G transport via MRP3 and MRP4
Transport of 7-HC-G over time was linear up to 20 minutes for both MRP3 and MRP4 (Fig. 
4A). Transport of different concentrations of 7-HC-G via MRP3 and MRP4 after 10 minutes 
showed normal Michaelis-Menten kinetics (Fig. 4B). K
m
 values for MRP3 and MRP4 were 187 
± 22 and 63 ± 11 µM, respectively. V
max
 values for MRP3 and MRP4 were 460 ± 20 and 920 ± 
50 pmol mg-1 min-1, respectively.
Figure 3 ATP-dependent transport of 7-HC-G by the efflux transporters MRP1-4, BCRP, 
and P-gp
Transport into membrane vesicles containing MRP1-4, BCRP, P-gp, or control protein (ctrl) was 
measured after 10 minutes of uptake in presence of 400 µM 7-HC-G at 37°C, and uptake per 
mg membrane vesicles per minute is plotted in the graph. Mean ± S.E.M. of three independent 
experiments is shown. 
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Discussion
In this study, we found that 7-HC-G is transported by the efflux transporters MRP3 and 
MRP4, whereas 7-HC is not transported by any of the efflux transporters studied. These 
results are in line with the distribution of these transporters in the human body, and the 
pharmacokinetic profile of coumarin and its metabolites.
The fact that 7-HC is not transported via efflux transporters is in accordance with a 
previous study, in which no transport of 7-HC via P-gp was found.20 Furthermore, perfusion 
Figure 4 Time- and concentration-dependent uptake for 7-HC-G uptake into control 
(), MRP3 (), and MRP4 ()containing membrane vesicles
(A) Uptake was measured in presence of 400 µM 7-HC-G at time points indicated on the x-axis, 
and uptake per mg membrane vesicles is plotted in the graph. (B) Uptake was measured after 
10 minutes at concentrations of 7-HC-G indicated on the x-axis, and uptake per mg membrane 
vesicles per minute is plotted in the graph. A Michaelis-Menten curve was fitted through the data 
points. Mean ± S.E.M. of three independent experiments is shown for both graphs. 
A
B
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studies in intestine from guinea pigs indicated that 7-HC is absorbed via passive transport 
processes in the intestine.21
The results from our transport studies with 7-HC-G point towards an important role for 
MRP3 in the efflux of this compound from the liver, and for MRP4 in the urinary excretion 
of 7-HC-G from the body. Although plasma concentrations in humans after clinical or food-
derived doses of coumarin are low (1-4 µM) as compared to the K
m
 of 7-HC-G for MRP3 (187 
µM) and MRP4 (63 µM), the rate of efflux will mainly depend on the intracellular concentration 
of 7-HC-G, which may very well be higher than the plasma 7-HC-G concentration.4, 22-24 
MRP3 is mainly expressed at the basolateral surface of cells in the small intestine, colon, 
liver, and kidney (thick ascending loop and distal convoluted tubule cells), and MRP4 has 
a dual membrane localization, which is basolateral, but minimal, in hepatocytes, apical 
in kidney proximal tubule cells, and still unresolved in intestinal epithelium.25, 26 After oral 
administration, coumarin enters the enterocytes, most likely via a passive drug-transfer 
process.21 Because the intestine appears to lack CYP2A6, the 7-hydroxylating enzyme of 
coumarin, oxidative metabolism and subsequent glucuronidation of coumarin in enterocytes 
is limited.27 After passage across the intestinal wall into the blood, coumarin will enter the 
liver, where 7-hydroxylation to 7-HC and glucuronidation to 7-HC-G will take place. Our 
results suggest that the glucuronide metabolite 7-HC-G is subsequently transported via 
the basolateral transporter MRP3 into the circulation, and not to the bile because it is not 
transported via the canalicular transporters MRP2, BCRP, or P-gp. After entering the general 
circulation, 7-HC-G will be taken up into the kidney proximal tubular cells, most likely via 
an organic anion transporter that remains to be identified (e.g. OAT1 or OAT3), and will be 
excreted via MRP4 at the apical side of these cells, which completes the urinary excretion 
of 7-HC-G.
Transporter-mediated efflux of glucuronide conjugates is an important step in the overall 
glucuronidation activity of a cell or tissue.28 This implicates that not only UGT activity, but 
also MRP3 or MRP4 transport capacity of cells can influence the rate of glucuronidation, 
which should be kept in mind when using 7-HC as a model compound for determining 
UGT activity. Furthermore, deleterious polymorphisms of MRP3 and MRP4 might alter the 
metabolic route for coumarin from glucuronidation to sulfation, or possibly even towards 
more toxic pathways.1, 29-31 
In short, this study showed that MRP3 and MRP4 are the efflux transporters involved in 
disposition and excretion of the main metabolite of coumarin, 7-HC-G, in humans.
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Abstract
Glucuronidation of drugs by uridine 5’-diphospho glucuronosyltransferases (UGT) in 
enterocytes and hepatocytes plays an important role in first pass metabolism in intestine 
and liver. The hydrophilic glucuronide metabolites are excreted more effectively from the 
body via bile or urine than the unconjugated parent drug. Multidrug resistance-associated 
proteins (MRP) are necessary for the efflux of glucuronide conjugates from cells. As UGT 
activity can be decreased by product inhibition, it is hypothesized that UGTs and MRPs 
synergistically cooperate in the excretion of compounds from the body: MRPs remove the 
product and thereby prevent product inhibition of UGTs. In this study, we explored the 
possibility of synergistic interplay between MRP3/4 and UGT2B15 in HEK293 cells studying the 
glucuronidation of the model compound 7-hydroxycoumarin (7-HC) to 7-hydroxycoumarin 
glucuronide (7-HC-G). We identified sulindac as a potent inhibitor of MRP3 and MRP4, 
previously shown to be the transporters of 7-HC-G, at concentrations that do not inhibit 
UGT2B15. Inhibition of the efflux of 7-HC-G in HEK-UGT2B15 cells with sulindac increased 
its intracellular concentration and decreased its excretion. In addition, total metabolite 
formation was decreased, which suggests that efflux of 7-HC-G can influence the rate of 
metabolism of 7-HC. This indicates that UGTs and MRPs can cooperate in synergy, thereby 
providing an efficient route of elimination of drugs via glucuronidation.
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Introduction
First pass metabolism plays a significant role in determining the systemic availability of orally 
administered drugs. Metabolism in the liver has always been pointed out as the key player in 
this process, but more recent studies have shown that metabolism in the intestine can also 
play a substantial role in first-pass metabolism.1, 2 One type of first pass metabolism that can 
occur is glucuronidation, in which a glucuronic acid is conjugated to the drug by enzymes 
belonging to the superfamily of uridine 5’-diphospho (UDP) glucuronosyltransferases (UGTs). 
Glucuronidation is a Phase II type of metabolism, enhancing the urinary and biliary excretion 
of a drug by increasing its aqueous solubility.3 UGTs are membrane bound enzymes, and can 
be divided into two subfamilies, 1A and 2B, of which multiple members are expressed in the 
intestine.4, 5 Glucuronidation is suggested to play a significant role in intestinal metabolism 
of drugs, e.g. of propofol and raloxifene.3, 6
Because glucuronidated metabolites are hydrophilic and ionized at physiological pH, they 
need transporters to be transferred across cell membranes.7 Indeed, many glucuronide 
conjugates are substrates of efflux transporters from the ATP-binding cassette (ABC) family 
including the multidrug resistance-associated proteins (MRP).8 Several MRPs are expressed 
on the plasma membrane of intestinal cells, either on the apical side (MRP2), or on the 
basolateral side (MRP1, MRP3), or possibly on both sides (MRP4).9-13 Thus, glucuronide 
conjugates can be transported out of enterocytes both to the intestinal lumen and to the 
blood perfusing the intestine.
Because MRPs mediate efflux of glucuronide metabolites that are produced intracellularly, 
MRPs and UGTs act in concert to excrete compounds from the body. For example, it has been 
shown that MRP transport increases the excretion of a glucuronide metabolite of morphine. 
14 Unfortunately, the authors did not describe whether this transport also increased the 
total metabolite formation. Therefore, this cooperation between UGTs and MRPs could 
simply be the result of an additive sequence of events, in which absence of the transporter 
limits the excretion but not the formation of the metabolite. The other possibility is that 
this interplay between MRPs and UGTs is synergistic, implicating that excretion of the 
glucuronide metabolite via MRPs prevents product inhibition by which the accumulated 
glucuronide conjugates inhibit the enzyme’s metabolic activity. 7 In this situation, the activity 
of UGTs is highly increased due to transport of the metabolite out of the cell (Fig. 1A). When 
efflux of the metabolite is reduced by inhibition of MRP activity, the intracellular glucuronide 
conjugate concentration increases, leading to inhibition of UGT metabolizing activity and a 
reduction of total metabolite formation by UGTs (Fig. 1B).
Here, we tested the hypothesis of synergistic interplay between MRPs and UGT2B15. For 
this purpose, we investigated the glucuronidation of the model compound 7-hydroxycoumarin 
(7-HC) to 7-hydroxycoumarin glucuronide (7-HC-G) by UGT2B15 overexpressed in HEK293 
cells. UGT2B15 is one of the many UGTs that glucuronidates 7-HC to 7-HC-G, and that is 
also expressed in the intestine.15 In a previous study (Chapter 4) we showed that 7-HC-G is 
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transported via MRP3 and MRP4. To selectively inhibit efflux transport and not metabolism, 
we identified a MRP3 and MRP4 inhibitor with less inhibitory potency against UGT2B15 
activity. We used this compound to investigate the effect of inhibiting 7-HC-G efflux on the 
rate of 7-HC glucuronidation by UGT2B15.
Figure 1 Model of interplay between UGTs and efflux transporters in the intestine
(A) Metabolism of drugs by UGTs in presence of active efflux transporters. (B) Metabolism of drugs 
by UGTs in absence of active efflux transporters. M, metabolite; D, drug.
Materials and methods
Materials
7-Hydroxycoumarin (7-HC), 7-hydroxycoumarin glucuronide (7-HC-G), adenosine 
5’-triphosphate magnesium salt (ATP) (from bacterial source), adenosine 5’-monophosphate 
monohydrate (AMP) (from yeast), perchloric acid (PCA), sodium butyrate, sulindac, quercetin, 
benzbromarone, dipyridamole, and uridine 5’-diphospho glucuronic acid (UDPGA) trisodium 
salt were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). MK571 was from 
Biomol (Hamburg, Germany). Bac-to-Bac and Gateway system, and DMEM + GlutaMAX-I 
culture medium were purchased from Invitrogen (Breda, the Netherlands). Fetal calf serum, 
culture flasks (175 cm2), and CellStar 12- and 24-wells culture plates were purchased from 
Greiner (Alphen aan de Rijn, the Netherlands). Rat tail collagen (type I) was from First Link 
Limited (United Kingdom). Purified Max Pab mouse polyclonal human UGT2B15-antibody 
(B01P) was from Abnova (Tapei, Taiwan).
A B
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Generation of baculovirus coding for UGT2B15 and control protein
A Gateway pDONR223 vector containing the full-length human UGT2B15 sequence equal to 
NM_001076 (HsCD00080128) was purchased from Harvard PlasmID database (Boston, MA, 
USA). Subsequently, the UGT2B15 construct was cloned into a VSV-G improved pFastBacDual 
vector for mammalian cell transduction using the Gateway system (Invitrogen).17 Full-length 
human enhanced yellow fluorescent protein (eYFP) was cloned as described previously, and 
used as a negative control.17 Baculoviruses were produced using the Bac-to-Bac system, as 
described by the manufacturer (Invitrogen).
Cell culture and transduction of HEK293 cells
HEK293 cells were cultured in DMEM-GlutaMAX-I supplemented with 10% fetal calf serum 
at 37°C under 5% CO
2
-humidified air. For the experiments, cell were transduced in different 
culture formats: 175 cm2 flasks, 12- and 24-well culture plates. For transduction of cells in 
175 cm2 flasks, HEK293 cells were cultured 40% confluent, after which culture medium was 
removed and a concentrated virus/medium mixture (3:7) was added. Cells were incubated 
for 15 minutes at room temperature. After incubation, 20 ml medium and sodium butyrate 
(5 mM) was added to obtain a final virus:medium ratio of 1:17. For transduction of cells in 
12- or 24-wells, respectively 350,000 and 150,000 cells were seeded in the wells. Before 
seeding the cells in 24-wells plates, the wells were coated with 500 µl of a 100 µg/ml rat tail 
collagen (type I) solution for at least two hours at 37°C. Coating was washed with phosphate-
buffered saline once, and HEK293 cells were seeded. 24 hours after seeding, the cells were 
incubated for 15 minutes with a concentrated virus mixture, after which medium with a 
final concentration of 5 mM sodium butyrate was added reaching a final virus:medium 
ratio of 2:25 in a total of 1000 µl (12-well) and 500 µl (24-well). After transduction in both 
flasks and wells-plates, the cells were cultured for three more days under normal culture 
conditions before performing the experiment or harvesting the cells. Protein concentration 
of homogenates and western blot samples was determined with a Bio-Rad protein assay kit 
from Bio-Rad Laboratories (Veenendaal, the Netherlands).
Western blot
HEK293-ctrl and HEK293-UGT2B15 cell pellets were lysed in mQ containing DNAse I (20 
U/µl) (Invitrogen) and Complete mini protease inhibitor cocktail (Roche Diagnostics, 
the Netherlands). A 24 µg protein sample was solubilized in SDS-polyacrylamide gel 
electrophoresis buffer and separated on SDS gel containing 12% acrylamide. Subsequently, 
they were blotted on nitrocellulose membrane using the iBlot dry blotting system (Invitrogen). 
Overnight incubation with mouse-anti-human UGT2B15 (1:2000) followed by 1 hour 
incubation with the secondary antibody fluorescent goat-anti-mouse IRdye800 (1:10000) 
(Rockland Immunochemicals, Gilbertsville, USA) was used for detection of UGT2B15. Signal 
was visualized using the Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE).
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Glucuronidation of 7-HC by intact HEK-UGT2B15 cells
For the determination of the kinetic characteristics of 7-HC glucuronidation in HEK-
UGT2B15 cells, we used HEK293 cells transduced with UGT2B15 in 12-wells culture plates. 
To determine the rate of glucuronidation, transduced cells were incubated at 37°C with 50 
µM 7-HC in Tris-HEPES buffer (10 mM HEPES, 132 mM NaCl, 4.2 mM KCl, 1 mM CaCl
2
, 1 
mM MgCl
2
, 5.5 mM D(+)-glucose, calibrated to pH 7.4 using 1M Tris solution), and medium 
was sampled after 2.15, 3, 4, and 6 hours. To determine the concentration-dependency 
of glucuronidation, cells were incubated at 37°C with different concentrations of 7-HC (5-
250 µM) in Tris-HEPES buffer. Medium was sampled after 3 hours. 7-HC-G concentration in 
medium samples was determined by HPLC.
Homogenate production of HEK-UGT2B15 cells
For HEK-UGT2B15 cell homogenate production, HEK293 cells were cultured and transduced 
with UGT2B15 in 175 cm2 flasks. Three days after transduction, cells were harvested 
by centrifugation at 2000g for 5 minutes. The cell pellet was resuspended in ice-cold 
homogenization buffer (50 mM HEPES, 150 mM KCl, 5mM MgCl
2
, pH was set at 7.4 with 
1M Tris solution) and sonicated for 5 x 15 seconds, separated by 1 minute of cooling at 
4°C, using the Bioruptor NextGen (Diagenode, Liège, Belgium). After centrifugation at 2500g 
for 10 minutes, the protein concentration of the supernatant was determined and aliquots 
were stored at -80°C.
7-HC glucuronidation by HEK-UGT2B15 homogenate and effect of MRP inhibitors
The kinetics of 7-HC glucuronidation by UGT2B15 were also determined in the HEK-UGT2B15 
cell homogenate. For the time curve, the reaction mixture consisted of 10 mM UDPGA and 
500 µM of 7-HC filled up with homogenization buffer to a total of 200 µl. After pre-incubation 
of this mixture, 0.25 mg/ml UGT2B15 homogenate was added in a total volume of 200 µl 
and the mix was incubated for 0-4 hours at 37 °C. The reaction was stopped by adding 10 µl 
70% PCA and centrifugation at 16,000g for 10 minutes at 4°C. The concentration of 7-HC-G 
in the supernatant was measured by HPLC. For the concentration curve, 0-500 µM of 7-HC 
was used and the mix was incubated for 1 hour at 37°C.
To test the effect of different MRP inhibitors on 7-HC glucuronidation by UGT2B15 alone, 
HEK-UGT2B15 homogenate was incubated with 100 µM 7-HC and different concentrations 
(0-300 µM) of benzbromarone, dipyridamole, quercetin, MK571, and sulindac.
Effect of MRP inhibitors on 7-HC-G transport into MRP3 and MRP4 vesicles
Membrane vesicle expressing MRP3 or MRP4 protein were made following a protocol 
described previously, with the exception that during vesicle isolation, the homogenized cells 
were centrifuged at 4000g instead of 1000g for 20 minutes.16 Subsequently, the membrane 
vesicles were used to study the effect of different concentrations of sulindac, quercetin, 
benzbromarone, and dipryidamol on the uptake of 7-HC-G into the membrane vesicles 
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using a rapid filtration technique. A sample of 30 µl reaction mix consisted of TS buffer (10 
mM Tris-HEPES, and 250 mM sucrose, pH 7.4), 4 mM ATP, 10 mM MgCl
2
, 100 µM 7-HC-G, 
MRP inhibitors dipyridamole, benzbromarone, quercetin, or sulindac (0.1 – 100 µM), and 
7.5 µg of membrane vesicles. The reaction was started when the mixture was incubated at 
37°C, and stopped after 10 minutes by placing the samples on ice and adding 150 µl of ice-
cold TS buffer. A Multiscreen
HTS
 HV, 0.45 µM, PVDF 96-well filter plate was pre-washed with 
TS buffer and diluted samples were filtered through this filter plate using a Multiscreen
HTS
-
Vacuum Manifold filtration device (Millipore, Etten-Leur, the Netherlands). The filters were 
washed twice with TS-buffer and were then separated from the plate. Compounds were 
extracted from filters by incubation with 20% acetonitrile for 1 hour at room temperature 
and vortexing thoroughly, and extracted samples were analyzed with HPLC. In control 
experiments, ATP was substituted with AMP. Net ATP-dependent transport was calculated by 
subtracting values measured in the presence of AMP from those measured in the presence 
of ATP. 
Effect of sulindac on cellular glucuronidation in HEK-UGT2B15 cells
To investigate the effect of sulindac on glucuronidation in intact HEK-UGT2B15 cells, 
HEK293 cells were seeded and transduced in collagen-coated 24-wells plates. During the 
experiment, cells were incubated with 350 µl of 100 µM 7-HC and sulindac (0 - 50 µM) in 
Tris-HEPES buffer at 37°C. After 2 hours of incubation, 200 µl of medium was sampled, and 
10 µl of 100% PCA was added to the sampled medium to stop the reaction and precipitate 
detached cells. The rest of the incubation medium was aspirated, and cells were washed 
twice with warm Tris-HEPES buffer (37°C). Cells were lysed in 100 µl mQ, and 5 µl of 100% 
PCA was added to precipitate the protein. All samples were centrifuged at 16,000g for 5 
minutes. Concentration of 7-HC-G in supernatant of these samples was analyzed by HPLC. 
HPLC analysis of 7-HC-G
The concentration of 7-HC-G in the samples was analyzed using reversed-phase high 
performance liquid chromatography (HPLC) and fluorescence detection with excitation and 
emission wavelength set at 316 nm and 382 nm. The HPLC consisted of a P2000 pump, an 
AS3000 autosampler and a FL3000 fluorescence detector (Thermo-Separation Products). 
Compounds were separated on a Grace-Smart RP-18 column (150x4.6 mm, 5 µm, Grace 
Division Discovery Sciences). The temperature of the column was set at 40°C and the 
injection volume was 50 µl. The mobile phase composition was 5% methanol and 0.2% 
acetic acid in water for solvent A, and 50% acetonitril with 0.1% tetrahydrofuran for solvent 
B. Separation was achieved using a linear gradient from 20% B to 50% B in 8 minutes with a 
flow rate of 1 ml/min. The gradient was then immediately returned to 20% B and the initial 
conditions were restored in 5 minutes. Because sulindac disturbed the analysis of samples 
from the experiment with intact HEK-UGT2B15 cells and sulindac, a different gradient was 
used for these experiments: 20% B (0-1 min), gradient of 20 to 80% B (1-3 min), 80% B (3-
86
Chapter 5
5
12 min), followed by re-equilibration of the column at 20% B until 18 min. Standard curve 
calibrations were performed on a concentration range of 7-HC (0.3 – 5 µM) and 7-HC-G (10 
– 500 nM) with or without PCA, dependent on the method used for preparing the samples. 
The limit of quantification for 7-HC-G was 10 nM. This implicates that for the experiments 
measuring intracellular amounts of 7-HC-G, the limit of quantification was 1 pmol.
RNA isolation and quantitative PCR for MRP3 and MRP4 expression
HEK293 cells were seeded in duplicate and transduced with UGT2B15 in collagen-coated 
24-wells plates. Three days after transduction, cells were harvested using trypsin and 
centrifugation at 2000g for 5 minutes. The cell pellets were resuspended in lysis buffer from 
the RNA isolation kit and, subsequently, RNA was isolated from the duplicate samples using the 
NucleoSpin® RNA II kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
instructions. Subsequently, a reverse transcriptase reaction was performed with 1 µg RNA 
using random primers (Invitrogen, Breda, the Netherlands) and an Omniscript® RT kit 
(Qiagen, Hilden, Germany), following manufacturer’s recommendations. Synthesized cDNA 
was used for quantitative PCR, performed in a C1000™ Thermal Cycler in combination with 
a  CFX96™ Real-Time system (Bio-Rad Laboratories, Veenendaal, the Netherlands) by means 
of the TaqMan® protocol (Applied Biosystems, Warrington, UK). ABCC3 (MRP3) and ABCC4 
(MRP4) mRNA expression (Ct) was normalized to the mRNA expression of the housekeeping 
gene β-actin (∆Ct) (n = 1, in duplicate). The primer-probe sets were obtained from Applied 
Biosystems (β-actin, 4352933E; ABCC3, Hs00978473_m1; ABCC4, Hs00195260_m1). 
Kinetic and statistical analysis
K
m
 and V
max
 values of UGT2B15-mediated 7-HC glucuronidation were determined according 
to Michaelis-Menten kinetics by using GraphPad Prism software, version 5.02 (GraphPad 
Software Inc., San Diego, CA). Inhibitory data of sulindac on MRP3- and MRP4-mediated 
transport of 7-HC-G and of 7-HC glucuronidation in HEK-UGT2B15 homogenate were 
analyzed according to a one-site binding model by non-linear regression analysis (GraphPad 
Prism 5.02) using the equation: y = bottom + (top-bottom)/(1 + 10x - logIC50). Statistical 
differences were determined using a one-way analysis of variance (ANOVA) followed by a 
Dunnett’s multiple comparison test in GraphPad Prism. Differences were considered to be 
significant at p < 0.05. 
Results
Metabolism of 7-HC to 7-HC-G in HEK293 cells overexpressing UGT2B15
Western blotting of UGT2B15-transduced HEK293 cells (HEK-UGT2B15) showed clear 
overexpression of this protein in comparison to HEK293 cells overexpressing a control protein 
(HEK-ctrl) (Fig. 2A). We determined kinetics of glucuronidation in intact cells by measuring 
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Figure 2 Metabolism of 7-HC to 7-HC-G in control () and UGT2B15 () overexpressing 
HEK293 cells and HEK-UGT2B15 homogenate
(A) Immunoblot detection of UGT2B15 in HEK293 cells expressing control protein (ctrl) or 
UGT2B15 (2B15). (B) Time-dependent metabolism of 50 µM 7-HC to 7-HC-G in intact HEK293 
cells overexpressing control or UGT2B15 protein. The graph shows the amount of 7-HC-G in 
the medium sampled per well at time points indicated on the x-axis. Mean ± S.D. of duplicate 
determinations of a representative experiment is shown (two independent experiments have 
been performed, total n = 2). (C) Time-dependent metabolism of 500 µM 7-HC to 7-HC-G in HEK-
UGT2B15 cell homogenate. Formation of 7-HC-G per mg of cell homogenate is plotted on the 
y-axis. Mean ± S.D. of duplicate determinations of a representative experiment is shown (total n = 
3). (D) Concentration-dependent metabolism of 7-HC to 7-HC-G in intact HEK-UGT2B15 cells. The 
graph depicts the amount of 7-HC-G excreted into the medium per well per hour during 3 hours 
at different concentrations of 7-HC. Mean ± S.D. of duplicate determinations of a representative 
experiment is shown (total n = 3). (E) Concentration-dependent metabolism of 7-HC to 7-HC-G in 
HEK-UGT2B15 cell homogenate. The graph depicts the amount of 7-HC-G produced per mg cell 
homogenate per hour during 2 hours of incubation with different concentrations of 7-HC. Mean ± 
S.D. of duplicate determinations of a representative experiment is shown (total n = 3).
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the excreted metabolites, which represents approximately 98% of total metabolite 
formation at a concentration of 100 µM 7-HC (Fig. 4). Metabolism of 7-HC to 7-HC-G in HEK-
UGT2B15 intact cells was time-dependent and linear up to 6 hours, at least, whereas there 
was no metabolism in HEK-ctrl cells (Fig. 2B). Metabolism to 7-HC-G by UGT2B15 in intact 
cells followed Michaelis-Menten kinetics, with a K
m
 of 61 ± 19 µM and a V
max 
of  119 ± 23 
pmol well-1 h-1 (Fig. 2D). In HEK-UGT2B15 cell homogenate, metabolism was linear up to 0.5 
hours but K
m
 and V
max
 could not be accurately determined in the concentration range used 
for this experiment. However, the K
m
 appeared to be much higher in cell homogenate than 
in intact HEK-UGT2B15 cells.
Expression of endogenous transporters
7-HC-G appeared to be excreted from HEK-UGT2B15 even though we did not overexpress 
transporters in these cells (Fig. 2B-C). This implicates that these cells express endogenous 
transporters, possibly the 7-HC-G transporters MRP3 and MRP4, that can efflux 7-HC-G into 
the medium. Quantitative PCR confirms the presence of MRP4 mRNA (Ct = 26.6, ∆Ct = 5.0) in 
HEK-UGT2B15 cells, whereas there appears to be very little MRP3 mRNA present (Ct = 35.0, 
∆Ct = 13.3).
Table 1 Inhibitory effect of various MRP inhibitors on uptake of 7-HC-G via MRP3 
and MRP4 into membrane vesicles and glucuronidation of 7-HC by HEK-UGT2B15 
homogenate. Data are presented as mean (95% confidence interval) of non-linear 
regression analysis of data of two independent experiments in duplicate
Inhibitor MRP3 MRP4 UGT2B15
IC
50
 (µM) Ki (µM)
a IC
50
 (µM) Ki (µM)
a IC
50
 (µM) Ki (µM)
a
Dipyridamole n.i. 26 (13-52) 10 38 (21-67) 33
Benzbromarone 55 (n.s.) 36 10 (7-13) 4 13 (11-17) 11
MK571 1 to >50b 1-10c 30 (22-41) 26
Quercetin > 100 > 65 7 (n.s.) 3 39 (24-63) 34
Sulindac 39 (16-98) 25 2 (1.6-3.2) 0.8 300 (210-440) 265
n.i. not inhibited at concentrations tested (up to 100 µM).
n.s. 95% confidence interval could not be further specified due to too little data points at linear 
part of the inhibition curve.
a Ki was calculated according to the formula: Ki = IC50 / (1 + [S]/Km), in which [S] was 100 µM in all 
experiments and K
m
 values were 187 and 63 µM for 7-HC-G uptake into MRP3 and MRP4 vesicles 
and approximately 700 µM for 7-HC-G formation in UGT2B15 homogenate.
b Literature IC
50
 values derived from inhibition of vesicular transport of estradiol-17β-D-
glucuronide and methotrexate with different concentrations of MK571.32, 33
c Literature IC
50
 values derived from inhibition of vesicular transport of fluorescent cyclic AMP 
and cellular efflux of 9-(2-phosphonylmethoxyethyl)adenine (PMEA).34, 35
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Identification of MRP3 and MRP4 inhibitors that do not inhibit UGT2B15
For the investigation of the influence of MRP3 and MRP4 on metabolism by UGTs in cells 
or tissues, an inhibitor should be used that only inhibits MRP-mediated transport of the 
glucuronide metabolite, and not the glucuronidation of the parent compound by the UGT 
itself. To identify such an inhibitor, we tested the potency of several known MRP4 inhibitors 
for inhibition of MRP3- and MRP4-mediated transport of 7-HC-G and of UGT2B15-mediated 
7-HC glucuronidation in homogenate (Table 1). Sulindac appeared to be the most promising 
MRP3/4 inhibitor that inhibited UGT2B15 only at higher concentrations (Fig. 3). The 
concentration at which 50% of transport or metabolism was inhibited (IC
50
) by sulindac was 
39 µM for transport of 7-HC-G via MRP3 (95% confidence interval  (CI) of 17-98 µM), 2 
µM for MRP4 transport (95% CI of 1.6-3.2 µM), and 300 µM for metabolism of 7-HC to 
7-HC-G by UGT2B15 homogenate (95% CI of 210-440 µM). This implicates that sulindac was 
approximately 150 and 10 times more potent in inhibiting MRP4 and MRP3, respectively, 
as compared to UGT2B15. The inhibitory potencies of the other compounds tested against 
MRP3, MRP4 and UGT2B15 activity were in a range similar to each other (Table 1). When 
calculated Ki values of sulindac are compared, sulindac is even 300 times more potent as an 
inhibitor of MRP4 than of UGT2B15 activity.
Figure 3 Effect of sulindac on MRP3- and MRP4-mediated 7-HC-G uptake into membrane 
vesicles and on 7-HC glucuronidation in HEK-UGT2B15 cell homogenate
(A) Effect of different concentrations of sulindac on transport of 100 µM 7-HC-G via MRP3 () 
and MRP4 () at 10 minutes of incubation. Transport rates were expressed as a percentage of 
the uptake measured in the absence of sulindac. Data points represent mean percentage ± S.D. 
of a representative experiment (total n = 3). (B) Effect of a range of concentrations of sulindac on 
metabolism of 100 µM 7-HC to 7-HC-G after 3 hours of incubation with HEK-UGT2B15 homogenate. 
Glucuronidation rates were expressed as a percentage of the glucuronidation activity measured 
in the absence of sulindac. Data represent mean percentage ± S.D. of a representative experiment 
(total n = 2).
A B
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Figure 4 Effect of sulindac on 7-HC-G formation in intact HEK-UGT2B15 cells after two 
hours of incubation with 100 µM 7-HC
(A) Effect of different concentrations of sulindac on 7-HC-G excretion into the medium. (B) Effect of 
different concentrations of sulindac on the intracellular amount of 7-HC-G. (C) Effect of sulindac on 
total 7-HC-G produced per 100,000 cells (medium and intracellular compartment together). Mean 
± S.D. is shown of three independent experiments, except for data points at 20 and 50 µM sulindac 
(n = 2). Statistically significant differences were determined using a one-way ANOVA followed by a 
post-hoc Dunnett’s multiple comparison test: * p < 0.05, ** p < 0.01, *** p < 0.001.
B
C
A
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Effect of sulindac on glucuronidation and excretion of glucuronide metabolites from intact 
HEK-UGT2B15 cells
To test the effect of the MRP3/MRP4 inhibitor sulindac on 7-HC-G formation and excretion in 
intact cells, we measured the intracellular and extracellular amounts of 7-HC-G produced by 
HEK-UGT2B15 cells in presence of different concentrations of sulindac (Fig. 4). The amount 
of glucuronide excreted in the medium was approximately 50% reduced at a concentration 
of 20 µM sulindac (Fig. 4A). The amount of intracellular 7-HC-G accumulated with increasing 
concentration of sulindac (Fig. 4B). Adding up the intracellular and extracellular amounts of 
7-HC-G produced per 100,000 cells showed that the total amount of glucuronides that was 
produced decreased by 30% in presence of 20 µM sulindac (Fig. 4C).
Discussion
In this study we investigated the cooperation between MRPs and UGTs. For this purpose, 
we developed assays to measure the amount of glucuronidation by UGT2B15 in intact HEK-
UGT2B15 cells and in homogenates of these cells. After testing the selectivity of multiple 
MRP inhibitors for inhibition of MRP3, MRP4, and UGT2B15, we selected sulindac as the 
most selective inhibitor of transport via MRP3/MRP4. Using sulindac, we investigated the 
effect of inhibition of efflux of 7-HC-G from HEK-UGT2B15 cells on total metabolite formation.
During the development of the metabolic assays, we discovered a difference in the K
m
 of 
7-HC-G formation in intact HEK-UGT2B15 cells and in homogenate of these cells, the K
m
 in 
homogenate being much higher than in intact HEK-UGT2B15 cells. This phenomenon also 
occurs for other glucuronidation models, e.g. human liver microsomes and hepatocytes, in 
which the K
m
 appears to be higher in the microsomes than in the intact hepatocytes.17 The 
K
m
 can be decreased by different incubation conditions, such as type of buffer, pH, and ionic 
strength, and the presence of pore-forming activators, which decrease the latency of the 
reaction.17-20 Furthermore, these differences in kinetic characteristics could have effect on 
the inhibitory potency of compounds against UGT activity.17, 20 Therefore, for future studies, 
it would be good to test different incubation conditions to lower the K
m
 of UGT2B15 7-HC 
glucuronidation in the homogenates towards the K
m
 of intact HEK-UGT2B15 cells, to improve 
comparison between these in vitro systems.
Due to their hydrophilic nature, glucuronide metabolites require transport via influx or 
efflux transporters to pass cellular membranes. Since 7-HC-G is excreted into the medium 
by HEK-UGT2B15 cells (Fig. 2) and the intracellular level of 7-HC-G is low under normal 
conditions (Fig. 4B), HEK293 cells likely express endogenous transporters on their plasma 
membrane that are able to efflux 7-HC-G into the medium. From a previous study we 
know that MRP3 and MRP4 mediate transport of 7-HC-G (Chapter 4), and therefore these 
transporters might be involved in the endogenous efflux of this metabolite. By means of 
quantitive PCR, we showed that MRP4 is endogenously expressed in HEK293-UGT2B15 cells, 
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whereas there is very little to no MRP3 expression, which is comparable to other studies 
investigating transporter expression in HEK293 cells.21, 22 Although we cannot exclude the 
possibility that other endogenously expressed transporters are involved in the transport 
of 7-HC-G out of HEK-UGT2B15 cells, MRP4 is a good candidate for this process because it 
transports 7-HC-G and is expressed in HEK293 cells.
To investigate the MRP4-UGT2B15 interplay in HEK-UGT2B15 cells endogenously 
expressing MRP4 we needed an MRP4 inhibitor that did not inhibit UGT2B15. Testing 
several MRP inhibitors, we showed that some caution has to be taken with the use of alleged 
specific MRP inhibitors in the investigation of enzyme-transporter interplay. We showed that 
several of these inhibitors also inhibited UGT2B15 (Table 1), rendering them unsuitable for 
separation of the UGT- from the MRP-component in metabolism of 7-HC. Because sulindac 
had the most favourable UGT2B15 and MRP4 inhibition profile, we selected this inhibitor for 
further investigation of transporter-enzyme interplay. 
Our results suggest that MRP4 and UGT2B15 act synergistically in the removal of 7-HC. 
Using the selected MRP4 inhibitor sulindac, we showed that the intracellular 7-HC-G amount 
is increased in HEK-UGT2B15 cells upon sulindac treatment, most likely due to inhibition of 
transport via MRP4 (Fig. 4). Furthermore, the excretion of 7-HC-G is reduced by 50% in 
presence of 20 µM sulindac, a concentration at which UGT2B15 activity in homogenate 
was not inhibited, whereas MRP4 vesicular transport activity was inhibited by 85% (Fig. 
3). This suggests that the decreased excretion is due to decreased efflux of the metabolite 
and not to inhibition of UGT2B15. At the same concentration of sulindac, total metabolite 
formation was reduced, implicating that this was a result of the impaired efflux of the 
glucuronide metabolites. Thus, transport of 7-HC-G out of the cell appears to increase 
the rate of metabolism of 7-HC to 7-HC-G by UGT2B15, suggesting a synergistic interplay 
between MRP4 and UGT2B15. Previous studies have also suggested that efflux transport 
is a rate limiting step in glucuronide excretion, for example for naringenin glucuronide.23 
In addition, critical review of studies employing similar techniques as ours suggests a 
synergistic interplay between UGTs and transporters in vitro, for example between UGT2B7 
and MRP1, MRP2, and MRP3 in morphine glucuronidation, and between UGT1A1 and breast 
cancer resistance protein in genistein glucuronidation.24-26 Therefore, these studies appear 
to support our hypothesis of a synergistic interplay, at least in vitro, between UGT enzymes 
and efflux transporters.
The mechanistic basis of the synergistic cooperation of transporters and UGT enzymes 
remains to be revealed. Although there is evidence that glucuronide metabolites can inhibit 
UGT enzymes, there is no proof of an inhibitory capacity of 7-HC-G towards UGT2B15 yet.27 
The decreased amount of 7-HC-G conjugation due to inhibition of efflux of 7-HC-G could also 
be explained by an increased deconjugation of the metabolite, for which β-glucuronidase 
that is located in the endoplasmic reticulum (ER) is thought to be reponsible.7, 28 After 
glucuronidation by UGTs in the ER, glucuronide metabolites are transported to the cytosol 
before excretion via efflux transporters.28-30 If the cytosolic concentration of 7-HC-G is 
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increased due to lowered efflux, this might also increase the concentration of 7-HC-G in 
the ER and thereby its deconjugation by β-glucuronidase, resulting in a lower total 7-HC-
G formation. However, in HEK293 cells, the β-glucuronidase activity appears to be low, 
and therefore it is questionable if deconjugation can be the explanation of the lowered 
metabolism.31 Further studies should be performed to unravel the mechanism responsible 
for the lower metabolism in absence of a functional efflux transporter.
In summary, this study showed that efflux of 7-HC-G from HEK-UGT2B15 cells is important 
for the glucuronidation of 7-HC and the excretion of 7-HC-G, and endogenously expressed 
MRP4 is hypothesized to be responsible for this transport. Our results suggest that the 
cooperation between UGT2B15 and the transporter is synergistic. Because glucuronide 
metabolites are often transported by multiple transporters, this could mean that in the 
in vivo situation, where multiple transporters are present in enterocytes or hepatocytes, 
transport will not be a limiting factor of the rate of metabolism.23 Networks of UGTs and 
transporters in intestine and liver will therefore provide an efficient route of elimination of 
drugs.
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Abstract
Multidrug resistance-associated protein 4 (MRP4) is a membrane transporter that mediates 
the cellular efflux of a wide range of anionic drugs and endogenous molecules. MRP4 
transport can influence the pharmacokinetics of drugs and their metabolites, therefore 
more knowledge about the molecular determinants important for its transport function 
would be of relevance. Here, we substituted amino acids Phe368, Trp995, and Arg998 with 
conservative or non-conservative residues, and determined the effect on transport of the 
model substrates estradiol 17-β-D-glucuronide (E
2
17βG), cyclic guanosine monophosphate 
(cGMP), methotrexate (MTX), and folic acid into membrane vesicles isolated from baculovirus 
transduced HEK293 cells overexpressing the mutant MRP4 proteins. This revealed that 
all Arg998 mutations appeared to be deleterious, whereas the effect of a Phe368 or Trp995 
replacement was dependent on the amino acid introduced and the substrate studied. 
Substitution of Phe368 with Trp (F368W) induced a gain-of-function of E
2
17βG transport and 
a loss-of-function of MTX transport, which could not be attributed to an altered substrate 
binding. Moreover, we did not observe any modification in ATP or ADP handling for F368W. 
These results, in combination with docking of substrates in a homology model of MRP4 in 
the inward- and outward-facing conformation, suggest that Phe368 and Trp995 do not play 
an important role in the initial binding of substrates. They, however, might interact with 
the substrates during rearrangement of helixes for substrate translocation, funneling the 
substrates to the exit site in the outward-facing conformation.     
99
Phe368 affects substrate-specific transport activity of MRP4
6
Introduction
Multidrug resistance-associated protein 4 (MRP4/ABCC4) is a member of the C subfamily 
of ATP-binding cassette (ABC) transporters. This drug efflux transporter translocates 
substrates across the plasma membrane of the cell in an ATP-dependent manner.1 MRP4 
is known to transport a wide variety of drugs, including antiviral, antibiotic, cardiovascular, 
and cytotoxic agents, and endogenous molecules that are involved in cellular signaling and 
communication, such as cyclic nucleotides, ADP, eicosanoids, uric acid, conjugated steroid 
hormones, folic acid, bile acids, and glutathione.1 MRP4 is widely expressed in various blood 
cells, neurons, cardiovascular tissue, and epithelia of organs that are involved in determining 
the disposition of drugs, including kidney, liver, blood-brain barrier and intestine, where 
it can be located either apically or basolaterally depending on the cell type.1-4 Because of 
its localization and its broad substrate specificity, MRP4 plays a role in the disposition of 
various drugs and their metabolites, and could have a key function in cellular protection 
and extracellular signaling pathways.1 MRP4 is encoded by the ABCC4 gene, comprising a 
protein of 1325 amino acids with a typical ABC transporter core structure. It is composed 
of two membrane spanning domains (TMDs), each consisting of six transmembrane helices 
(TM) important for drug binding, and two nucleotide binding domains (NBDs), which bind 
and hydrolyze ATP to drive transport. ABCC4 is a highly polymorphic gene, and several non-
synonymous polymorphisms have been found in different human populations. Previous 
studies showed that some of the polymorphisms in ABCC4 affect transport of substrates 
(e.g. antiviral agents and chemotherapeutic drugs), mainly by affecting the MRP4 protein 
expression and localization, and might thereby affect the pharmacokinetics of these drugs.5-7 
Because MRP4 plays an important role in the distribution and excretion of drugs and 
their metabolites, it would be interesting to gain more knowledge about the molecular 
determinants important for its transport function. To understand the molecular basis of 
transport, mutational studies of functionally important amino acids are indispensable. In 
contrast to MRP1, 2, and 3, for MRP4 only one study has been performed that focused 
on identification of amino acids important for substrate recognition and binding. In that 
study, we revealed that Phe368, Phe369, Glu374, Arg375, and Glu378 in TM6, and Arg998 in TM12 of 
MRP4 are important for its transport function.8 In addition, we demonstrated that Arg375 is 
involved in MTX transport, but not in cGMP transport.
To further explore which amino acids are important for the transport functionality of 
MRP4, we investigated the effect of Phe368 (TM6), Trp995 and Arg998 (TM12) amino acid 
substitutions on the substrate-dependent transport activity of MRP4. We selected Trp995 
and Arg998 because these amino acids are highly conserved within the MRP family (Fig. 
1). Moreover, our previously described homology model showed that Phe368 was located 
opposite to Trp995 in the substrate binding cavity of MRP4.8 Hence, Phe368, Trp995, and Arg998 
mutants were expressed in human embryonic kidney 293 (HEK293) cells. Several functional 
characteristics of the transporters were investigated using membrane vesicles isolated from 
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these cells. The results from this study suggest that sequential to initial substrate binding, 
the aromatic amino acids in TM6 and TM12 can induce substrate-dependent conformational 
changes, which funnel the substrates to their exit sites.
Materials and Methods
Materials 
[6,7-3H(N)]-estradiol 17-β-D-glucuronide (E
2
17βG) (41.8 Ci/mmol) was purchased from 
Perkin Elmer (Groningen, the Netherlands). [3,5,7-3H(N)]-methotrexate disodium salt (MTX) 
(23 Ci/mmol), [8-3H]-guanosine 3’,5’-cyclic monophosphate ammonium salt (cGMP) (13.5 
Ci/mmol), and [3,5,7,9-3H(N)]-folic acid diammonium salt (48.6 Ci/mmol) were purchased 
from Moravek, Inc. (Brea, USA). Bac-to-Bac and Gateway system, DMEM + Glutamax-I 
culture medium, Tris and fetal calf serum were purchased from Life Technologies (Bleiswijk, 
the Netherlands). Triple flasks (500 cm2) were purchased from Sanbio BV Biological Products 
(Uden, the Netherlands). Unlabeled E
2
17βG, cGMP, folic acid, and MTX, sodium butyrate, 
HEPES, DL-dithiothreitol (DTT), and adenosine 5’-triphosphate magnesium salt (ATP) (from 
bacterial source), and adenosine 5’-monophosphate monohydrate (AMP) (from yeast) were 
purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Sodium monovanadate 
(anhydrous) was from E. Merck (Darmstadt, Germany) and MgCl
2
 was from BOOM (Meppel, 
the Netherlands). D(+)-saccharose was purchased from VWR (Leuven, Belgium). Protein 
concentrations were determined with a Bio-Rad protein assay kit from Bio-Rad Laboratories 
(Veenendaal, the Netherlands).
Site-directed mutagenesis of MRP4 and generation of expression vectors and baculovirus 
The previously described Gateway entry vector containing the human MRP4 coding 
sequence8 was used as a template for site-directed mutagenesis of the following amino 
acids: F368W, F368Y, F368A, W995F, W995Y, W995A, R998S, R998K, R998Y, and R998L. The 
mutagenesis was performed as described previously.8 Briefly, forward and reverse primers 
Figure 1 Alignment (ClustalW2) of amino acid sequences of human MRP1-MRP6
The marked amino acids, F368 in TM6, and W995 and R998 in TM12 of MRP4 have been substituted 
in this study.
101
Phe368 affects substrate-specific transport activity of MRP4
6
(Biolegio, Nijmegen, the Netherlands) were designed for the specific amino acid substitutions 
and were used to perform a site-directed mutagenesis PCR on the MRP4 entry vector. After 
confirmation of the mutations by sequence analysis, the MRP4 mutant entry vectors were 
cloned into a VSV-G improved pFastBacDual vector for mammalian cell transduction using 
the Gateway system.8 Baculoviruses were produced as described in the Bac-to-Bac manual 
(Life Technologies, Bleiswijk, the Netherlands).
Cell culture and transduction of HEK293 cells with baculovirus of MRP4 and mutants
HEK293 cells were grown in DMEM-Glutamax-I supplemented with 10% fetal calf serum at 
37°C under 5% CO
2
-humidified air. For transduction, HEK293 cells were seeded in 500 cm2 
triple flasks at a confluence of 20%. After 24 hours, the culture medium was removed and 
a mixture of 25 ml medium and 10 ml of the negative control (enhanced yellow fluorescent 
protein/eYFP), wild type MRP4, or MRP4 mutant baculovirus was added. After an incubation 
of 15 min at 37oC, another 40 ml medium was added. Sodium butyrate (5 mM) was added 
6 hours after transduction and the cells were further incubated at 37oC under 5% CO
2
-
humidified air. Three days after transduction, the cells were harvested by spinning them 
down at 3500g for 10 minutes. Pellets we stored at -80°C until further use. 
Isolation of membrane vesicles
Isolation was performed according to a previously described method, with slight 
modifications.9 Briefly, cells were lysed in ice-cold hypotonic buffer supplemented with 
protease inhibitors and centrifuged at 100,000g. The pellet was homogenized in ice-
cold TS buffer (10 mM Tris-HEPES, and 250 mM sucrose, pH 7.4) with protease inhibitors 
using a Dounce homogenizer and the suspension was centrifuged at 2000g. Membranes 
(in supernatant) were spinned down by a 100,000g centrifugation step and vesicles 
were produced using passage through a 27-gauge needle. Protein concentrations were 
determined by Bio-Rad protein assay kit, and crude membrane vesicles were dispensed in 
aliquots, frozen in liquid nitrogen, and stored at -80°C until further use.
Western blotting
15 µg of membrane vesicle preparation was solubilized in Laemmli loading buffer with 0.1 
M DTT, and loaded onto a 7.5% SDS-polyacrylamide gel, after which gel electrophoresis 
was performed to separate proteins. Subsequently, they were blotted on nitrocellulose 
membrane using the iBlot dry blotting system (Life Technologies, Bleiswijk, the Netherlands). 
MRP4 and its mutant proteins were detected using the polyclonal rabbit-anti-human MRP4 
antibody (pAb hM4, 1:5000)10 and the secondary goat-anti-rabbit antibody Alexa Fluor 680 
(Life Technologies, Bleiswijk, the Netherlands, 1:10000). Signals were visualized using the 
Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE) and the expression ratio between 
wild type MRP4 and mutant protein per membrane vesicle preparation was determined 
using Odyssey software version 2.1. We used this ratio to correct transport activity for 
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protein expression of each mutant protein in separate batches of membrane vesicles.
Vesicular transport assay to screen transport activity of mutant MRP4 proteins for different 
substrates
Transport activity of control (eYFP), MRP4, and all MRP4 mutant proteins was tested using 
different substrates. Uptake of [3H]-E
2
17βG, [3H]-cGMP, [3H]-MTX or [3H]-folic acid into 
membrane vesicles was performed using a rapid filtration technique as described previously.9 
Briefly, 7.5 µg of membrane vesicles was incubated in TS buffer with 4 mM AMP or ATP, 10 
mM MgCl
2
 and one of the radioactive substrates at the concentration indicated in the legend, 
at 37oC for 5 ([3H]-E
2
17βG), 7.5 ([3H]-folic acid), or 10 minutes ([3H]-cGMP and [3H]-MTX), 
time points for which time-dependent transport was found to be linear (data not shown). 
The concentrations of radiolabeled substrates used in the screen were 0.12 µM radiolabeled 
E
2
17βG, 10.8 µM cGMP (0.8 µM radiolabeled and 10 µM unlabeled), 0.5 µM MTX (0.22 µM 
radiolabeled and 0.28 µM unlabeled), and 0.1 µM radiolabeled folic acid. After stopping the 
reaction with ice-cold TS buffer, the samples were filtered by a Multiscreen HTS-Vacuum 
Manifold filtration device (Millipore, Etten-Leur, the Netherlands) through a 0.45 µm pore, 
PVDF 96-well filter plate (Millipore) and washed twice with TS buffer. After separation from 
the plate, 2 ml of scintillation fluid was added to each filter and radioactivity was measured 
using a liquid scintillation counter. Net ATP-dependent transport was calculated by 
subtracting values measured in the presence of AMP from those measured in the presence 
of ATP. The transport data were corrected for expression of mutant compared to wild type 
MRP4 of each different batch, and experiments were performed in three different batches 
of membrane vesicles. In this setup (ATP present in the incubation media and not inside the 
vesicles) only the transport into inside-out vesicles is measured. 
Kinetic analysis of MRP4 mutant proteins
To determine the apparent K
m
 and V
max
 values of wild type and mutant MRP4 proteins F368W, 
F368Y, W995F, and W995Y, concentration curves were made for the different substrates. 
Transport was performed as described in the previous section, and the same concentrations 
of radiolabeled substrates were supplemented with unlabeled substrate to obtain different 
concentrations. Each experiment was performed with three different batches of vesicles. 
The concentration-dependent transport was corrected for expression levels compared to 
control of each batch. For mutant F368W the K
m
 value of ATP was determined by measuring 
the uptake rate of 200 µM E
2
17βG in presence of different concentrations of ATP (up to 4 
mM). K
m
 and V
max
 values were determined by non-linear regression analysis of the data 
according to the Michaelis-Menten equation using GraphPad Prism, version 5.02 (GraphPad 
Software Inc., San Diego, CA). 
Trapping of ADP during E
2
17βG transport using vanadate
To test the effect of ADP trapping on E
2
17βG transport via MRP4 and mutant F368W, the 
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vesicular transport assay was performed for E
2
17βG transport according to description in 
the section for the vesicular transport assay, using 100 µM E
2
17βG in presence of different 
concentrations of vanadate. Inhibitory data of vanadate were fitted to a one-site binding 
model by non-linear regression analysis (GraphPad Prism 5.02) using the equation: y = 
bottom + (top-bottom)/(1 + 10x -logIC50). 
Molecular modeling and docking
The homology model of MRP4 was built with the YASARA molecular modeling program.11 
The outward-facing model has been described previously.8 For the inward-facing model 
the X-ray structure of P-glycoprotein (P-gp) from Mus musculus solved at 3.8-Å resolution12 
was used as a template (PDB ID: 3G5U). The alignment of the MRP4 sequence against this 
template was created with the T-Coffee multiple alignment algorithm13, using additional 
sequences to guide the alignment. The resulting alignment was manually tuned to account 
for single residue insertions and deletions. Loops were modeled by scanning a non-
redundant subset of the PDB (>8000 structures) for fragments with matching anchor points, 
a minimal number of bumps, and maximal sequence similarity. Side chains were added 
with YASARA’s implementation of SCWRL14, and then the model was subjected to an energy 
minimization with the YAMBER force field as described previously.11 Since membrane was 
absent during this minimization, the backbone of residues copied from the template was 
kept fixed. Validation of the model with WHAT_CHECK15 yielded an average quality Z-score 
of -1.47, which is better than the template (-4.72). A PDB file of the model and the alignment 
is available upon request. 
Docking was performed with AutoDock 4.216 using the default docking parameters 
supplied in the AutoDock ‘examples’ subdirectory and point charges assigned according to 
the AMBER03 force field.17 The MRP4 homology models were used as receptors, and E
2
17βG, 
MTX, cGMP, and folic acid structures, retrieved from PubChem (CID 66424, 126941, 24316, 
6037, respectively), were used as ligand. The simulation cell was defined by selection of 5 
Å box around the amino acids involved in binding.12 The setup was done with the YASARA 
molecular modeling program.11
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Figure 2 Western blot analysis of wild type MRP4 and MRP4 mutant protein expression
Membrane vesicles from HEK293 cells overexpressing wild type MRP4 and Phe368, Trp995, and Arg998 
mutants were loaded on SDS-PAGE and blotted. eYFP expressing membrane vesicles were loaded 
as a negative control (ctrl). Polyclonal rabbit-anti-human MRP4 antibody was used for detection.
Figure 3 Effect of MRP4 amino acid substitutions of Phe368, Trp995, and Arg998 on transport 
of different substrates
Uptake was measured in presence of 4 mM AMP or ATP into membrane vesicles from HEK293 
cells containing wild type and MRP4 mutants. Radiolabeled substrates were used in the following 
concentrations: 0.12 μM E
2
17βG (A), 10.8 μM cGMP (B), 0.5 μM MTX, or 0.1 μM folic acid (D). 
All transport values were corrected for endogenous transport in control membrane vesicles. 
ATP-dependent transport activity of wild type MRP4 was set at 100% for each experiment and 
transport activity was corrected for protein expression of the mutants in each batch. Mean 
percentage ± S.E.M. of transport activity in three independent experiments, using different 
batches of membrane vesicles, is shown. 
A
C
B
D
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Results
Expression of MRP4 wild type and Phe368, Trp995, and Arg998 mutants in isolated membrane 
vesicles
Using site directed mutagenesis, the aromatic amino acids phenylalanine at position 368 
in TM6 (Phe368/F368) and tryptophan at position 995 (Trp995/W995) in TM12 of MRP4 were 
exchanged with alanine (Ala/A) or the aromatic amino acids Phe, Trp, or tyrosine (Tyr/Y). 
The positively charged amino acid arginine at position 998 (Arg998/R998) was substituted 
with the positively charged lysine (Lys/K), the polar uncharged serine (Ser/S), the aromatic 
Tyr, or the hydrophobic leucine (Leu/L). Sequence analysis confirmed the construction of 
the correct mutants (data not shown). Next, immunoblot analysis performed on membrane 
vesicles from HEK293 cells overexpressing MRP4 wild type and mutant transporters showed 
a clear expression of all MRP4 proteins compared to the negative control (Fig. 2). Overall, 
the expression levels of the mutants and wild type MRP4 were similar. 
cGMP, E
2
17βG, MTX, and folic acid transport by MRP4 wild type and mutants
The effect of MRP4 amino acid substitutions was investigated with a vesicular transport assay 
using the [3H]-labeled substrates E
2
17βG, cGMP, MTX, and folic acid (Fig. 3A-D). Transport 
values of these substrates for wild type MRP4 were 0.58 ± 0.03, 3.5 ± 0.3, 0.65 ± 0.14, 0.27 
± 0.04 pmol mg-1 min-1 for E
2
17βG, cGMP, MTX, and folic acid, respectively. Substitution 
of Phe368 and Trp995 with Ala, and all amino acid substitutions of Arg998 almost completely 
disrupted transport activity for all substrates tested. Transport via W995F and W995Y was 
not completely abolished, but the aromatic substitutions significantly decreased transport of 
all substrates compared to wild type MRP4. Whereas amino acid substitutions of Trp995 and 
Arg998 diminished or completely abolished transport of all substrates, substitutions F368W 
and F368Y had dual effects on the transport function, which appeared to be substrate- and 
mutation-dependent. F368Y-mediated cGMP transport was increased to 160 ± 15% (Fig. 3B), 
while transport of the other substrates was decreased by 20-50% compared to wild type 
MRP4 activity (Fig. 3A,C-D). Moreover, F368W-mediated E
2
17βG transport was increased to 
250 ± 11% of wild type MRP4 (Fig. 3A), whereas cGMP transport was drastically decreased 
to 24 ± 2% (Fig. 3B), and MTX and folic acid transport was also reduced to 55-80% of wild 
type transport activity (Fig. 3C-D).
Kinetic properties of MRP4 wild type and F368W, F368Y, W995F, and W995Y mutants
To further explore the mechanism by which the amino acid substitutions affected MRP4 
transport activity, we determined the apparent affinity (K
m
) and maximum transport capacity 
(V
max
) of wild type MRP4 and mutants F368W, F368Y, W995F and W995Y for E
2
17βG, cGMP, 
MTX, and folic acid. As F368A, W995A, and all mutations of Arg998 completely disrupted 
the transport activity of MRP4, it was not possible to include these mutant proteins into 
the kinetic analysis. Figure 4 shows the concentration-dependency of E
2
17βG, cGMP, MTX, 
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and folic acid transport of the wild type and mutant transporters tested. K
m
 and V
max
 values 
derived from these plots are presented in Table 1. 
Most of the effects on transport activity by the aromatic amino acid substituted Phe368 
and Trp995 mutants in Figure 3 appeared to be due to changes in the V
max
, only sporadically 
accompanied by a change in apparent K
m
 (Table 1). Surprisingly, the significant gain of E
2
17βG 
transport function by mutant F368W appeared to be completely due to a 3-fold increase in 
V
max
, whereas the K
m
 was exactly the same as for wild type MRP4. For MTX transport by this 
mutant, the K
m
 was also unaffected, but in contrast to E
2
17βG, the V
max
 was significantly 
reduced.
Figure 4 Kinetics of ATP-dependent transport of different substrates into membrane 
vesicles from HEK293 cells containing wild type MRP4 () or MRP4 mutants F368W (), 
F368Y (), W995F (), and W995Y ()
Concentration-dependent transport of E
2
17βG (A), cGMP (B), MTX (C), and folic acid (D) was 
determined in presence of 4 mM AMP or ATP. ATP-dependent uptake is expressed as percentage 
compared to control (%), with V
max
 of wild type MRP4 set at 100% per batch of membrane vesicles. 
Data points represent mean ± S.E.M. of three different batches of membrane vesicles, corrected 
for protein expression. Curves were plotted and K
m
 and V
max
 were determined by non-linear 
regression analysis based on one-site Michaelis-Menten kinetics.
A
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ATP and ADP handling of MRP4 wild type and F368W mutant
We explored the possibility of a changed handling of ATP or ADP by F368W during E
2
17βG 
transport. For this purpose, we investigated E
2
17βG transport by mutant F368W and wild 
type MRP4 in presence of different concentrations of ATP, and the inhibitory effect of 
vanadate, which traps ADP to the NBDs. Figure 5A shows the ATP-dependency of E
2
17βG 
transport via MRP4 and F368W at a fixed E
2
17βG concentration (200 µM). The K
m
 values of 
the wild type and F368W mutant were similar (1.5 ± 0.4 mM and 1.7 ± 0.7 mM, respectively). 
In addition, Figure 5B shows that vanadate inhibited E
2
17βG transport by MRP4 and F368W 
with comparable IC
50
 values (160 ± 40 µM and 180 ± 30 µM, respectively). 
Docking of substrates in MRP4
The homology model of the MRP4 outward-facing state was based on the Sav1866 structure 
(Fig. 6B).8, 18 In addition, we constructed a new inward-facing model of MRP4 based on the 
mouse P-gp structure (Fig. 6A).12 These MRP4 models were used as receptor for docking of 
E
2
17βG, MTX, cGMP, and folic acid structures. The maximum binding energies were 11.0, 
6.8, 7.7, and 7.7 kcal/mol in the inward-facing model, and 10.6, 6.2, 7.2, and 7.9 kcal/mol in 
the outward-facing model, for binding of E
2
17βG, MTX, cGMP, and folic acid, respectively. 
The highest binding energy of E
2
17βG was in good agreement with the highest binding 
affinity (17 μM) we determined. It is difficult to predict which binding site within the pocket 
is used by the substrates. We therefore depicted the molecular surface of all 100 E
2
17βG 
docking results, which provides a good indication of the substrate-binding pocket (Fig. 6).    
A B
Figure 5 Effect of different concentrations of ATP (A) and vanadate (B) on ATP-
dependent E
2
17βG uptake into membrane vesicles containing wild type () and mutant 
F368W () MRP4
(A) Uptake of 200 µM E
2
17βG was measured after 10 minutes in presence of different ATP 
concentrations. Data were normalized to V
max
, which was set at 100%, and subsequently pooled. 
Mean ± S.E.M. of four independent experiments is shown. (B) ATP-dependent transport of 100 µM 
E
2
17βG was measured after 10 minutes in presence of different concentrations of vanadate. V
max
 
was set at 100%, and mean ± S.E.M. of four to five independent experiments are shown.
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Discussion
In the present study, we used mutational analysis to explore the role of amino acids Phe368 in 
TM6, and Trp995 and Arg998 in TM12 in transport activity of MRP4. All amino acid substitutions 
of Arg998 appeared to be deleterious, whereas the effect of Phe368 or Trp995 substitutions was 
dependent on the amino acid introduced and the substrate studied. We found substrate-
dependent effects for the transport activity of mutant F368W that were not related to a 
change in apparent K
m
 but due to an altered V
max
. We hypothesize that in this mutant, not 
the binding of the substrate is altered, but that the subsequent conformational changes, 
Figure 6 Homology models of MRP4 
MRP4 in the inward- (A) and outward–facing (B) conformation. The molecular surface of all 100 
E
2
17bG docking results is shown in grey in each panel. In addition, the side chains of Phe368, Arg375, 
Trp995 and Arg998 are shown in a close-up of the substrate-binding pocket in the inward- (C) and 
outward-facing (D) state.     
A B
C D
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ultimately leading to substrate release, are affected in a substrate-dependent manner. 
The substitutions of Arg998 appeared to be deleterious for transport of all substrates 
tested (Fig. 3). In a previous study we already showed that R998A disrupted transport of 
MTX and cGMP.8 Here, we showed that replacing Arg998 with another positively charged 
amino acid (Lys) is not sufficient to maintain transport activity. Similar results were obtained 
with the MRP1 homolog of Arg998, Arg1249, for which mutation to Ala, Asp or Lys, completely 
disrupted transport of different substrates and binding of leukotriene C
4
 (LTC
4
), indicating its 
importance for substrate binding.19, 20 According to the homology model of the inward-facing 
pump, Arg998 is located at the cytosolic interface of TM12, at the bottom of the substrate 
binding pocket, pointing into the pore (Fig. 6). This localization, in combination with the 
mutagenesis results, suggests that Arg998 plays a prominent role in gating the substrates into 
their binding site. 
Trp995 is a highly conserved amino acid in the ABCC family (Fig. 1). In this study, we 
showed that substitution of Trp995 in MRP4 with Ala completely disrupted transport 
activity, whereas the substitution with more conservative amino acids (Phe and Tyr) led 
to a decreased transport activity for all substrates tested. To obtain more information on 
the role of the amino acids of interest in substrate handling, we determined K
m
 and V
max
 
values of the mutant transporters for different substrates; K
m
 representing the apparent 
affinity for substrate binding of the transporter, and V
max
 being the maximum transport rate 
of the transporter. The decreased transport of W995F and W995Y appeared to be mainly 
caused by a decreased V
max
, indicating a decreased catalytic turnover number of these MRP4 
mutants. In addition, the increased apparent K
m
 for cGMP (W995Y) indicates that binding 
of this substrate might have been affected (Fig. 4 and Table 1). The conserved amino acid 
homologues of this amino acid have also been studied in MRP1, MRP2, and MRP3 (Trp1246, 
Trp1254, and Trp1242, respectively). Conservative substitutions of these Trp residues with Phe 
and Tyr revealed substrate-selective effects, supposedly due to decreased binding of the 
substrate to the mutant transporters.21-23 However, the apparent affinities of these mutants 
for different substrates were not reported. Trp995 is predicted to be located in TM12 at the 
bottom of the binding pocket just above Arg998 (Fig. 6). Our results indicate that Trp995 might 
only play a minor role in binding of some substrates (e.g. cGMP), which is also suggested by 
its position in the inward-facing conformation (at the edge of the binding pocket). 
Mutation of Phe368 to Ala decreased transport of all substrates tested, whereas conservative 
substitutions with the aromatic Trp and Tyr residues caused substrate-dependent effects. 
Similar effects have also been shown for Phe594 substitutions in MRP1 (equal to Leu363 in 
MRP4) (Fig. 1). Phe594 was hypothesized to be implicated in substrate binding, because 
mutation of this amino acid to Ala abrogated binding and transport of LTC
4
 by MRP1.24 In 
the present study, we observed that the F368W mutation induced an increased transport 
rate of E
2
17βG, whereas transport rates of cGMP and MTX were reduced. The decreased 
transport of cGMP could be explained by an increased K
m
 value, which implicates a reduced 
substrate binding. However, F368W did not affect the K
m
 values for MTX and E
2
17βG 
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transport, implicating it is not involved in initial binding of these substrates. Although we 
cannot exclude a possible effect of this mutation on the number of substrate binding sites 
for E
2
17βG and MTX, this does not seem a very plausible explanation because this would 
most likely have affected the K
m
 values. Therefore, the effects of F368W on E
2
17βG and MTX 
transport appeared to be caused by an oppositely directed change in V
max
, indicating that 
the transport rate of F368W is influenced in a substrate-dependent fashion. 
Mutations in a TM domain could affect ATP binding and hydrolysis, or ADP release at the 
NBDs.19 E
2
17βG transport activity of F368W and wild type MRP4 (Fig. 5A) revealed no effect 
of F368W substitution on the apparent affinity for ATP, indicating that it does not affect the 
rate of ATP binding and release. In addition, inhibition of E
2
17βG transport with increasing 
concentrations of vanadate, a phosphate analog that traps ADP to the NBDs25, showed no 
effects on vanadate sensitivity of the mutant transporter (Fig. 5B). These results indicate 
that handling of ATP and ADP by mutant F368W is similar to that of wild type MRP4. 
Because neither a change in substrate nor in ATP or ADP binding of F368W appeared to 
explain its opposite effects on rate of transport of E
2
17βG and MTX, we made homology 
models of MRP4 to visualize the localization of this amino acid (Fig. 6). In the inward-
facing, substrate binding, state of the homology model, Phe368 is positioned outside the 
binding cavity, whereas it moves into the binding cavity in the outward-facing state (Fig. 6). 
Therefore, this residue does not seem to be involved in the formation of the initial binding 
site, but it might be important for the conformational changes after initial binding of a 
substrate. For P-glycoprotein, it has been shown that the protein conformation adapts to 
the substrate that is transported, implicating translocation of multiple substrates, but also a 
substrate-dependent movement of the helices.26 This could provide an explanation for the 
finding that the MRP4 substitution F368W increased the catalytic turnover rate of E
2
17βG 
transport, whereas it decreased that of MTX, implicating that Phe368 plays a crucial role in 
the substrate-dependent conformational changes that are involved in the transport of MTX 
and E
2
17βG to the extracellular side. Another explanation for these opposite effects of the 
F368W mutant could be that Phe368 plays a role in the dissociation of these substrates in 
the outward-facing conformation. Future studies should provide further evidence for one 
of these theories.   
Docking of substrates to the MRP4 homology models illustrates the role of the two 
positively charged Arg residues and the aromatic Phe and Trp residues at the entrance of 
the binding pocket (Fig. 6). In the inward-facing situation substrates can bind to several 
sites within the pocket, possibly followed by an induced fit. Next, ATP- and substrate-
dependent rearrangement of the TM helices and repositioning of Phe368, Trp995, Arg375 and 
Arg998 facilitates translocation of substrate across the membrane. These amino acids most 
likely funnel the substrates to their binding site at the opposite side of the membrane. 
Eventually, Arg375 is positioned at the bottom of the binding pocket, whereas Arg998 is now 
located somewhat more to the side of the pocket. Moreover, Phe368 and Trp995 are forming 
an aromatic wedge inside the outward-facing binding pocket, which could decrease binding 
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and facilitate the release of substrates. 
In summary, Arg998 seems to be essential for transport of all substrates tested, whereas 
the effect of a Phe368 or Trp995 replacement was dependent on the amino acid introduced 
and the substrate studied. F368W increased E
2
17βG transport and reduced MTX transport, 
which was not due to an altered substrate affinity. In conclusion, Phe368 and Trp995 do not 
play an important role in the initial binding of substrates, but might funnel the substrates 
to the exit site in the outward-facing conformation. Revealing the importance of different 
amino acid for substrate binding by MRP4 in combination with other technologies such as 
pharmacophore and homology modeling will ultimately lead to a better understanding of 
the substrate binding pocket of MRP4. This knowledge could be used for the development 
of specific inhibitors of MRP4, which could be helpful for further investigation of MRP4 
function in vitro and in vivo and might be of therapeutic potential. 
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Introduction
The concentration of central nervous system (CNS) drugs in the brain is often limited by 
transport and metabolism of these drugs at the BBB or intestine via drug efflux transporters 
and metabolizing enzymes.1 If compounds could be selected that have limited efflux or 
metabolism, CNS drugs with a better pharmacokinetic profile could be developed. In this 
thesis, different in vitro tools are described that were developed to investigate the transport 
of new compounds via efflux transporters. Besides using these tools to select compounds 
that are not transported via efflux transporters in CNS drug development, they can also be 
used to identify substrates for these proteins. Using P-gp transport affinity as a selection 
criterion is interesting for compounds that should not enter the brain to prevent unwanted 
CNS-mediated adverse effects. This was also thought to be an interesting strategy in the 
development of peripheral CB1 receptor antagonists, which would have less neuropsychiatric 
side effects than the brain-penetrating CB1 receptor antagonist rimonabant in treatment 
of obesity. In this thesis, the influence of drug efflux on the brain disposition of a class of 
3,4-diarylpyrazoline CB1 receptor antagonists has been investigated (Chapter 2 and 3). In 
this chapter, the implications of using efflux transporter activity in the development of safe 
CB1 receptor antagonists in comparison to other strategies to improve the cost-benefit ratio 
of these antagonists are discussed. Furthermore, the advantages and disadvantages of our 
tools to identify substrates of efflux transporters and the use of these tools in CNS drug 
development are considered.
The progress made in improving the benefit-risk ratio of CB1 receptor 
antagonists
Inhibition of one of the key players of the endocannabinoid system, the cannabinoid type 1 
(CB1) receptor, with the CB1 receptor antagonist/inverse agonist rimonabant has positive 
effects on weight, waist circumference, and cardiometabolic risk factors.2, 3 However, 
two years after its release on the European market, rimonabant was withdrawn due to 
psychiatric side effects of this compound in additional clinical studies.4-6 Although many 
companies subsequently stopped their CB1 receptor antagonist development programmes 
(i.e. for taranabant, surinabant, otenabant, and ibipinabant), some researchers thought it 
should be possible to increase their benefit-risk ratio.5 The possibilities to avoid adverse 
events comprised treatment of a subset of patients which might benefit the most from 
treatment, and the development of neutral or peripheral CB1 receptor antagonists.5 
Based on the results from clinical studies with rimonabant, researchers hypothesized 
that patient selection could increase the benefit-risk ratio of already existing CB1 receptor 
antagonists.7, 8 Patients expected to benefit most from rimonabant treatment were 
people with abdominal obesity who have a cardiometabolic risk profile that is worse than 
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people with the same body mass index and global obesity. Rimonabant treatment had an 
increased benefit in these patients because it decreased the intra-abdominal fat and the 
associated cardiometabolic risk factors.8 In addition to selecting patients with a certain 
type of obesity, one should exclude patients with a history of depression to reduce the 
psychiatric side effects.8, 9 Comparing clinical studies including or excluding these patients 
showed that patients with a history of depression or anxiety were more likely to have 
recurring psychiatric events upon rimonabant treatment.8, 9 In addition, polymorphisms 
in genes encoding the CB1 receptor and the serotonin reuptake transporter (SERT) 
that lead to a lower expression of both proteins are correlated with a higher risk for 
anxiety and depression.9 These findings create opportunities for the development 
of pharmacogenomic tests and questionnaires to select patients with a lower risk for 
psychiatric adverse events for treatment with rimonabant. If the inclusion and exclusion 
criteria for most benefit of treatment and lowest risk for adverse events are applied, 
the benefit-risk ratio of CB1 receptor antagonist treatment should be much improved.8 
Although progress has been made in understanding the involvement of CB1 receptor 
inhibition in anxiety or depression, and investigating possibilities to select patients with 
an increased benefit-risk ratio, this has not yet evolved in the re-approval of rimonabant 
for a subset of patients.
Another option was to develop neutral antagonists of the CB1 receptor instead of 
inverse agonists, such as rimonabant.5 In theory, inverse agonists decrease the basal 
activity of a receptor, whereas neutral antagonists only inhibit its ligand-mediated 
activity.10 Researchers hypothesized that the psychiatric side effects of rimonabant might 
be due to inhibition of the basal activity of the CB1 receptor and that neutral CB1 receptor 
antagonists might have a favourable pharmacodynamic profile.11, 12 However, it  is difficult 
to distinguish between neutral antagonists and inverse agonists with current assay 
technologies, because it depends on the sensitivity of the assay whether weak inverse 
agonistic activity may be revealed, possibly indicating false neutral antagonistic activity 
of a compound.10 In addition, endogenous endocannabinoid levels are thought to cause 
a basal endocannabinoid tone leading to additional ligand-mediated constitutive activity 
of the CB1 receptor that could be inhibited by a neutral antagonist, thereby displaying 
inverse agonistic properties.12, 13 After withdrawal of rimonabant, an increasing number 
of putative neutral CB1 receptor antagonists has been developed (summarized by Ward 
et al).12 One of these neutral antagonists, AM4113, retained beneficial effects on food 
intake and weight loss, but appeared to cause less nausea and a smaller contextual fear 
response and less anxiolytic effects than CB1 inverse agonists in rats. 14-16 These results 
suggest that these compounds are as effective as rimonabant in reducing weight, with 
less side effects. However, there is still a chance that these compounds fail in clinical 
trials due to psychiatric side effects because the anxiolytic effects of these compounds 
have only been studied in a few animal studies. To further investigate their therapeutic 
potential, more animal studies with putative neutral antagonists should be performed.
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Probably the most effective option for reduction of centrally mediated psychiatric side 
effects would be developing CB1 receptor antagonists that only act on peripheral CB1 
receptors. However, these compounds might have less effect on food intake and weight, 
as these actions were shown to be largely mediated via the central CB1 receptor.17, 18 On 
the other hand, it was hypothesized that peripheral CB1 receptor antagonists preserve the 
effects of CB1 receptor antagonists on cardiometabolic risk factors that are thought to be, at 
least partly, affected by CB1 receptors in peripheral tissues.5, 19-21 Several putative peripheral 
CB1 receptor antagonists have been developed in the past years, of which two potent 
compounds, AM6545 and BPR697, convincingly show a role for peripheral CB1 receptors 
in energy balance and metabolism.12, 22-25 In animal studies, these compounds improved 
cardiometabolic risk factors, such as hepatic triglycerides, insulin, glucose, adiponectin, and 
leptin levels, and even caused weight loss or decreased weight gain, which is probably due to 
increased lipid oxidation.22-25 On the other hand, they did not interrupt with agonist-induced 
hypothermia, hypomotility, catalepsy, and analgesia mediated via the central CB1 receptor, 
indicating that they do not penetrate the brain.22, 23 Furthermore, AM6545 did not induce 
anxiolytic effects, while rimonabant did.22 In addition to being a peripheral antagonist, 
AM6545 is a neutral antagonist, and it was also shown to cause less nausea, most likely 
because of its lack of inverse agonistic action.24, 25 Parallel to the development of AM6545 
and BPR697, the biotech company 7TM Pharma has made efforts to design a peripheral 
CB1 receptor antagonist, TM38837, and this compound has entered clinical studies.26, 27 
They state that it is a potent compound in animal studies for obesity and type 2 diabetes 
and that a Phase I clinical study in 24 men showed that a therapeutic dose of TM38837 
does not affect CNS-mediated effects of the CB1 receptor agonist ∆9-tetrahydrocannabinol, 
indicating that it does not enter the brain.26 In conclusion, these compounds appear to 
have beneficial effects on cardiometabolic risk factors with reduced CNS-mediated side 
effects, and therefore might serve as good therapeutics for treatment of metabolic disease 
associated with obesity. To further support the exploration of the therapeutic potential 
of peripheral CB1 receptor antagonists, we investigated how transport of CB1 receptor 
antagonists via efflux transporters might limit the brain penetration of these compounds, to 
provide a strategy for selection of peripheral compounds early in drug development.
 
The role of efflux transporters in reducing brain penetration of CB1 receptor 
antagonists
The research described in Chapter 2 and 3 of this thesis was focused on the transport and 
interaction of a series of 3,4-diarylpyrazoline CB1 receptor antagonists with the efflux 
transporters MRP1, MRP2, MRP3, MRP4, and P-gp. We were the first to report interaction 
of CB1 receptor antagonists with MRP1-4. Vesicular interaction studies using membrane 
vesicles of HEK293 cells overexpressing these transporters showed that most of them 
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interacted with the transporters. The 3,4-diarylpyrazolines mainly inhibited MRP1- and 
MRP4-mediated E
2
17βG transport and P-gp-mediated NMQ transport, whereas they 
stimulated transport of E
2
17βG by MRP2 and MRP3 (Chapter 2 and 3). The inhibitory action 
of 13, rimonabant, and most likely also of 15 on MRP1 and MRP4 was non-competitive, 
whereas for MRP2 and MRP3 the interaction appeared to be competitive (Chapter 2). 
Additional in vivo data of the effective dose (ED
50
) of compounds 4, 11, 14, and 15 in 
inhibiting CB1 agonist-induced hypotension suggested active transport of compound 4, 11, 
and 14 from the brain, for which MRP4 might be responsible (Chapter 2). On the other 
hand, the cellular accumulation assay using HEK293 cells overexpressing P-gp showed that, 
although all CB1 receptor antagonists inhibited P-gp-mediated NMQ transport, only one of 
them appeared to be a substrate of P-gp in this assay (Chapter 3). This suggests that the 
vesicular interaction assay is not predictive for transport of a compound via the transporter 
of interest. Therefore, transport studies with 3,4-diarylpyrazolines in cellular transport 
assays or knockout mice should be performed to determine the possible involvement of 
MRP1-4 in limiting the brain penetration of 3,4-diarylpyrazoline CB1 receptor antagonists.
By determining the accumulation of CB1 receptor antagonists in HEK293 cells 
overexpressing P-gp or a control protein, we showed that only 3,4-diarylpyrazoline 23 was 
transported via P-gp (Chapter 3). An in vivo study in rats revealed that the brain penetration 
of this compound was also reduced compared to rimonabant, which was not a P-gp 
substrate, and inhibition of P-gp with elacridar showed that P-gp was largely responsible 
for the limited brain penetration of 23 (Chapter 3). This implies that transport of CB1 
receptor antagonists via P-gp could be used in the development of peripheral CB1 receptor 
antagonists. 
In addition to P-gp, BCRP might also play a role in limiting the brain penetration of CB1 
receptor antagonists. BCRP is present at the luminal membrane of the BBB and recent 
studies using LC-MS/MS quantification of proteins present at the human BBB revealed that 
BCRP abundance is even somewhat higher than P-gp (about 1.3-1.5 fold difference).28, 29 In 
rats and mice about 3- to 4-fold more P-gp than BCRP is present at the BBB. Therefore, the 
importance of BCRP transport in humans might be underestimated in studies with these 
animals.30, 31 In Chapter 3, we studied the transport of 23 and rimonabant via BCRP, and 
revealed that in addition to being a P-gp substrate, 23 is also a BCRP substrate. Although 
the influence of BCRP on 23 brain penetration in rats might be limited, together with P-gp it 
might form a very effective barrier at the human BBB against CB1 receptor antagonists (Fig. 
1). Therefore, it would be interesting to further investigate the possibility to select for BCRP 
substrate activity in addition to P-gp activity to further reduce human brain penetration of 
peripheral CB1 receptor antagonists.
In our studies, we have focused on the possibility of using P-gp in the development of 
peripheral CB1 receptor antagonists and showed that transport via P-gp might serve as 
a selection criterion in this process. In fact, one other group showed that P-gp was the 
most important factor for limiting the brain penetration of their peripheral CB1 receptor 
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antagonist AM6545.22 Another study speculates that some of the CB1 receptor antagonists 
developed are expected to have a lower brain/plasma ratio because they are substrates 
of P-glycoprotein and also have a high polar surface area (PSA).32 Unfortunately, brain and 
plasma concentrations have not been measured in that study to provide evidence for a 
low brain penetration of those compounds. However, the oral ED
50
 necessary for reversing 
CB1 agonist-induced hypotension was much higher for P-gp substrate than for non-P-
gp substrate CB1 receptor antagonists, suggesting lower brain penetration or poor oral 
availability.32 Other ways to lower the brain penetration of compounds could be lowering 
the lipophilicity or increasing the PSA of a compound.27 Changing these physicochemical 
characteristics will decrease their ability to penetrate membranes, and this method appears 
to be useful in lowering the brain penetration of CB1 receptor antagonists.27 It would be 
interesting to investigate the tissue distribution of these type of compounds, because their 
low lipophilicity might also reduce their penetration into other tissues than the brain, where 
the target CB1 receptors are localized, thereby lowering the pharmacodynamic effect of 
these CB1 receptor antagonists. For P-gp substrate peripheral CB1 receptor antagonists, 
this problem is less likely to occur. However, for this type of compounds a decreased oral 
availability due to intestinal P-gp transport might be a problem in development.
Figure 1 Transport by P-gp and, possibly, BCRP at the BBB limits the brain penetration 
of 3,4-diarylpyrazoline CB1 receptor antagonist 23 and not of rimonabant
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P-gp transport can lower the oral availability of drugs, and this could be a general problem 
of using the P-gp transport strategy to develop peripheral CB1 receptor antagonists.33 
However, the impact of P-gp on intestinal absorption is thought to be lower than on BBB 
penetration because the higher concentrations of drug in the intestine appear to saturate 
intestinal P-gp.34 Indeed, there are drugs for which P-gp transport activity has proven to 
be useful to limit the central side effects, in which P-gp has limited effects on determining 
the intestinal absorption after oral administration, such as domperidone, fexofenadine, and 
loperamide of which respectively about 100%, 30% and 65% of the oral dose is absorbed 
at the intestine.35-43 In addition, P-gp transport also did not appear to restrict the oral 
availability of the peripheral antagonist (and P-gp substrate) AM6545, because its plasma 
concentration was similar after oral and peritoneal dosing.22 Furthermore, in the CaCo-2 
cell model for oral availability, AM6545 had an efflux ratio of 1.1, which indicates that its 
oral availability is not limited by active transport.22 Cellular assays to estimate the intestinal 
penetration have also been performed for the 3,4-diarylpyrazoline CB1 receptor antagonists 
in our study, and the efflux ratio for the P-gp substrate 23 in CaCo-2 cells was 1.5, and 28% 
of its dose passed the membrane of LLC-PK1-MDR1 cells (unpublished data). This indicates 
that oral availability of 23 is not expected to be limited by lower membrane passage and 
active efflux at the intestinal wall. Whether a compound will pass the intestinal barrier will 
not only depend on whether a compound is a P-gp substrate, but also on a combination of 
physicochemical characteristics, such as logP, PSA, or size, in addition to active transport via 
influx and efflux transporters. If future CB1 receptor antagonist are selected on the basis 
of their P-gp transport affinity, additional cellular permeability studies predictive for oral 
availability could give an indication of what compounds to select for further development.
Importance of efflux transporters for the development of CNS drugs
The reduction of the brain concentration of CB1 receptor antagonist 23 by P-gp (Chapter 3), 
underlines that P-gp-mediated efflux at the BBB can lower the brain penetration of drugs. 
Previous studies evaluating the P-gp substrate activity of CNS drugs compared to non-CNS 
drugs revealed that only few marketed CNS drugs are transported via P-gp compared to non-
CNS drugs, indicating that P-gp transport activity is not favourable for brain penetration.1, 44 
The knowledge that this transporter is an important gatekeeper of the brain has led to the 
use of multiple tools to predict or determine substrates of P-gp.
Identification of P-gp substrates using computational models could provide a cost-effective 
method to select lead compounds early in drug development.45 Multiple computational 
models have been developed that describe the structure-activity-relationship (SAR) of 
compounds with P-gp and, over the past decades, the predictability of these models for P-gp 
substrates has increased.46, 47 However, because P-gp has multiple substrate binding sites, 
which explains its wide substrate specificity, it has been difficult to produce a conclusive 
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SAR model for P-gp substrate activity of compounds.48 Different pharmacophore models, 
which describe the chemical properties of a compound that determine interaction with a 
binding site, should be developed for the different bindings sites to predict the wide range of 
substrates. Not only P-gp, but also other efflux transporters, such as MRPs, possess a complex 
binding pocket with multiple drug binding sites (Chapter 6).49-54 This is further emphasized 
by the fact that mutation of amino acids that might be part of the substrate binding 
pocket of MRP4 showed different effects for varying substrates (Chapter 6). In addition, 
the discrepancy between the effects of mutation of W995 in MRP4 and its homologues 
in MRP1-3 on transport of estradiol 17β-D-glucuronide (E
2
17βG) and methotrexate (MTX) 
suggests that the role of this amino acid homologue in the transport binding pocket is 
different between the transporters (Table 1).55-57 Therefore, binding of substrates will rely 
on interaction of substrates with several amino acids in the pocket that might differ for 
each substrate, leading to multiple binding sites. Combining SAR with substrate binding 
site modeling might improve the computational models to predict substrates for efflux 
transporters in CNS drug development.48
Because the computational models cannot give a conclusive answer as to whether a 
compound is a substrate of P-gp, transport activity should be verified using experimental 
models. Different experimental tools are available to assess whether compounds are 
substrates or inhibitors of efflux transporters (summarized in Table 2).58-60 In this thesis, 
we mainly used HEK293 cells overexpressing different efflux transporters for a cellular 
Table 1 Effects of homolog amino acid substitutions in MRP1-4 on E
2
17βG and MTX 
transport activity
Mutation Substitution E
2
17βG (%)a MTX (%)a
MRP1 – Trp1246 Ala <10 <10
Tyr <10 10
MRP2 – Trp1254 Ala <10 14
Tyr 100 1
MRP3 – Trp1242 Ala 250 20
Tyr 700 20
MRP4 – Trp995 Ala 0 5
Tyr 30 40
Data are from Ito et al. and Oleschuk et al and Chapter 6.55-57
a Normalized transport activity of mutant compared to wild type (100%) 
transporter using 400 nM E
2
17βG and 1000 nM MTX for determining 
MRP1-3 transport activity, and 120 nM E
2
17βG and 500 nM MTX for MRP4.
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accumulation assay or a vesicular transport assay to assess interaction of compounds with 
efflux transporters (Fig. 2). 
Vesicular transport assay
The vesicular transport assay is an experimentally convenient assay to investigate efflux 
transporters and it has been used for more than 20 years. In this thesis, we have used the 
vesicular transport assay for multiple purposes: I) Investigation of interaction of compounds 
with efflux transporters (Chapters 2, 3, and 5); II) Substrate identification via direct transport 
measurements (Chapter 4); III) Mutational analysis of transporter function (Chapter 6).
Interaction of compounds with the transport of a probe substrate into membrane vesicles 
has been used frequently to identify new modulators of transport.61-64 Using this method, 
drug-drug interactions can also be detected.61, 65 Because modulators might have different 
effects on transport of different probe substrates, it would be best to use the combination 
of drugs that will be co-administered to investigate drug-drug interactions. Interaction of 
a compound with a transporter, inhibiting or stimulating transport of the probe substrate, 
might implicate that it is also transported via the transporter. However, comparison of the 
interaction of CB1 receptor antagonist with P-gp in membrane vesicles with their actual 
transport via this transporter in cells, revealed that interaction with this transporter did not 
necessarily predicted its substrate activity (Chapter 3). Therefore, one should be careful 
with the interpretation of transport interaction data in relation to possible substrate activity 
of a compound.
A better way to determine substrate specificity, is to measure the transport of the 
compound directly. Previously, this has been limited to radiolabeled or fluorescent 
compounds, but by using high-pressure liquid chromatography (HPLC), often combined with 
tandem mass spectrometry (LC-MS/MS), it is also possible to quantify vesicular transport 
of non-(radio)labeled compounds.66-68 Chapter 4 illustrates the use of measuring direct 
transport of the model compound 7-HC and 7-HC-G into membrane vesicles using HPLC. 
By investigation of transport of 7-HC and 7-HC-G via different efflux transporters, we were 
able to identify the efflux transporters influencing the human pharmacokinetics of coumarin 
and its metabolites 7-HC and 7-HC-G (Chapter 4). However, we also found that this method 
sometimes produces false negative results. In the case of CB1 receptor antagonist 23, we 
identified it as a P-gp substrate using the cellular accumulation assay, whereas we could not 
detect uptake of this compound into P-gp vesicles (unpublished results). This might be due to 
the high lipophilicity of the CB1 receptor antagonists, having a greater propensity to diffuse 
over the vesicular membrane, leading to a higher background in the samples and a smaller 
difference between control and transporter-expressing vesicles. Substrates of P-gp are often 
more lipophilic than substrates of MRPs and BCRP. 69, 70 The fact that the vesicular transport 
assay is less suitable for identification of lipohilic compounds is reflected by the fact that 
there are only few articles describing vesicular transport using P-gp vesicles, whereas there 
are many available describing transport into MRP- and BCRP-overexpressing vesicles.
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vesicles are often used to elucidate the mechanism of transport activity of these proteins. 
Introducing amino acid mutations might reveal which amino acids are important for substrate 
binding or for other steps in the transport cycle (Chapter 6).50, 56, 71-75 Because the vesicular 
transport assay is very suitable for the investigation of kinetic characteristics of transport 
activity of wild type and mutant proteins, e.g. determination of K
m
 and V
max
, it provides a 
useful tool to characterize the mechanism of substrate transport via the transporter.
Figure 2 Schematic overview of vesicular (A) and cellular (B) transport studies using 
control and transporter-expressing cells
Dashed lines represent passive transport of the compound of interest, whereas straight lines 
indicate active transport. Additional ATP should be added in substrate mix for vesicular transport 
studies to enable active transport via hydrolysis of ATP to AMP and phosphate (Pi).
A
B
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Table 2 Comparison of different in vitro models to identify substrates and inhibitors of 
efflux transporters 
Model Identifies Advantages Disadvantages
ATPasea I -  no need for specific 
compound detection 
method
- poor predictability 
of substrates and 
inhibitors
- results depend on 
experimental conditions
- difficult assay for 
transporters due to high 
background ATPase 
activity
Vesicular transporta S, I - measuring direct 
transport of compounds 
(substrate identification)
- determination of kinetic 
transport characteristics 
(K
m
 or Ki)
- high throughput
- false negative results 
for substrates with high 
passive permeability 
or non-specific binding 
(often P-gp substrates)
Cytotoxicity assayb S, I - no need for specific 
compound detection 
method 
- only cytotoxic 
substrates can be 
identified as substrates
- cytotoxicity varies 
between cell types
Cellular accumulationb, c S, I - measuring direct 
transport of compound 
(substrate identification)
- relatively high 
throughput possible
- determination of Ki of 
inhibitors
- hydrophobic substrates 
may be not detected 
due to rapid passive 
diffusion
- transport of low 
permeable compounds 
may be underestimated
Transwell transportc S, I - measuring direct 
transport of compounds 
(substrate identification)
- determination of kinetic 
transport characteristics 
(K
m
 or Ki)
- polarized cells with 
functional localization 
of transporters
- assessment of 
permeability of 
compounds
- labour intensive and 
more expensive
- depends on passive 
permeability of 
compound
- standard protocols 
should ensure tightness 
of cell monolayer
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Cellular accumulation assay
The principle of efflux via transporters to protect the cell from accumulation of (toxic) 
compounds has been used in the development of cellular accumulation assays to identify 
substrates or inhibitors of efflux transporters. Previously, these assays were restricted 
to cytotoxic, radiolabeled or fluorescent compounds, but with new LC-MS/MS methods 
it is possible to investigate a wide variety of compounds in this assay.59, 60, 76 Because the 
assay is based on the accumulation of a compound due to its passive diffusion over the 
cell membrane, this assay is more suitable for lipophilic compounds than for hydrophilic 
compounds, which will not diffuse into the cell. However, too lipophilic compounds may 
escape efflux transport due to rapid diffusion into and out of the cell, which might also lead 
to false-negative results.46, 59 The advantage of HEK293 cells for this assay is that these cells 
are very suitable for transient expression of transporters using baculovirus. HEK293 cells 
transiently expressing a control protein serve as a good control for transporter-expressing 
HEK293 cells because these cells are treated equally and will diverge less in morphology 
and functionality than cell lines stably overexpressing control and transporter protein. A 
disadvantage of HEK293 cells is that they have a tendency to detach from the culture plates 
during washing. Furthermore, they express endogenous transporters that might reduce 
the effect induced by the overexpressed transporter, especially for high affinity substrates 
(Table 3).77 However, endogenous transporters are present in most cell types, and might 
even differ between stable control and transporter expressing cell lines.78 Other groups have 
also performed accumulation assays with different cell types overexpressing transporters, 
often in combination with transport inhibitors.79, 80 However, one should be careful with only 
using inhibitors to verify which transporter is involved, because they often lack transporter 
specificity (Chapter 5).62 Furthermore, we found that the P-gp inhibitor elacridar influenced 
the availability of some CB1 receptor antagonists in the medium. Because some of these 
lipophilic compounds had poor solubility or appeared to attach to the cells or the plate 
surface, less than the nominal concentration of CB1 receptor antagonists was available 
in the medium (Chapter 2). Adding the P-gp inhibitors similarly increased the medium 
concentration and thereby the cellular accumulation of some CB1 receptor antagonists, 
leading to false positive results if only the effect of P-gp inhibition in P-gp overexpressing cells 
Table 2 continued
Content is based on experience with models used in this thesis and reviews describing other 
models.46, 58
S, substrate; I, inhibitor
a, b, c Preparations used for identification: 
a Membrane vesicles of cells overexpressing transporters or lipid membranes with reconstituted 
transporters.
b Unpolarized cells overexpressing transporters, such as HEK293-P-gp.
c Polarized cells overexpressing transporters, such as MDCKII-P-gp or LLC-PK1-P-gp.
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would have been tested (unpublished data). However, by comparing the accumulation in a 
HEK293 control to the accumulation in P-gp overexpressing cells, we circumvented this issue.
Comparison of transporter assays
Transwell transport studies that determine vectorial transport of a compound through a 
polarized cell line overexpressing P-gp are seen as the golden standard for the identification 
of P-gp substrates.46, 81 However, most of the limitations of the accumulation assay, e.g. 
high dependence on compound permeability, are also limitations to this type of transport 
studies (Table 2). The main advantage of using polarized instead of non-polarized cells is 
that it represent a more physiologically relevant model and that transport direction (apical 
to basolateral or basolateral to apical) and passive permeability can be determined.59 
Furthermore, there are papers describing how to determine kinetic characteristics of 
transport using these studies, which is more difficult in cellular assays.82, 83 On the other 
hand, the accumulation assay does serve as a more practical assay to identify lipophilic and 
membrane permeable substrates and it would allow for a higher throughput than transwell 
studies. For hydrophilic, less membrane permeable compounds the vesicular transport 
assay will provide a more suitable assay for substrate identification. These assays could 
therefore provide good alternatives for the polarized transport assays in the (CNS) drug 
Table 3 Determination of mRNA expression of efflux transporters in HEK293 cells using 
a whole genome expression array77
Efflux transporter Expressed
ABCC1 (MRP1) yes
ABCC4 (MRP4) yes
ABCC5 (MRP5) yes
ABCB1 (P-gp) yes
ABCC6 (MRP6) yes
ABCC10 (MRP7) yes
ABCG2 (BCRP) yes
ABCC3 (MRP3) no
ABCC2 (MRP2) no
ABCC12 (MRP12) no
ABCC11 (MRP8) no
A GeneChip Human Genome U133 Plus 2.0 Array from Affymetrix was used to determine mRNA 
expression. Absent/present calls for individual gene expression values were obtained from a data 
set generated with the MAS5 (Affymetrix Microarray Suite version 5.0; Affymetrix) algorithm.77
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development process for finding MRP1-4 (vesicles), BCRP (vesicles/cell accumulation) or P-gp 
(cell accumulation) substrates.
Metabolism of CNS drugs
Metabolism of CNS drugs is also an important determinant of their plasma and eventually 
brain concentration.1 Therefore, many companies use in vitro methods to study whether lead 
compounds in drug development are substrates or inhibitors of metabolism to estimate in vivo 
metabolism or drug-drug interactions.84-86 Because transporters and enzymes are thought to 
work in concert, an assay including both metabolizing enzymes and transporters might provide 
a more physiological assay to estimate metabolism and transport in vivo.86, 87 If the interaction 
between specific enzymes and transporters is studied, a cell model should be used in which 
endogenous transporters and metabolizing enzymes would not influence the metabolism and 
transport of the compound of interest. Previously, HEK293 cells co-expressing UGT2B7 and 
MRP1, MRP2 or MRP3 have been used to study the effect of transport on glucuronidation.88, 
89 In our study, we also used HEK293 cells overexpressing UGT2B15 to study glucuronidation 
of the model compound 7-HC (Chapter 5). The absence of accumulation of the hydrophilic 
metabolite 7-HC-G, however, indicated the presence of endogenous transporters in these 
cells. Indeed, MRP4, one of the efflux transporters of 7-HC-G (Chapter 4), appears to be 
endogenously expressed in HEK293 cells (Chapter 5 and Table 3).77 Therefore, a co-expression 
model of an enzyme and MRP4 in these HEK293 cells is less suitable to investigate enzyme-
transporter interplay of parent compounds that have metabolites with a high substrate affinity 
for MRP4, because these metabolites are likely to be transported by endogenous MRP4.
Investigating intestinal metabolism of one of the 3,4-diarylpyrazoline CB1 receptor 
antagonists in Ussing Chamber experiments with human intestinal tissue showed that 
enzymes in the intestine could play a significant role in metabolism of this compound (personal 
communication, prof. dr. G. Groothuis, Groningen). Preliminary experiments studying 
metabolism of this compound in HEK-CYP3A4 and HEK-CYP3A5 cells suggested that CYP3A4 is 
involved (unpublished results). Because this metabolite was mainly effluxed to the apical side 
of the human intestinal tissue, it was hypothesized that P-gp might play a role in its transport. 
The HEK293 cell model would provide an interesting tool to investigate the interplay between 
CYP3A4 and P-gp in the metabolism of this CB1 receptor antagonist.
Conclusion and future perspectives
In this thesis, we used several in vitro models to study transport of compounds via drug 
efflux transporters and we argue that these tools could be implemented in CNS drug 
development. Especially the membrane vesicular transport assay could provide a useful tool 
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for pharmaceutical industry to screen transport of new compounds via MRPs, which are 
currently largely neglected in drug development.
In the development of peripheral CB1 receptor antagonists, the P-gp transport assay 
was used successfully to select CB1 receptor antagonists that do not enter the brain due to 
active P-gp efflux. The efficacy of peripheral antagonists, of which the development could 
be accelerated using the P-gp substrate strategy, as drugs against obesity and metabolic 
disease should be further established in (pre-)clinical studies.
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English summary
Introduction
Absorption, distribution, metabolism, and excretion (ADME) are key determinants of drug 
efficacy and safety because these processes determine the availability of a drug at its target 
site. Before a drug reaches its site of action, it needs to cross several cellular barriers, such 
as the intestinal wall and the blood-brain barrier (BBB). Different transport proteins are 
located at these barriers that can influence the disposition of a drug in the body. One class of 
transporters expressed at the intestinal wall and the BBB are efflux transporters belonging 
to the ATP-binding cassette (ABC) transporter family. These proteins translocate substrates 
from inside the cell to outside the cell and need energy for their transport activity, which 
is provided by hydrolysis of ATP. P-glycoprotein (P-gp/ABCB1), multidrug resistance-
associated proteins (MRP/ABCC), and breast cancer resistance protein (BCRP/ABCG2) are 
ABC transporters that have been shown to handle clinically relevant drugs. The intestinal 
wall plays an important role in determining the uptake of drugs into the blood after oral 
administration, and the oral availability of drugs can be influenced by their transport via 
efflux transporters in enterocytes. The BBB is formed by endothelial cells lining the small 
blood vessels in the brain together with a basal membrane covered with astrocytes. The 
main purpose of the BBB is to supply the brain with energy and to protect it from harmful 
compounds. Drug efflux transporters expressed at the BBB endothelial cells are involved in 
the latter task, and P-gp has been viewed as the most important gatekeeper of the brain. 
Therapeutic drugs that act on the central nervous system (CNS) have to cross both barriers 
before they enter the brain and can be effective. The clinical development of CNS drugs is 
lagging behind the development of other drugs, partly because intestinal and BBB efflux 
transporters limit their entrance into the brain. 
In this thesis, we studied the role of efflux transporters in limiting the brain penetration of 
a class of anti-obesity drugs, cannabinoid type 1 (CB1) receptor antagonists. Furthermore, 
we investigated the interplay of these transporters with drug metabolizing enzymes and 
how efflux transporters can determine the rate of drug metabolism. In addition, we further 
explored how different amino acids contribute to the transport functionality of the efflux 
transporter MRP4.
Role of efflux transporters in the development of CB1 receptor antagonists as a treatment 
for obesity
Obesity is an illness defined by abnormal or excessive body fat accumulation that presents 
a risk to health. It is becoming an increasing burden to society and at least 2.8 million adults 
die each year as a result of overweight or obesity. Hyperactivity of the endocannabinoid 
system, of which the CB1 receptor is one of the key players, has been shown to play a role 
in the development of obesity. Therefore, inhibitors of the CB1 receptor were developed 
for treatment of obesity. One of these compounds, rimonabant, entered the market as an 
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effective anti-obesity drug in 2006. However, rimonabant was withdrawn in 2008 because 
it gave neuropsychiatric side effects, such as depression and anxiety. These adverse effects 
appeared to be caused by the action of rimonabant on CB1 receptors in the brain. Recently, 
it was found that the positive effects of the drug, such as a reduction of cardiometabolic 
risk factors, are also mediated via inhibition of CB1 receptors in the periphery of the body. 
Therefore, peripheral CB1 receptor antagonists, which act only on peripheral and not on 
brain CB1 receptors, were proposed to be effective drugs for treatment of metabolic disease 
and obesity without neuropsychiatric side effects. Because drug efflux transporters at the 
BBB can block the access of a compound to the brain, we hypothesized that affinity for 
these transporters could be used as a specific feature in the development of peripheral 
CB1 receptor antagonists. To test this hypothesis, we investigated whether a series of 
3,4-diarylpyrazoline CB1 receptor antagonists were transported via these proteins, and 
whether transport could limit their brain penetration. 
In Chapter 2, we showed that most of the 3,4-diarylpyrazoline CB1 receptor antagonists 
interact with MRP1, MRP2, MRP3, and MRP4 in a vesicular transport interaction assay. 
Rimonabant inhibited MRP1 transport activity more potently than MRP4, whereas the 
3,4-diarylpyrazolines were stronger inhibitors of MRP4- than MRP1-mediated transport. A 
number of CB1 receptor antagonists, including rimonabant, stimulated MRP2 and MRP3 
transport activity at low, but inhibited transport at high substrate concentrations. The 
interaction of 3,4-diarylpyrazolines and rimonabant with MRP1-4 indicate their potential for 
drug-drug interactions. Preliminary in vivo data of the effective dose (ED
50
) of compounds 
4, 11, 14, and 15 in inhibiting CB1 agonist-induced hypotension suggest active transport of 
compound 4, 11, and 14 out of the brain, for which MRP4 might be responsible. However, 
follow-up studies with 3,4-diarylpyrazolines in cellular transport assays and knockout mice 
are required to determine whether MRP1-4 are actually involved in limiting the brain 
penetration of 3,4-diarylpyrazoline CB1 receptor antagonists. 
In Chapter 3, we investigated for the same series of CB1 receptor antagonists if transport 
by the brain efflux transporter P-gp could be used as a selection criterion in the development 
of peripheral CB1 receptor antagonists. All 3,4-diarylpyrazolines and rimonabant inhibited 
P-gp transport activity in membrane vesicles isolated from HEK293 cells expressing the 
transporter, but only the 1,1-dioxo-thiomorpholino analogue 23 exhibited a reduced 
accumulation (-38 ± 2%) in these cells, which could be completely reversed by the P-gp/
BCRP inhibitor elacridar. In addition, 23 appeared to be a BCRP substrate, whereas 
rimonabant was not. To further investigate the importance of P-gp and BCRP transport in 
limiting brain penetration of these compounds, we performed an in vivo experiment in rats 
in which we studied the effect of elacridar on the brain/plasma concentration ratio of 23 
and rimonabant. The brain/plasma ratio and brain concentration of 23 was significantly 
lower than for rimonabant, indicating a lower penetration of 23 than of rimonabant into 
the brain. Co-administration of elacridar resulted in an 11-fold increase of the brain/plasma 
ratio for 23, and only 1.4-fold for rimonabant, confirming the involvement of P-gp, and 
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possibly BCRP, in limiting the brain entrance of 23 in vivo. In conclusion, these data support 
the conception that transport via efflux transporters such as P-gp and BCRP can limit the 
brain penetration of CB1 receptor antagonists, and this property could be used in the 
development of peripheral antagonists for the treatment of obesity and metabolic disease.
The interplay between efflux transporters and  metabolizing enzymes
Glucuronidation of drugs by uridine 5’-diphospho glucuronosyltransferases (UGTs) in 
enterocytes and hepatocytes plays an important role in first pass metabolism of drugs in 
intestine and liver. The hydrophilic glucuronide metabolites are excreted more effectively 
from the body via bile or urine than the unconjugated parent drug. Transport via efflux 
transporters such as MRPs is necessary for the extrusion of glucuronide conjugates from 
the cell. Because UGT metabolic activity can be decreased by product inhibition, it is 
hypothesized that UGTs and MRPs cooperate synergistically in the excretion of compounds 
from the body; MRPs remove the product and thereby prevent product inhibition of UGTs 
and increase the rate of UGT activity and total metabolism. 
To test the hypothesis of a synergistic interplay between efflux transporters and 
glucuronidating enzymes, we used 7-hydroxycoumarin (7-HC) as a model substrate. 7-HC is 
a metabolite of coumarin (1, 2-benzopyrone), a natural compound that has been used as a 
fragrance in the food and perfume industry, and could have therapeutic usefulness in the 
treatment of lymphedema and different types of cancer. 7-HC and its glucuronide conjugate, 
7-HC-G, are the main metabolites formed in humans, and active transport processes appear 
to be involved in the excretion of 7-HC-G into the urine. Because 7-HC is glucuronidated to 
7-HC-G by multiple UGTs and active transport is required for efflux of 7-HC-G from cells, 
7-HC would provide a good model substrate to study the transporter-enzyme interplay. The 
efflux transporters involved in 7-HC and 7-HC-G transport were unknown. Therefore, we first 
investigated whether the efflux transporters MRP1-4, BCRP, or P-gp play a role in 7-HC and 
7-HC-G transport in Chapter 4. For this purpose, we measured uptake of the metabolites 
into membrane vesicles overexpressing these transporters. Our results showed that 7-HC 
is not transported by any of the efflux transporters tested, whereas 7-HC-G was a substrate 
of MRP3 and MRP4. These results are in line with the pharmacokinetic profile of coumarin, 
and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the 
coumarin metabolite 7-HC-G from liver and kidney. Furthermore, these results confirm that 
7-HC is a good model substrate to study interplay between MRPs and UGTs.
In Chapter 5, we explored the possibility of synergistic interplay between the 
7-HC-G transporters MRP3/4 and UGT2B15 in HEK293 cells using 7-HC. We identified 
sulindac as a potent inhibitor of MRP3 and MRP4 at concentrations that do not 
inhibit UGT2B15. Additionally, we showed that MRP4 is endogenously expressed 
in HEK293 cells, whereas there is very little expression of MRP3. Therefore, 
endogenous MRP4 is the most likely candidate to facilitate the excretion of 7-HC-
G from HEK-UGT2B15 cells. Inhibition of efflux of 7-HC-G from these cells with the 
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MRP3/4 inhibitor sulindac increased the intracellular concentration of 7-HC-G and decreased 
its excretion. In addition, total metabolite formation was decreased, which suggests that 
efflux of 7-HC-G via MRP4 can influence the rate of metabolism of 7-HC by UGT2B15. This 
indicates that UGTs and MRPs can cooperate in synergy, thereby providing an efficient route 
of drug elimination via glucuronidation.
Molecular mechanism of substrate transport via MRP4
MRP4 is a membrane transporter that mediates the cellular efflux of a wide range of 
anionic drugs and endogenous molecules in different tissues, including the BBB. Because 
transport via MRP4 can influence the disposition of CNS drugs and their metabolites, it 
is relevant to gain more knowledge about the molecular determinants important for its 
transport function. In Chapter 6, we substituted amino acids Phe368, Trp995, and Arg998 with 
conservative or non-conservative residues, and determined the effect on transport of the 
model substrates estradiol 17-β-D-glucuronide (E
2
17βG), cyclic guanosine monophosphate 
(cGMP), methotrexate (MTX), and folic acid into membrane vesicles isolated from baculovirus-
transduced HEK293 cells overexpressing the mutant MRP4 proteins. This revealed that 
all Arg998 mutations appeared to be deleterious, whereas the effect of a Phe368 or Trp995 
replacement was dependent on the amino acid introduced and the substrate studied. 
Substitution of Phe368 with Trp (F368W) induced a gain-of-function of E
2
17βG transport and 
a loss-of-function of MTX transport, which could not be attributed to an altered substrate 
binding. Moreover, we did not observe any modification in ATP or ADP handling for F368W. 
These results, in combination with docking of substrates in a homology model of MRP4 in 
the inward- and outward-facing conformation, suggest that Phe368 and Trp995 do not play an 
important role in the initial binding of substrates. They, however, might interact with the 
substrates during rearrangement of helixes for substrate translocation, funneling them to 
the exit site in the outward-facing conformation.
Conclusions and future perspectives
In this thesis, we used several in vitro models to study transport of compounds via drug 
efflux transporters and we argued in Chapter 7 that these tools could be implemented in 
CNS drug development. Especially the membrane vesicular transport assay could provide a 
useful tool for pharmaceutical industry to screen transport of new compounds via MRPs, 
which are currently largely neglected in drug development.
In the development of peripheral CB1 receptor antagonists, the P-gp transport assay 
was used successfully to select CB1 receptor antagonists that do not enter the brain due to 
active P-gp efflux. The efficacy of peripheral antagonists, of which the development could 
be accelerated using the P-gp substrate strategy, as drugs against obesity and metabolic 
disease should be further established in (pre-)clinical studies.
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Nederlandse samenvatting
Introductie
Nadat een geneesmiddel via de mond (oraal) is ingenomen, bepalen de processen van 
absorptie, distributie, metabolisme en uitscheiding (excretie) de lotgevallen van het middel in 
het lichaam. Omdat de werkzaamheid van een geneesmiddel afhangt van de beschikbaarheid 
van de stof op de plaats van werking, zijn deze processen medebepalend voor de effectiviteit 
en veiligheid van een geneesmiddel. Er zijn verschillende weefselbarrières in het lichaam die 
een geneesmiddel moet passeren voordat het de plaats van werking bereikt. Voorbeelden 
van deze barrières voor middelen die op de hersenen aangrijpen zijn de darmwand en de 
bloed-hersenbarrière. Hoewel sommige stoffen de cellen in de barrières vrijelijk kunnen 
passeren, zijn er voor andere stoffen membraangebonden eiwitten die het transport door 
deze weefsels bevorderen of juist verhinderen.  Deze transporteiwitten zijn aanwezig op 
de plasmamembranen van de cellen en kunnen de passage door de barrière bepalen en 
daarmee de verspreiding (dispositie) van een geneesmiddel in het lichaam beïnvloeden. 
Een belangrijke klasse van dergelijke transporteiwitten behoort tot de ATP-binding-cassette 
(ABC)-familie. Deze eiwitten transporteren stoffen, zogenaamde substraten, van de 
binnenkant van de cel naar de buitenkant, een proces dat efflux wordt genoemd. Voor dit 
transport hebben ze energie nodig die vrijkomt door hydrolyse van ATP. Transport via deze 
eiwitten kan de cel beschermen tegen ophoping van schadelijke stoffen. P-glycoproteïne 
(P-gp/ABCB1), leden van de multidrug-resistance-associated-protein(MRP/ABCC)-
subfamilie en breast-cancer-resistance-protein (BCRP/ABCG2) behoren tot deze klasse van 
transporteiwitten en het is bekend dat ze een rol spelen bij de efflux van geneesmiddelen. 
Na orale inname speelt de darmwand een belangrijke rol in het bepalen van de opname van 
geneesmiddelen in het bloed (orale beschikbaarheid). Transport door effluxtransporters in 
de darmwand kan de orale beschikbaarheid van een geneesmiddel beperken. De bloed-
hersenbarrière wordt gevormd door endotheelcellen van de bloedvaten in de hersenen 
samen met de basaalmembraan die bedekt is met astrocyten, een soort zenuwcellen. 
De barrière tussen het bloed en de hersenen is extra sterk om ervoor te zorgen dat het 
centrale zenuwstelsel (CZS) wordt beschermd tegen schadelijke stoffen. Daarnaast zorgt 
de bloed-hersenbarrière voor de gecontroleerde aanvoer van voedingsstoffen en afvoer 
van afvalstoffen. Effluxtransporters zijn belangrijk voor het beschermen van de hersenen 
tegen schadelijke stoffen, omdat ze stoffen na binnenkomst in de cel weer terug naar het 
bloed transporteren. P-gp wordt gezien als de belangrijkste poortwachter van de hersenen. 
Als geneesmiddelen hun werking in het CZS hebben moeten ze zowel de darmwand als 
de bloed-hersenbarrière passeren voordat ze hun werk kunnen doen. De laatste jaren 
blijft de ontwikkeling van nieuwe CZS-geneesmiddelen achter in vergelijking tot perifere 
middelen, deels omdat transporteiwitten in de darmwand en in de bloed-hersenbarrière 
hun beschikbaarheid en daarmee hun werking in de hersenen kunnen beperken.
In dit proefschrift hebben we onderzocht of deze transporteiwitten ook een rol kunnen 
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spelen in het beperken van de orale en CZS-beschikbaarheid van een bepaalde klasse van 
geneesmiddelen tegen overgewicht, de cannabinoïd-type-1(CB1)-receptorantagonisten. 
Daarnaast hebben we onderzocht hoe effluxtransporters samenwerken met 
biotransformerende enzymen die de omzetting van geneesmiddelen in metabolieten 
katalyseren en zo de excretie bevorderen. We hebben hierbij het effect onderzocht van het 
remmen van metabolietefflux uit de cel op de snelheid van de vorming van deze metaboliet. 
Verder hebben we onderzocht hoe verschillende aminozuren bijdragen aan de structuur-
transportfunctie van het effluxtransporteiwit MRP4.
Rol van effluxtransporters in de ontwikkeling van CB1-receptorantagonisten voor de 
behandeling van obesitas
Obesitas is een ziekte waarbij er sprake is van een abnormale of excessieve hoeveelheid 
lichaamsvet die een risico vormt voor de gezondheid door het ontstaan van diabetes en hart- 
en vaatziekten (metabool syndroom). Steeds meer mensen lijden aan obesitas en vanwege 
de gezondheidsproblemen vormt dit een toenemende last voor de maatschappij. Minstens 
2,8 miljoen mensen overlijden wereldwijd elk jaar aan de gevolgen van overgewicht of 
obesitas. De afgelopen jaren is gebleken dat overactiviteit van het endocannabinoïdsysteem 
een belangrijke rol speelt bij de ontwikkeling van obesitas. Om die reden zijn er antagonisten 
(remmers) van de CB1-receptor ontwikkeld voor de behandeling van obesitas. Eén van deze 
stoffen, rimonabant, is in 2006 geregistreerd als een effectief geneesmiddel tegen obesitas. 
In 2008 is rimonabant echter al weer van de markt gehaald omdat het ernstige bijwerkingen 
veroorzaakte zoals depressie en angst. Deze bijwerkingen bleken ook een gevolg te zijn van 
het remmende effect van rimonabant op CB1-receptoren in de hersenen. De laatste jaren 
is er steeds meer bewijs gevonden dat het enkel remmen van CB1-receptoren in andere 
gebieden in het lichaam dan de hersenen, ook wel de periferie genoemd, nog steeds 
positieve effecten heeft op het verbeteren van een aantal cardiometabole risicofactoren 
die geassocieerd zijn met obesitas. Voor deze gunstige effecten lijkt remming van de CB1-
receptor in de hersenen niet nodig te zijn, terwijl hierdoor wel de ongewenste psychiatrische 
bijwerkingen ontstaan. Daarom heeft men bedacht dat perifere CB1-receptorantagonisten, 
die dus alleen de CB1-receptor in de perifere weefsels remmen en niet in de hersenen, 
een uitkomst zouden kunnen bieden voor een veiligere behandeling van obesitas. Omdat 
effluxtransporters in de bloed-hersenbarrière de toegang van een geneesmiddel tot 
de hersenen kunnen blokkeren heeft dit geleid tot de hypothese dat transport via deze 
eiwitten kan worden gebruikt in de ontwikkeling van perifere CB1-receptorantagonisten. 
Om deze hypothese te testen hebben we voor een serie van 3,4-diarylpyrazoline CB1-
receptorantagonisten onderzocht of ze worden getransporteerd via deze eiwitten, en of dit 
transport hun beschikbaarheid in de hersenen kan beperken.
In Hoofdstuk 2 hebben we laten zien dat de meeste 3,4-diarylpyrazoline CB1-
receptorantagonisten en rimonabant een interactie aangaan met de effluxtransporters 
MRP1, MRP2, MRP3, en MRP4. Dit zou kunnen betekenen dat ze door deze eiwitten 
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worden getransporteerd. Om de interactie te bepalen hebben we membraanblaasjes 
(vesikels) gemaakt van cellen waarin deze transporteiwitten op de celmembraan 
aanwezig zijn. Deze vesikels hebben we gebruikt voor een transportexperiment waarin 
de opname van een radioactieve stof in de vesikels kan worden gemeten en het effect 
van de CB1-receptorantagonisten op de opname van dit substraat kan worden bepaald. 
Rimonabant remde het transport via MRP1 sterker dan het transport via MRP4, terwijl 
de 3,4-diarylpyrazolines juist betere remmers van MRP4- dan van MRP1-transport waren. 
Verschillende CB1-receptorantagonisten, inclusief rimonabant, stimuleerden het transport 
via MRP2 en MRP3 bij een lage substraatconcentratie en remden het transport bij een hoge 
substraatconcentratie. De interactie van de 3,4-diarylpyrazoline CB1-receptorantagonisten 
en rimonabant met MRP1-4 geeft aan dat deze stoffen een substraat kunnen zijn en mogelijk 
interacties kunnen geven als ze gecombineerd worden met andere geneesmiddelen die 
door deze eiwitten worden getransporteerd. Er zijn dierproeven gedaan met ratten waarin 
de effectieve dosis (ED
50
) van de CB1-receptorantagonisten 4, 11, 14 en 15 is bepaald 
die nodig is om de helft van een stimulator(agonist)-gemedieerd, bloeddrukverlagend 
effect te remmen. Deze resultaten suggereren dat actief transport van 4, 11 en 14 de 
hersenconcentratie van deze stoffen heeft verlaagd, waarvoor MRP4 verantwoordelijk zou 
kunnen zijn. Om deze resultaten te bevestigen zouden er vervolgstudies moeten worden 
uitgevoerd waarin wordt getest of de 3,4-diarylpyrazolines daadwerkelijk substraat zijn voor 
MRP1-4 en of dit hun concentratie in de hersenen beïnvloedt. Hiervoor zouden cellulaire 
accumulatie-experimenten kunnen worden uitgevoerd of er kan worden onderzocht hoe 
deze stoffen de hersenen van normale (wild-type) muizen penetreren in vergelijking met de 
hersenen van knock-out-muizen waarin deze transporteiwitten niet aanwezig zijn.
In Hoofdstuk 3 hebben we voor dezelfde serie CB1-receptorantagonisten onderzocht of 
transport via P-gp, de belangrijkste poortwachter van de hersenen, kan worden gebruikt 
als selectiecriterium in de ontwikkeling van perifere CB1-receptorantagonisten. Alle 
3,4-diarylpyrazoline CB1-receptorantagonisten en rimonabant remden het transport van 
een bekend substraat via P-gp in de vesikels. Slechts één van hen, de 1,1-dioxythiomorfolino 
analoog 23, bleek zelf een P-gp-substraat te zijn. Overexpressie van P-gp in cellen zorgde voor 
een 38% lagere ophoping (accumulatie) van 23, die met behulp van de P-gp/BCRP-remmer 
elacridar kon worden verhoogd naar het niveau van 23 in cellen zonder P-gp. Naast dat 23 
een P-gp-substraat was, bleek het ook een substraat voor BCRP te zijn, terwijl rimonabant 
door geen van beide werd getransporteerd. Om de rol van P-gp- en BCRP-transport in het 
belemmeren van de hersenpenetratie van CB1-receptorantagonisten verder te onderzoeken 
hebben we een dierexperiment (in vivo) met ratten uitgevoerd. In dit experiment hebben 
we 23 of rimonabant in het bloed gespoten met of zonder elacridar. Vervolgens hebben 
we op een vast tijdstip de bloed(plasma)- en hersenconcentraties bepaald van de stoffen 
en de hersen/plasma-concentratieratio berekend. Hieruit bleek dat de hersen/plasma-ratio 
en de hersenconcentratie van 23 lager was dan van rimonabant, wat duidt op een lagere 
penetratie van 23 in de hersenen dan van rimonabant. Wanneer de dieren tegelijkertijd 
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elacridar kregen bleek de hersen/plasma-ratio van 23 11 keer hoger te zijn, terwijl dit voor 
rimonabant slecht 1,4 keer hoger was. De remming van transport van P-gp, en mogelijk BCRP, 
met elacridar zorgde dus voor een betere hersenpenetratie van 23 en niet van rimonabant. 
Dit bevestigt een rol voor P-gp, en mogelijk BCRP, in het beperken van de hersenconcentratie 
van CB1-receptorantagonist 23 in vivo. Deze resultaten ondersteunen dus de hypothese 
dat transport van CB1-receptorantagonisten via effluxtransporters aanwezig op de bloed-
hersenbarrière, zoals P-gp en BCRP, de penetratie van deze stoffen in de hersenen kan 
beperken. Deze eigenschap zou kunnen worden gebruikt in de ontwikkeling van perifere 
CB1-receptorantagonisten voor de behandeling van obesitas en het metabool syndroom.
Het samenspel tussen effluxtransporteiwitten en biotransformerende enzymen
Geneesmiddelen die oraal worden ingenomen kunnen in de darmwand en in de lever 
worden omgezet (gebiotransformeerd) naar andere stoffen (metabolieten). Glucuronidering 
van geneesmiddelen is één van de omzettingen die kan plaatsvinden en deze wordt 
gefaciliteerd door enzymen in darm- en levercellen die behoren tot de familie van uridine 
5’-difosfoglucuronosyltransferases (UGTs). Conjugatie (koppeling) met glucuronide zorgt 
ervoor dat het geneesmiddel beter oplosbaar wordt in water, waardoor het effectiever kan 
worden uitgescheiden via de gal of de urine. Omdat deze metabolieten goed wateroplosbaar 
zijn kunnen ze de lipofiele celmembraan niet goed meer passeren. Daarom zijn eiwitten zoals 
MRPs nodig om deze glucuronidemetabolieten uit de cel te transporteren. Biotransformatie 
via UGTs kan worden geremd door productinhibitie, wat inhoudt dat ophoping van het 
product, ofwel de glucuronidemetaboliet, in de cel de activiteit van het enzym vermindert. 
Omdat MRPs ervoor kunnen zorgen dat de glucuronidemetaboliet niet ophoopt in de cel, 
is het idee ontstaan dat MRPs en UGTs op een synergistische manier samenwerken; MRPs 
verwijderen het product uit de cel en voorkomen hiermee de productinhibitie van UGTs, 
wat resulteert in een optimale activiteit van UGT en dus meer biotransformatie.
Om de hypothese van een synergistisch samenspel tussen MRPs en UGTs te testen 
hebben we gebruik gemaakt van het modelsubstraat 7-hydroxycoumarine (7-HC). 7-HC is 
een metaboliet van coumarine (1,2-benzopyrone), een natuurlijke stof die eerder gebruikt 
is als geurstof in de voedsel- en parfumindustie maar ook van therapeutische waarde zou 
kunnen zijn in de behandeling van lymfoedeem en verschillende soorten kanker. 7-HC en 
zijn glucuronideconjugaat, 7-HC-G, zijn de belangrijkste metabolieten in de mens. Actieve 
uitscheiding via transporteiwitten blijkt een belangrijke route te zijn voor de uitscheiding van 
7-HC-G via de urine. Omdat 7-HC door meerdere UGTs wordt gebiotransformeerd tot 7-HC-
G en actief transport door de cel nodig is om 7-HC-G uit te scheiden, leek 7-HC een goed 
modelsubstraat om de samenwerking tussen transporteiwitten en UGTs te bestuderen. Het 
was nog niet bekend welke transporteiwitten betrokken zijn bij de uitscheiding van 7-HC-G 
en 7-HC, en daarom hebben we in Hoofdstuk 4 onderzocht of MRP1-4, P-gp en BCRP hierin 
een rol spelen. Daarom hebben we de opname van 7-HC en 7-HC-G bepaald in vesikels 
waarin deze transporteiwitten aanwezig waren. Hieruit bleek dat 7-HC door géén van de 
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eiwitten werd getransporteerd, terwijl 7-HC-G een substraat bleek te zijn voor MRP3 en 
MRP4. Deze resultaten komen overeen met wat bekend is over de distributie en excretie van 
deze coumarinemetabolieten in de mens en suggereert dat MRP3 en MRP4 de belangrijkste 
transporteiwitten zijn voor uitscheiding van 7-HC-G door lever en nieren. Daarnaast 
bevestigen deze resultaten dat 7-HC een goede modelstof is om de samenwerking tussen 
MRPs en UGTs te onderzoeken.
In Hoofdstuk 5 hebben we de mogelijkheid voor een synergistische samenwerking tussen 
MRP3/4 en UGT2B15 bestudeerd in HEK293-cellen waarin dit biotransformerende enzym 
tot overexpressie is gebracht. Eerst hebben we de glucuronidering van 7-HC door UGT2B15 
bepaald. Als tweede hebben we sulindac geïdentificeerd als een krachtige remmer van 
MRP3 en MRP4, terwijl UGT2B15 bij eenzelfde concentratie van deze stof slechts zwak 
wordt geremd. Daarnaast hebben we met behulp van kwantitatieve PCR aangetoond dat 
MRP4 van nature voorkomt in HEK293-cellen, terwijl MRP3 nauwelijks tot expressie komt in 
deze cellen. Daarom lijkt MRP4 de meest voor de hand liggende kandidaat voor uitscheiding 
van 7-HC-G gevormd door UGT2B15 in HEK293-cellen. Remming van 7-HC-G-transport uit 
de cel met behulp van de MRP3/4-remmer sulindac verhoogde de concentratie van 7-HC-
G in de cel en verlaagde de uitscheiding van 7-HC-G, wat duidt op verminderd transport 
van 7-HC-G uit de cel. Daarnaast reduceerde sulindac ook de totale glucuronidevorming, 
hetgeen suggereert dat transport van 7-HC-G via MRP4 de mate van glucuronidering van 
7-HC via UGT2B15 beïnvloedt. Dit impliceert dat UGTs en MRPs inderdaad in synergie 
samen kunnen werken, waardoor ze op een efficiënte wijze geneesmiddelen uit het lichaam 
kunnen uitscheiden door middel van glucuronidering en transport.
Moleculaire mechanisme van substraattransport door MRP4
MRP4 is een membraaneiwit dat betrokken is bij het transport van zeer diverse, doorgaans 
negatief geladen, stoffen, zoals geneesmiddelen en lichaamseigen moleculen, in 
verschillende weefsels waaronder de bloed-hersenbarrière. Omdat transport via MRP4 de 
verdeling van CZS-geneesmiddelen en hun metabolieten in ons lichaam kan beïnvloeden, 
is het relevant om meer kennis te vergaren over de aminozuren die belangrijk zijn voor de 
transportfunctie van dit eiwit. Een eiwit bestaat uit een keten van bouwstenen, aminozuren 
genaamd, die op een bepaalde manier wordt gevouwen om een actief eiwit te krijgen. De 
aminozuurvolgorde bepaalt welke functionele onderdelen een eiwit heeft en het blijkt dat 
sommige aminozuren belangrijker zijn dan anderen. Om te onderzoeken welke aminozuren 
belangrijk zijn voor de transportfunctie van MRP4 hebben we in Hoofdstuk 6 de aminozuren 
fenylalanine op positie 368 in de aminozuurketen (Phe368) en tryptofaan en arginine op 
positie 955 en 998 (Trp995 en Arg998) vervangen met conservatieve (vergelijkbare chemisch-
fysische eigenschappen) en niet-conservatieve aminozuren. Hierna hebben we het effect 
van deze substituties op het transport van een aantal modelsubstraten bepaald met 
behulp van vesikels waarin deze mutante MRP4-eiwitten aanwezig waren. We hebben als 
substraten estradiol-17β-D-glucuronide (E
2
17βG), cyclisch guanosinemonofosfaat (cGMP), 
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methotrexaat (MTX) en foliumzuur gebruikt. De transportstudies lieten zien dat de Arg998-
mutanten totaal geen transportactiviteit meer vertoonden, terwijl de activiteit van de Phe368- 
en Trp995-mutanten afhankelijk was van het aminozuur waarmee het was vervangen en het 
substraat waarvan het transport werd gemeten. Substitutie van Phe368 met het conservatieve 
aminozuur tryptofaan (F368W) induceerde een toename van transportactiviteit voor het 
substraat E
2
17βG, terwijl het een afname van MTX-transport gaf. Deze veranderingen in 
transportactiviteit bleken niet veroorzaakt door een veranderde binding van het substraat 
aan het transporteiwit. Daarnaast zagen we tijdens E
2
17βG-transport door F368W ook 
geen verandering in de binding van ATP of ADP, belangrijk voor de energie die nodig is 
voor conformatieveranderingen van de transporter. Deze resultaten, in combinatie met het 
bepalen van de locatie van de binding van de substraten in een homologiemodel van MRP4 
in de in- en uitwaartsgerichte conformatie, suggereren dat Phe368 en Trp995 geen belangrijke 
rol spelen in de initiële binding van substraten aan MRP4. Ze zouden echter wel tijdens 
het herschikken van de transmembraanhelices een interactie met de substraten kunnen 
aangaan die van invloed is op de verplaatsing van het substraat van de binnenkant van de cel 
naar de uitgang van het transporteiwit aan de buitenkant van de cel in de uitwaartsgerichte 
conformatie.
Conclusie en toekomstperspectieven
In dit proefschrift hebben we verschillende celmodellen gebruikt om transport van 
stoffen via effluxtransporteiwitten te bestuderen. In Hoofdstuk 7 beschrijven we hoe 
deze transportstudies zouden kunnen worden gebruikt in de ontwikkeling van CZS-
geneesmiddelen. Vooral de transportexperimenten met vesikels zouden een geschikt 
gereedschap kunnen zijn voor de farmaceutische industrie om het transport van nieuwe 
stoffen via MRPs te testen; Deze transporteiwitten zijn op dit moment onderbelicht in het 
proces van geneesmiddelontwikkeling.
Voor de ontwikkeling van perifere CB1-receptorantagonisten hebben we de cellulaire 
transportstudies succesvol gebruikt om een stof te selecteren die in vivo door P-gp verhinderd 
werd om de hersenen te penetreren. Door middel van deze P-gp-transportstrategie zou 
de ontwikkeling van perifere CB1 receptor antagonisten kunnen worden versneld. De 
therapeutische effectiviteit van deze middelen bij obesitas en metabool syndroom moet 
nog verder worden bevestigd in (pre-)klinische studies.
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List of abbreviations and glossary
7-HC  7-hydroxycoumarin
7-HC-G  7-hydroxycoumarin glucuronide
7-HC-S  7-hydroxycoumarin sulfate
∆9-THC  ∆9-tetrahydrocannabinol, natural CB1 receptor agonist
A  alanine, small hydrophobic amino acid
ABC  ATP binding cassette
ABCB1  gene name for P-glycoprotein (P-gp) / multidrug resistance protein 1 
  (MDR1)
ABCC  gene name for multidrug resistance-associated proteins (MRPs)
ABCG2  gene name for breast cancer resistance protein (BCRP)
ACN  acetonitrile
ADP   adenosine 5’-diphosphate
agonist  a molecule that produces a physiological response through activation of 
  a receptor by binding to the receptor in the active state
Ala  alanine, small hydrophobic amino acid
AM4113  brain-penetrating neutral CB1 receptor antagonist developed at the  
  laboratory of Alexandros Makriyannes at the Centre for Drug Discovery, 
  Northeastern University Boston, USA
AM6545  peripheral and neutral CB1 receptor antagonist and P-gp substrate 
  developed at the laboratory of Alexandros Makriyannes at the Centre for 
  Drug Discovery, Northeastern University Boston, USA
AMP   adenosine 5’-monophosphate
ANOVA  analysis of variance
Arg  arginine, positively charged amino acid
Asp  asparagine, polar uncharged amino acid
ATP  adenosine 5’-triphosphate
BBB  blood-brain barrier
BCRP  breast cancer resistance protein
BPR697  peripheral CB1 receptor antagonist developed by the group of M-S Hung 
  at the Institute of Biotechnology and Pharmaceutical Research, Miaoli,
  Taiwan
BSA  bovine serum albumine
CaCo-2  colon carcinoma cell line that is often used as a representative for 
  intestinal cells
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CB1  cannabinoid type 1
cGMP  cyclic guanosine 3',5'-cyclic monophosphate
Ci  Curie
CI  confidence interval
cLogP  calculated octanol:water coefficient
CNS  central nervous system
CP55,940 CB1 receptor agonist
Ct  number of PCR cycles before threshold is reached
CYP  cytochrome P450 enzyme
DMEM  Dulbecco Eagle’s modified medium
E
1
S  estrone sulfate
E
2
17βG  estradiol-17β-D-glucuronide
EC
50
  concentration at which 50% of maximum response to that modulator is 
  reached
ED
50
  effective dose at which 50% of maximum response to that modulator is 
  reached
elacridar mixed P-gp/BCRP inhibitor, also called GF120918 or G918
ER  endoplasmic reticulum 
ex vivo  an experiment that is done with living tissue outside a living animal/
  human
eYFP  enhanced yellow fluorescent protein 
F  phenylalanine, aromatic amino acid
FCS  fetal calf serum
GF120918 elacridar, mixed P-gp/BCRP inhibitor
GSH  reduced glutathione
HBSS  Hank’s balanced salt solution
HEK293  human embryonic kidney cell line 293
HPLC  high pressure liquid chromatography
IC
50
  concentration at which 50% of maximum enzyme activity is inhibited
inverse agonist molecule that reverses constitutive receptor activity by binding the 
  receptor in the inactive state
in vitro  an experiment that is done in test tubes or plastic in the laboratory
in vivo  an experiment that is done in a living animal/human
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K  lysine, positively charged amino acid
Ki  equilibrium constant for inhibitory affinity. Is equal to IC50 with non-
  competitive binding. Is lower than IC
50
 with competitive binding.
K
m
  Michaelis constant: the substrate concentration at which an enzyme-
  catalyzed reaction proceeds at 50% of its maximum velocity
L  leucine, hydrophobic amino acid
LC-MS/MS HPLC combined with tandem mass spectrometry, technique to quantify 
  chemical compounds
Leu  leucine, hydrophobic amino acid
LLC-PK1  pig kidney epithelial cell line, often used for transwell experiments
LTC
4
  leukotriene C
4
Lys  lysine, positively charged amino acid
MDCKII  Madine Darby canine kidney cell line II
MDR1  multidrug resistance protein 1 / P-glycoprotein
mQ  milli-Q, ultrapure water
MRP  multidrug resistance-associated protein
MS  mass spectrometry
MTX  methotrexate
NBD  nucleotide binding domain, binds and hydrolyzes ATP
neutral  molecule that competes with the agonist for the same binding domain of 
antagonist the receptor
NMQ  N-methyl quinidine
PAGE  polyacrylamide gel electrophoresis
PCA  perchloric acid
PCR  polymerase chain reaction
Pi  phospate, is released during hydrolysis of ATP to ADP
Phe  phenylalanine, aromatic amino acid
P-gp  P-glycoprotein / multidrug resistance protein 1
PSA  polar surface area
R  arginine, positively charged amino acid
S  serine, polar uncharged amino acid
SAR  structure-activity-relationship
S.D.  standard deviation, represents variation in the experiment
SDS  sodium dodecyl sulfate
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S.E.M.  standard error of the mean, represents variation in the population
Ser  serine, polar uncharged amino acid
substrate compound that is subjected to a reaction catalyzed by an enzyme or 
  transporter
synergy  a cooperation in which the total effect exceeds the effect expected from 
  the sum of the individual effects 
TFA  trifluoroacetic acid
TM  transmembrane helix
TMD  transmembrane domain, consist of 5 or 6 membrane helices for ABC 
  transporters and can bind substrates
TM38837 peripheral CB1 receptor antagonist developed by 7TM Pharma
Trp  tryptophan, aromatic amino acid
TS buffer Tris-sucrose buffer  
Tyr  tyrosine, aromatic amino acid
UDP  uridine 5’-diphosphate
UDPGA  uridine 5’-diphospho glucuronic acid
UGT  uridine 5’-diphospho glucuronosyltransferase
u-HPLC  ultra high pressure liquid chromatography
vanadate phosphate (Pi) analog that traps ADP to the nucleotide binding domain
vesicles  small bubbles of isolated membranes from cells expressing a transporter 
  or control protein. Compounds can be transported into the cavity of 
  inside-out oriented vesicles.
V
max
  the maximum velocity of an enzyme reaction when the binding site is 
  saturated with substrate
VSV-G  vesicular stomatis virus
W  tryptophan, aromatic amino acid
Y  tyrosine, aromatic amino acid
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